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Abstract
This thesis describes the detection and partial characterisation of large precursor 
forms of insulin-like growth factor II (IGF-II), secreted by MCF-7 human breast 
cancer cells transfected with IGF-II cDNA (MI7) or control vector (MN2). Due to 
technical difficulties with radioimmunoassay, and the fact that this method provides 
no information on the size or nature of secreted IGF-II, an immunoblotting technique 
has been developed and optimised, using a commercially available monoclonal 
antibody. The technique is specific, sensitive, and semi-quantitative, by the use of 
enhanced chemiluminescence. MI7 cells secreted IGF-II in large precursor forms (22 
and 15kDa) and the mature 7kDa growth factor, whilst control cells (MN2) secreted 
no detectable IGF-II. Conditioned media from MI7 cells caused proliferation of 
MCF-7 cells, and the 15kDa form was separated from the 22 and 7kDa IGF-II by 
cation-exchange chromatography. Secretion of large precursors may be due to 
saturation of the processing machinery normally involved in cleavage of prepro-IGF- 
II to the mature growth factor, and these data are discussed in relation to processing of 
IGF-II, and the biological activity of large precursors.
In contrast, four non-transfected breast cancer cell lines secreted mainly mature 7kDa 
IGF-II, with trace amounts of a large 15kDa form. Oestradiol induced secretion of 
mature IGF-II in oestrogen-responsive cells (T47D and MCF-7 McG), whilst having 
no effect on higher constitutive levels in oestrogen-unresponsive MDA-231 and 
HBL-100 cells. MCF-7 (9) cells rendered oestrogen-unresponsive by transfection 
with a mixed cDNA library also secreted large precursors of IGF-II, whilst oestrogen- 
responsive wild-type cells secreted no IGF-II. Conditioned media from two ovarian 
cancer cell lines contained large precursors of IGF-II, PEG 14 oestrogen receptor 
negative cells secreting higher levels of IGF-II (22, 15 and 7kDa), than PE04 
oestrogen receptor positive cells which only secreted 15 and 7kDa IGF-II. The levels 
of IGF-n were higher when conditioned media was prepared in 5% serum than with 
serum-free media. These data are discussed in relation to the role of IGF-II in 
oestrogen-mediated proliferation and progression to hormone-independence.
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CHAPTER 1 INTRODUCTION
1.1 HORMONES, GROWTH FACTORS AND BREAST CANCER
1.1.1 Normal breast - development and growth
The main hormones involved in the development and growth of normal and 
neoplastic breast are oestrogens and progestins (Anderson and Battersby, 1989). 
Oestradiol, the most potent oestrogen, in needed for both normal mammary 
development through adolescence, but also in lobule formation during pregnancy 
(Topper and Freeman, 1980), however, the direct effect of oestrogen is difficult to 
assess, due to the plethora of other hormones and growth factors that are induced at 
puberty (Illig et al., 1982). Although oestrogens are clearly implicated in the 
development of the breast, the highest mitotic index, in epithelial cells, occurs in the 
luteal phase (Ferguson and Anderson, 1981), when progesterone levels are high, and 
oestrogen levels at their lowest, suggesting that either progesterone is mitogenic, or 
that oestrogen mediates it's effect via a number of other factors. Other hormones 
induced at puberty include androgens, and gonadotrophins. Studies on the role of 
gonadotrophins on the development of the breast have shown a critical role, for 
patients with gonadal dysgenesis will only develop normal breasts upon oestradiol 
administration if the hypothalamic-pituitary axis is functioning (Pertzelan et al., 
1982). Strengthening this observation, animal studies also show that oestrogen 
treatment of ovariectomised rats will not induce breast formation if they have 
undergone pituitary ablation as well (Lyons, 1958). The role of progestins both in the 
growth of the normal breast, and genesis of breast cancer have been reviewed 
elsewhere (King, 1991). Androgens have a different role, in that they antagonise the 
effect of oestrogens on the breast, and may explain why boys do not develop breasts 
at puberty (Drife, 1986).
1.1.2 Breast cancer
Whilst oestrogens are involved in the growth and development of the normal breast, 
they are also implicated in both the generation and progression of breast cancer
(Thomas, 1984). The evidence for oestrogen being an initiator of cancer is not as 
strong as for its promotional action, but in two epidemiological cases, oestrogens are 
implicated in the genesis of cancer. Firstly, daughters of women who took 
diethylstilboestrol, in the 1950's, to prevent aborted pregnancies, have a higher 
incidence of vaginal adenocarcinoma (Herbst et al., 1971). Secondly, early forms of 
oestrogen replacement therapy (ERT), which used high doses of unopposed 
oestrogens in the 1970's, showed in a short time, that users had a higher incidence of 
endometrial cancer (Smith et al., 1975), and this was also found with early forms of 
the contraceptive pill (Henderson et al., 1983).
Abundant evidence both from epidemiological and cellular studies suggest the 
involvement of oestrogens as promotional agents in breast cancer. Rats treated with 
7,12-dimethylbenz(fl)anthracene will develop oestrogen-dependent tumours that will 
not grow if the rats have non-functioning ovaries, or are ovariectomised (Dao, 1972). 
This can be reversed by the administration of pharmacological doses of oestrogens 
(Huggins et al., 1961). The first evidence for oestrogen as a promotional agent in 
humans, came from the observation by Beatson (1896), that bilateral ovariectomy 
could cause regression in patients with breast cancer. This early observation led to 
the linking of ovarian activity with growth of breast cancer, and to the development of 
endocrine deprivation as a treatment for advanced breast cancer (Miller, 1990).
Epidemiological evidence implicates oestrogens in breast cancer (Boyle, 1988). High 
risk factors, such as early menarche, late menopause and nulliparity, all suggest that it 
is the cumulative exposure of oestrogen to the breast that is the promotional agent. 
This is confirmed by the fact that surgical menopause decreases breast cancer risk, 
breast cancer occurs in women at about 1(X) times the frequency as men, even though 
the male breast contains the same epithelial components, and the low frequency in 
men is seen to rise in transvestites, receiving oestrogen therapy. The discovery and 
purification of the oestrogen receptor (ER) (Jensen, 1991), has strengthened these 
arguments, with the finding that about 70% of breast tumours contain this receptor.
the majority of which respond to endocrine treatment, whilst those without receptor 
invariably fail to respond, and are generally more aggressive.
1.1.3 Treatment of breast cancer
As mentioned above, the discovery by Beatson (1896), that bilateral ovariectomy 
could cause regression of breast tumours, led to the development of endocrine 
deprivation as a treatment for advanced breast cancer (Miller, 1990). This type of 
regime, however, only produces regression in about 30-40% of women with advanced 
breast cancer, and leads to the major problem with breast cancer therapy, in that 
inevitably the patient will die from cancer, with the breast tumour often being 
oestrogen-unresponsive. The low success rate of such treatments led to the search for 
therapies that were reversible, and less toxic than chemotherapy and surgery, the most 
widely used being antioestrogens.
The first non-steroidal antioestrogen was described by Lemer et al. (1958), and was 
named MER25. Since that discovery, many non-steroidal antioestrogens have been 
produced, and tested in clinical trials, but none have been so successful as tamoxifen 
(ICI46,474; Nolvadex), which has minimal toxicity, can inhibit growth of hormone- 
responsive advanced breast cancer (Furr and Jordan, 1984), and can prolong survival 
if given adjuvantly (Early breast cancer triallist's collaborative group, 1988). 
Interestingly, tamoxifen not only causes regression in ER-positive (Lippman and 
Chabner, 1986), but also in a small number of ER-negative tumours (Nolvadex 
Adjuvant Trial Organisation, 1988). The beneficial effects of tamoxifen therapy, are 
marred however, by the fact that most oestrogen-dependent tumours will eventually 
return, usually in a hormone-independent state, and kill the host. The recurrence of 
the tumour, requires a change of treatments, which are more toxic, and unpleasant for 
the patient e.g. chemotherapy.
1.1.4 Progression from oestrogen-sensitive to independent state
The progression of breast cancer from an apparent hormone-dependent or sensitive 
state to independence is a major clinical problem. The work of Foulds (1969), on 
mouse mammary tumours, indicated that this progression could proceed via a number 
of pathways, with changes in steroid sensitivity that paralleled the complex nature of 
human breast cancer (Figure 1.1). Oestrogen-unresponsive cells generally grow faster 
in vivo (King and Darbre, 1989) and in cell culture (Darbre and King, 1988), 
suggesting that the cells have overcome the need for oestrogen, and now have a 
growth advantage. If increased proliferation is by pathways separate from oestrogen- 
mediated growth, then anti-hormone therapy will select for these insensitive cells, so 
promoting progression, and therapy failure (Figure 1.2). The mechanisms whereby 
cells can grow in the absence of oestrogen, or gain that ability, are poorly understood, 
but the importance of secreted growth factors, and their modulation by oestrogen, led 
to the autocrine hypothesis (reviewed in Clarke et aL, 1991). There are several 
growth factor mediated pathways by which cells could bypass oestrogen-dependence; 
1) upregulation of stimulatory or downregulation of inhibitory growth factors 
previously under control of oestrogen, which can act in an autocrine manner, 2) 
growth by paracrine factors, 3) upregulation of growth factor receptors, sensitising 
cells to the ligand and 4) switch of growth response to pathway not under the control 
of oestrogen (Figure 1.3). The progression of breast cancer from the responsive to 
independent state can be observed in cell culture by either the spontaneous generation 
of resistant clones from oestrogen-responsive cells, or the transformation of 
responsive cells to the independent state by long-term steroid withdrawal. In the 
former case, most cell have abnormal ER (Reddel et aL, 1988), but in the latter, cells 
retain functional ER, but do not proliferate in response to oestrogen (Darbre and Daly,
1989). The basal growth rate in these cells increases to that of parent cells grown in 
the presence of oestrogen, suggesting that cells have gained the ability to proliferate 
faster, which is accompanied by changes in growth factor expression (Daly et al.,
1990). However, in a human breast cancer cell line, T47D, we have an example of
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Figure 1.1 Multiple pathways for progression of normal hormone-sensitive cells 
to hormone-unresponsive cancer (adapted from King, 1992).
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Figure 1.2 Progression by cell selection. Hormone treatment stops growth of 
hormone-dependent cells, but selects for hormone-sensitive cells, 
which are unaffected (adapted from King, 1992).
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Figure 1.3 Four possible mechanisms whereby breast cancer cells could 
upregulate or control their own proliferation, and so become 
independent of oestrogen for growth. The growth factors and 
receptors mentioned are only examples. New pathways, represents 
those not under the control of oestrogen, or those which we have not 
yet been discovered. IGF-IR - type I IGF receptor. PDGFR - Platelet- 
derived growth factor receptor (Adapted from Westley and May,
1991).
the problems of drawing conclusions from cell culture, for unresponsive clones, 
derived from responsive parent cells have increased transforming growth factor P 
mRNA levels, a growth factor that inhibits proliferation of most breast cancer cells, 
and is upregulated by antioestrogens (Knabbe et al., 1987). The advances in the 
understanding of the oestrogen receptor, will hopefully elucidate the mechanisms 
whereby cells can progress from a hormone-dependent to an insensitive state.
1.1.5 The oestrogen receptor
The oestrogen receptor (ER) is a member of a large family of nuclear transcription 
regulators, including receptors for androgens, progestins, thyroid hormone and 
retinoids (Jensen, 1991). The first indication that oestrogen effects were mediated via 
a receptor came from the observation by Jensen (1960), that rat uterine tissue could 
bind radiolabelled-oestradiol, and the solubilised receptor was subsequently isolated 
by centrifugation of homogenised uterine tissue (Toft and Gorski, 1966). Detection 
of the ER in both cytosolic and nuclear fractions led Jensen et al. (1968) to propose 
the two-step mechanism, whereby unoccupied ER in the cytoplasm bound oestrogen 
and transferred to the nucleus, whereupon it then bound to acceptor sites in the 
genome, and altered transcription of specific genes. The generation of monoclonal 
antibodies to the ER, however, immunolocalised ER to the nucleus (King and Greene, 
1984), and subsequent enucleation studies indicated that the majority of unoccupied 
receptor resided in the nucleus (Welshons et al., 1984). Debate still continues as to 
the presence and function of unoccupied cytoplasmic receptors (King, 1989; Jensen,
1990), but the two step hypothesis, although not directly involving translocation of 
the receptor to the nucleus, still holds true in respect of ligand activation of the 
receptor, and subsequent transcriptional activation (Figure 1.4).
1.1.5.1 Receptor transformation
Unoccupied ER migrates as an 8 S form on a low salt sucrose gradient, but in high salt 
conditions (over 300mM), transforms to a 4S form or a 5S dimer (Miller et al., 1985).
BRm+ h
HR
HR
H
H + R
HRi
HR
Figure 1.4 The two-step hypothesis for oestrogen-receptor (ER) action. ER (R) 
present outside the nucleus (A) or confined to nucleus (B). H - 
hormone. Rn  - native (untransformed) receptor. R j  - transformed 
receptor (adapted from Jensen, 1992).
HSP90
HORMONE
Figure 1.5 Hypothetical model for transformation of the oestrogen receptor (ER) 
by hormone (triangle), which promotes dimérisation by dissociation of 
HSP90. ER is represented as three domains. A, C (DNA binding) and 
E (hormone binding). Adapted from Jensen, 1992.
This transformation can be performed by oestrogen, and results in activation of the 
receptor, so that it has a higher affinity for DNA, chromatin and nuclei (Figure 1.5). 
Dialysis, ammonium sulphate precipitation, and an increase in temperature also cause 
transformation, which led to the finding that it was not just simple dimérisation of the 
receptor, but conversion of the 8S form to the 5S dimer proceeded via loss of other 
proteins such as HSP90 (Jensen, 1990). Whether the HSP90 actually prevents 
dimérisation of the receptor, or is able to mask the DNA binding domain is not 
known, but mutated receptors lacking the hormone binding domain do not bind 
HSP90 (Chaumbraud et al., 1990), and are able to activate transcription, albeit at a 
lower efficiency than the full length receptor (Kumar et al., 1987). After 
dimérisation, the ER, being a nuclear transcription factor binds to short DNA 
sequences in target genes, called oestrogen response elements (ERE), via zinc 'fingers' 
(Kumar et al., 1987). The ERE is an enhancer element, promoting transcription, and 
shares the majority of the properties of an enhancer i.e. it is active irrespective of 
orientation, and when placed at varying distances both upstream and downstream of a 
promoter (Seiler-Tuyns et al., 1986).
1.1.6 Cellular effects of oestrogen
A greater understanding of the action of oestrogens came from the establishment of 
breast cancer cell lines (Table 1.1), many of which contain detectable levels of ER, 
and are growth-responsive or dependent upon the hormone (Darbre and King, 1988). 
Initial studies on the effect of oestrogen on breast cancer cell lines, proved 
inconclusive, as some groups showed increased proliferation, whilst others detected 
no effect, but could however reduce proliferation with tamoxifen, and reverse this 
effect with oestradiol (Lykkesfeldt and Briand, 1986). This apparent difference was 
solved by the Katzenellenbogen group, who showed that the pH indicator widely used 
in cell culture at the time, phenol red, was itself a very weak oestrogen, with about 
0.001% of the affinity of oestradiol (Berthois et al., 1986). The high concentrations 
of the indicator (up to 50p,M), apparently masked the effects of exogenous oestradiol.
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and since its removal, by use of phenol red-free media, the effect of oestradiol and 
tamoxifen on proliferation of a range of cell lines has been well documented (Darbre 
et al., 1983; Darbre et al., 1984). Since this observation, and the cloning of the ER 
(Green et al., 1986), a tremendous amount of research has been directed at 
determining the effects of oestrogen on breast cancer cells. Two major effects of 
oestrogen are; 1) increased proliferation, 2) enhanced secretion of proteins (e.g. 
proteases, growth factors). The first effect, increased proliferation can be divided into 
two sets of responses; a) regulation of DNA synthesising proteins, b) regulation of 
secreted growth factors. The function of the second effect, enhanced secretion of a 
variety of proteins, is not entirely clear, but the number of proteases secreted suggest 
that it may be involved with tumour spread in vivo. Plasminogen activator, 
collagenase and cathepsin-D (a protease), are all upregulated in MCF-7 cells by 
oestradiol (Cullen and Lippman, 1989), and may be responsible, in the in vivo state, 
for invasiveness of tumours. A common marker of oestrogen receptor functionality, 
is the progesterone receptor. Treatment of MCF-7 cells with oestradiol results in a 3- 
4 fold upregulation of progesterone receptor after 4 days, and this induction can be 
blocked by tamoxifen (Horwitz and McGuire, 1978). The laminin receptor is 
induced by oestradiol in MCF-7 cells (Albini et al., 1986), which is thought again to 
be involved in tumour spread. Together with these proteins, oestradiol can also 
regulate proteins such as HSP27 (Edwards et al., 1980), pS2 (Masiakowski et al., 
1982) and several glycoproteins (Westley and Rochefort, 1980).
1.1.6.1 Regulation of DNA synthesising proteins
Oestradiol upregulates the activity of several DNA replicating enzymes in MCF-7 
cells, and decreases these upon tamoxifen addition, the best characterised being 
thymidine kinase, an enzyme directly involved in production of deoxynucleotides, 
which increases 4-fold in activity (Bronzert et al., 1981). Increased enzyme activity 
is a result of induction of mRNA and protein synthesis. Other enzymes increased by
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oestrogen are carbamoyl-phosphate synthetase, aspartate transcarbamylase, orotate 
pyrophosphorylase and orotidine decarboxylase (Aitken and Lippman, 1983).
1.1.6.2 Regulation of growth factor secretion
The regulation of secretion of a variety of growth factors led from the observation by 
De Larco and Todaro (1978), that sarcoma-virus transformed fibroblasts secreted 
polypeptide growth factors (termed sarcoma growth factors), that were able to sustain 
growth of the cell line, in serum-free conditions, and stimulate cells to grow in soft 
agar. The purified growth factors, transforming growth factor (TGF) a  and p, are 
both produced by breast cancer cells (King et al., 1989), and can be detected in breast 
tumours (Ciardiello et al., 1991). Additionally, in clinical cases, the finding that ER 
and epidermal growth factor receptor (EGER) are negatively correlated in tumour 
samples, and that low ER status signifies a bad prognosis, all suggest that TGFa may 
be involved in the progression of breast cancer. The discovery that TGFa, was 
oestrogen regulated in some ER-positive cells, and secreted constitutively by many 
faster growing ER-negative cells lines (Lippman et al., 1987), seemed to provide 
proof for the autocrine hypothesis i.e. unresponsive cells have overcome oestrogen- 
regulation of T G Fa, and can control their own proliferative rate. However, blocking 
the EGFR, does not inhibit oestrogen-mediated proliferation of MCF-7 cells (Arteaga 
et al., 1988), and transfection of TGFa cDNA into oestrogen-responsive MCF-7 cells 
does not result in autocrine poliferation (Clarke et al., 1989).
Another growth factor induced by oestrogen in MCF-7 cells is platelet-derived 
growth factor (PDGF) (Bronzert et al., 1987), which is not actually a mitogen for 
breast cancer cells, as they do not contain the PDGF receptor. This growth factor 
provides an example of the difficulty in interpreting studies on single cell lines, for a 
role for PDGF in paracrine stimulation of breast cancer cell proliferation can be 
postulated. PDGF causes proliferation of fibroblasts, and can induce secretion of 
insulin-like growth factor-I (Clemmons et al., 1981), which is a potent mitogen for 
breast cancer cell lines (Osborne et al., 1989). A large amount of research is now
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being focused at the insulin-like growth factors (IGF's). A growing body of evidence 
indicates a possible role for IGF's in breast cancer cell proliferation and will be 
discussed in the Section 1.3 after description of the IGF's in Section 1.2.
1.2 INSULIN-LIKE GROWTH FACTORS
1.2.1 Discovery and purification
Since their discovery as the somatomedins in 1957, the IGF's were not actually 
purified and sequenced until 1976 (reviewed in Schofield, 1992). The somatomedins 
were thought to be produced by the liver in response to growth hormone (GH), and 
promote bone elongation in an endocrine manner. Although this has proved true for 
IGF-I, IGF-II is minimally GH dependent, and is thought to be important in fetal 
growth and development. The IGF's can bind to two specific cell surface receptors 
(type 1 and 2 IGF receptor), and to a lesser extent with the insulin receptor (IR), and 
their action is regulated by high affinity IGF binding proteins (IGFBP), of which six 
have so far been identified. The IGF's were discovered through three independent 
areas of research: 1) investigation of the endocrine mediators of GH action, 2) 
analysis of insulin-like activity in plasma and 3) purification of autocrine factors 
secreted by rat cell lines, that could sustain their growth in serum-free conditions.
1.2.1.1 Growth hormone action
The first discovery of the IGF's came from research into the effect of GH on cartilage 
growth in the rat. Hypophysectomised rats have a defect in the synthesis of matrix 
proteins, that can be reversed by administration of GH. This effect could not be seen, 
however, when GH was added to cartilage in vitro, but was corrected by the addition 
of normal rat serum (Salmon and Daughaday, 1958). Serum from 
hypophysectomised rats was inactive, suggesting that serum-borne factors were 
mediating the effect of GH, and these were termed sulphation factors or the 
somatomedins. The somatomedin hypothesis (Daughaday, 1989) has been confirmed 
by several groups, but now also encompasses autocrine and paracrine effects of the
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somatomedins, as GH directly injected into cartilage plate of the tibia stimulates 
growth in the bone (Isaksson et aL, 1985), that can be blocked by antibodies against 
IGF-I (Schlechter et al., 1986). Multiple somatomedins were purified by a number of 
groups, and given several names (somatomedin A, C, basic), although all have been 
shown to be identical to IGF-I (Humbel, 1990)
1.2.1.2 Non-suppressible insulin-like activity (NSILA)
The production of antibodies to insulin allowed several workers (Slater et al., 1961; 
Leonards et al., 1962) to show that insulin did not account for total insulin-like 
activity in plasma. Intensive research into the other components led to the 
purification of an activity that was partially extracted in acid ethanol (non 
suppressible insulin-like activity soluble, NSILA-S). Rinderknecht and Humbel 
(1976) discovered two distinct but similar peptides in this fraction, and purification 
and sequencing showed their close homology to insulin (Rinderknecht and Humbel, 
1978a, b). Due to the close similarity in structure and activity, they were designated 
IGF-I and IGF-II.
1.2.1.3 Multiplication-stimulating activity (MSA)
MSA, an autocrine growth factor, was partially purified by Dulak and Temin (1973), 
in a rat liver cell line (BRL-3A), that grew well in the absence of serum. Further 
purification and characterisation was performed by several laboratories, but it was not 
until 1981 that the growth factor was finally sequenced (Marquardt et al., 1981), and 
found to be nearly identical to human IGF-II (94% amino acid homology).
The three independent lines of research, mentioned above, were therefore, 
investigating the same peptides, but the difference in the research areas, highlights the 
complex number of interaction the IGF's can elicit. The advancement in techniques 
for purification and measurement of the IGF's has indicated their involvement in a 
large number of processes within the body.
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1.2.2 IGF genes
IGF-I and II mRNA are both transcribed from single copy genes, IGF-I on 
chromosome 12 and IGF-II, contiguous (3') with the insulin gene on chromosome 11 
(Daughaday, 1988; Humbel, 1990) (Figure 1.6). The human IGF-I gene contains five 
exons, is at least 90kb long, and has two distinct transcription products with different 
3' regions, which arise by alternative mRNA processing; IGF-IA containing exons
1.2.3 and 5, whilst IGF-IB contains exons 1,2,3 and 4 (Figure 1.6A). The human 
IGF-II gene is about 30kb long, and consists of four promoters, five non-coding exons 
and three protein-coding exons (Figure 1.6B). The presence of multiple promoters 
and polyadenylation signals can generate a plethora of mRNA products, with northern 
analysis of IGF-II mRNA often showing up to 6 separate transcripts.
1.2.2.1 IGF gene expression
IGF-I and II mRNA species are found in a number of tissues (Daughaday, 1988), and 
can be regulated by several developmental and hormonal signals. The main regulator 
of IGF-I gene expression is GH, which can increase IGF-I mRNA in selected tissues, 
but it is also regulated by a number of hormonal, nutritional and developmental 
factors. The factors regulating IGF-II mRNA expression are poorly understood. In 
the rat, expression is highest during fetal development, and declines in the postnatal 
period, however it stays relatively high in most adult human tissues. This method of 
this attenuation in the rat is not understood, but maybe due to the lack of the promoter 
PI, present in human liver.
1.2.3 Protein structure
Purification and sequencing of IGF-1 (Rinderknecht and Humbel, 1978a) and II 
(Rinderknecht and Humbel, 1978b) from Cohn fraction IV of plasma has been 
verified by the isolation of their cDNAs (Jansen et al., 1983; Bell et al., 1984). IGF-I 
is a 70 amino acid peptide with a predicted molecular weight, by mass spectrometry, 
of 7648.7 daltons, whilst IGF-II is a 67 amino acid peptide with a predicted weight of
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Figure 1.6A Structure of the human IGF-I gene, with the two main mRNA
transcripts. Shaded boxes represent exons, with zig-zag lines, mRNA 
splicing (adapted from Humbel, 1990).
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Figure I.6B Structure of the human IGF-II gene. Promoters labelled P I-4. Boxes 
represent exons that are non-coding (open) or code for prepro-IGF-II 
(shaded). The six main mRNA transcripts are indicated, with zig-zag 
lines representing mRNA splicing (adapted from Humbel, 1990).
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7649.4 daltons. They share -75% homology with each other and are closely related 
to pro-insulin (-50% homology). Prepro-insulin contains an N-terminal signal 
sequence, and pro-insulin (Figure 1.7) has three distinct domains termed A, B and C. 
Mature IGF's have domains with homology to these, but also have a carboxy terminal 
extension (D domain), and in addition, in pro-IGF there is a carboxy terminal 
extension (E domain). With IGF-I, two distinct precursor peptides have been 
predicted from the cDNA (Jansen etal.^ 1983; Rotwein, 1986); IGF-IA contains 153 
amino acids, and the IGF-IB precursor 195 residues. The amino acid sequences of the 
two peptides are identical for the first 130 amino acids, with the IGF-IA precursor 
containing another 23 residues and the IGF-IB precursor, another 65. The primary 
amino acid sequence of IGF-II includes a 24 amino acid signal sequence, 67 residue 
mature IGF-II and an 89 amino acid carboxy terminal extension (E Domain). Both 
the IGF's are highly conserved between species, with mature IGF-I showing only 4 
amino acids differences between human, rat and mouse IGF-I, and 100% homology 
with bovine and porcine IGF-I, whilst IGF-II shows conservation not only in mature 
IGF-II (61/67 amino acids identical) but also in the E Domain (68/89 amino acids 
identical), between human, rat and mouse IGF-II (Daughaday, 1988).
1.2.3.1 Processing of precursors
As mentioned above, both IGF's are initially translated as precursor peptides (Prepro- 
IGF), containing a recognised signal sequence, cell-free translation studies indicating 
for both IGF-I (Rotwein et al., 1987) and IGF-II (Yang et a i, 1985a), that the N- 
terminal leader peptide can act as a cotranslationally cleaved signal sequence. 
Cleavage and processing of prepro-IGF to pro-IGF occurs by signal peptidase, upon 
sorting of the peptide to secretory vesicles (Yang et al., 1985a). Very little is known 
about the enzymes involved in cleavage of pro-IGF to the mature growth factor, but 
three lines of evidence indicate that for IGF-II, several cleavages occur within the E- 
domain: 1) Pro-IGF-I and II both have an arginine residue at the first position of the 
carboxy terminal E domain (Rinderknecht and Humbel, 1978a, b) suggesting that a
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Figure 1.7 Diagramatic representation of human insulin and IGF prepro peptides. 
The shaded areas in IGF peptides represent sequences with close 
homology with the A and B chain of insulin (adapted from Bell et al., 
1984).
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cleavage enzyme with a monobasic recognition site is responsible for processing, 2) 
Yang et al. (1985b) showed that by biosynthetically labelling the rat liver cell line, 
BRL-3A, intracellular IGF-II was discovered as 20kDa pro-IGF-II, but outside the 
cell as 19, 16, 15, 10, 8 and the mature 7kDa form and 3) the discovery of a plethora 
of large molecular weight forms of IGF-II in human serum (Table 1.2). Although 
mature IGF-I and II peptides are cleaved at single arginine residues, processing of 
amino acids most often occurs at pairs of basic amino acids, there being four such 
pairs, in the E domain of IGF-II (Rinderknecht and Humbel, 1978b), which may give 
rise to the number of different forms of IGF-II detected in the BRL-3A cell line, and 
in serum. Purification and characterisation of these large forms will be essential for 
complete elucidation of the processing system, and to discover what role this plays in 
regulation of the activity of the two growth factors.
1.2.3.2 Large forms of IGF-II
In the 15 years since Rinderknecht and Humbel purified and sequenced IGF-II, a 
number of precursor forms have been detected in a wide variety of sources, which fall 
into three main areas: 1) rat cell line conditioned media, 2) normal human body 
fluids, and 3) tumour tissue and serum (selection from category 2 and 3 in Table 1.2). 
High molecular weight forms of rat IGF-II were first discovered by Moses et al. 
(1980), in the BRL-3A cell line as 16 (MSA I), 8.7 (MSA II) and 7.1 (MSA-IH) kDa 
peptides, and further purification and characterisation by Rechler et al. (1981), 
indicated that these were partially processed forms of IGF-II. Yang et al. (1985b) 
showed the presence of 19,15,10, 8 and 7kDa forms of rat pro-IGF-II, and Hylka et 
al. (1985) discovered a fragment of pro-IGF-II corresponding of Met^^^ to lys^^^, 
which is the last forty amino acids of the carboxy terminal extension (E domain). All 
lines of evidence suggest therefore that rat pro-IGF-II is converted to the mature form 
by a number of cleavages of the E domain.
Human IGF-II was initially purified as a large precursor form by Zumstein et al. 
(1985), with sequencing of a lOkDa species from human serum indicating that it
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M.wt
(kDa)
Amino acid 
substitution
E domain Reference
Normal
Spinal fluid 9 ND ND Haselbacher et al. 
(1982)
Serum 10 ser^^—>CGN Arg68 to
Lys^^
Zumstein et al. (1985)
Serum 15 None ND Gowan et al. (1987)
Serum 8 ser29-^RLPG ND Hampton et al. (1989)
Tqmour serum
Leiomyosarcoma 10 ND ND Daughaday et al. 
(1988)
Adrenal
pheochromocytomas
10 ND ND Haselbacher et al. 
(1987)
Hepatomas 10 ND ND Daughaday et al. 
(1990)
Table 1.2 Selection of high molecular weight form of IGF-II detected in human 
serum and spinal fluid from normal and cancer patients. E domian 
represents the number of amino acids extrension on mature IGF-II. 
ND - not determined.
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contained mature IGF-II with a 21 amino acid extension from Arg^^ to Lys^^. 
Although large forms of IGF-II have been identified in human spinal fluid 
(Haselbacher and Humbel, 1982), extracts of brain, pituitary and mesenchymal 
tumours (Haselbacher et al., 1985), serum and tissues of foetuses (Hill, 1990), 
tumours associated with hypoglycaemia (Daughaday et al., 1988; Zapf et al., 1992) 
and colon-carcinoma cell lines (Tricoli et al., 1986; Culouscou et al., 1990), their 
purification and characterisation has proved difficult. Hudgins et al. (1992) purified a 
15kDa form of IGF-II from human serum, that contained mature IGF-II, with the 21 
amino acid extension seen by Zumstein et al. (1985), but was posttranslationally 
modified on Thr^^ in the E domain, by 5kDa of 0-linked glycosylation (Hudgins et 
al., 1992). The significance of this modification is as yet unknown. The cleavage of 
pro-IGF-n at single basic amino acids (Arg^^ and Lys^^), the ability for cleavage at 
four pairs of basic amino acids, and posttranslational modification provides the 
possibility for generation of a plethora of precursor peptides, with different length 
carboxy-terminal extensions.
1.2.3.3 Biological activity of large forms of IGF-II
Partial processing of mature IGF-II, either directed by the cell, or due to saturation of 
processing enzymes, may provide another level of regulation for IGF-II. For this 
reason, several workers have investigated the biological activity of large forms of 
IGF-II, but the majority of the data remains conflicting, due to the different assay 
techniques used, and the different forms of IGF-II purified. Zumstein et al. (1985) 
showed that a lOkDa form of IGF-II was less active in a rat fat cell bioassay than 
mature IGF-II, whilst Haselbacher and Humbel (1982) indicated that a 9kDa species 
purified from human spinal fluid was more potent than mature IGF-II at stimulation 
of [^H]-thymidine incorporation in NIH3T3 cells. More recent and detailed studies 
have indicated that the presence of a carboxy-terminal extension on mature IGF-II, 
does not affect binding to type 1 IGF receptor (Perdue et al., 1991), or type 2 IGF
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receptor and IGFBP-2 (Gowan et al., 1987). No recent investigations have been 
performed on the activity of large forms of IGF-II secreted by tumours.
1.2.4 Insulin-like growth factor receptors
Early binding studies indicated that not only did IGF-I and II interact with the insulin 
receptor (IR), but that they had their own high affinity receptors, termed the IGF-I and 
IGF-n receptors (Kasuga et al., 1981; Rechler and Nissley, 1985). However, the 
complex nature of the interactions of the three ligands (In, IGF-I and IGF-II), with the 
two receptors, led them to be renamed type 1 IGF receptor (previously IGF-I 
receptor) and type 2 IGF receptor (previously IGF-II receptor). The type 1 IGF 
receptor is structurally homologous to the IR, being a ligand-stimulated tyrosine 
kinase (Figure 1.8). The receptor can bind both IGF-II and In (Table 1.3), and clearly 
mediates most of the effects of both IGF-I and II. The type 2 IGF receptor, is 
structurally homologous to the mannose-6-phosphate receptor, which is involved in 
targeting of proteins containing this moiety to lysosomes. The role of this receptor, if 
any, in IGF signalling, remains unclear.
1.2.4.1 Type 1 IGF receptor
Structurally similar to the IR, the type 1 IGF receptor is a heterodimer of 350kDa that 
can be reduced to 135 and 95kDa peptides by dithiothreitol (Jacobs et al., 1983; 
Rubin et al., 1983) (Figure 1.8). The receptor has a high affinity for IGF-I (Kd 1x10" 
9m), but can cross react with both IGF-II (0.5x10"^M) and In (lxlO"^M), eliciting 
both mitogenic and metabolic responses. Ligand activation results in 
autophosphorylation (Jacobs and Cuatrecasas, 1986), on four tyrosine residues in the 
cytoplasmic tail of the receptor, three of the same residues as in the IR, tyrosines 
1131, 1135 and 1136 (Moxham et al., 1989), and activates the tyrosine kinase (Yu et 
al., 1986). Although direct evidence for the role of tyrosine phosphorylation in type 1 
IGF receptor signalling is scarce, ligand activation of the receptor results in a series of 
phosphorylations inside the cell, associated with signalling by other tyrosine kinase
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Ligand Specificity Kd (xlO^M)
Insulin IGF-I IGF-II
Insulin receptor 1 0.01 0.01
Type 1 receptor 0.01 1 0.5
Type 2 receptor 0 0 0.2
Table 13  Specificity of insulin and IGF receptors for their respective ligands 
(references in text).
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receptors (Ullrich and Schlessinger, 1990). Two proteins phosphorylated by the type 
1 IGF receptor, are also the major substrates of the IR, namely ppl85, and pp240 
(Kadowaki et a/., 1987; Shemer et al.y 1987). ppl85, cloned by Sun et al. (1991), is a 
novel signal transduction protein, named insulin receptor substrate 1 (IRS-1), which 
has 35 putative phosphorylation sites throughout the protein, of which 10 are potential 
tyrosine phosphorylation sites (Myers and White, 1993). Crucially, six of these have 
the sequence Tyr-Met-X-Met (YMXM), which is thought to recruit other signalling 
proteins, via regions of proteins termed src homology 2 (SH2) domains (Felder et al., 
1993), providing recognition motifs for specific phosphotyrosine containing 
receptors. Several proteins containing SH2 domains can associate with activated 
growth factors, such as phospholipase c-y, GTPase activating protein (GAP) and 
phosphatidylinositol (PI) 3'-kinase associated p85. Ligand activation of the type 1 
IGF receptor, results in rapid phosphorylation of IRS-1, which can then associate with 
p85 and can activate PI3-kinase (Ruderman et al., 1990). Although, in many other 
cells, PI 3-kinase activity is associated with a mitogenic response, the mechanism by 
which this response is elicited is not clear, with the products of PI 3-kinase not being 
substrates for phospholipase C (Serunian et al., 1989). To date, no link has been 
made between the type 1 IGF receptor and other classical growth factor signalling 
molecules (GAP, ras, raj).
Stimulation of cells with IGF-I rapidly activates Mitosis Associated Protein 2 
(MAP2) kinase (Hoshi et al., 1988). Although no direct evidence exists for it being a 
direct substrate of the type 1 IGF receptor, it is one of only a few serine/threonine 
kinases, that is itself phosphorylated on tyrosine residues (Ray and Sturgill, 1988). 
Recent advances in the understanding of MAP proteins in receptor signalling and 
regulation of the cell cycle are beyond this introduction, but are opening up new 
avenues of research, and may be involved in type 1 IGF receptor signalling, if only 
through cross receptor pathways (Pazin and Williams, 1992).
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Whilst abundant evidence exists that the tyrosine kinase activity of EGFR is essential 
for most of the biological responses of EGF e.g. internalisation and downregulation 
(Wiley et al., 1991), there is evidence against direct involvement of tyrosine 
phosphorylation in responses of the type 1 IGF receptor. Steele-Perkins et al. (1988) 
transfected CHO cells with type 1 IGF receptor cDNA, and discovered that IGF-I 
gave the expected mitogenic and metabolic responses, but that the same effect was 
mimicked by a-IR3, a monoclonal antibody against the type 1 IGF receptor, without 
tyrosine phosphorylation. There is no explanation for this effect, with a-IR3 
normally acting as an antagonist, rather than in this instance as an agonist. The result 
may be due to the abnormally high level of overexpressed receptor, with the antibody 
simply inducing receptor oligomerisation, serine/threonine phosphorylation and 
internalisation. The number of specific tyrosine kinase inhibitors, recently developed, 
may provide further insight into the mechanism of IGF-I signalling.
1.2.4.2 Type 2 IGF receptor
Cloning and sequencing of the receptor cDNA (Morgan, 1987; MacDonald et al.,
1988), led to the prediction of the primary amino acid sequence of the type 2 IGF 
receptor (Figure 1.8). It is a single transmembrane protein of 274kDa, with 93% of 
the total protein being extracellular, composed of 15 conserved repeats of 150 amino 
acids containing a highly conserved pattern of eight cysteine residues, and 19 N- 
linked glycosylation sites, important in expression of IGF-II binding activity. The 
cytoplasmic domain is hydrophilic, containing several potential phosphorylation sites, 
but has no homology with other protein tyrosine kinases.
Comparison of the sequence of the type 2 IGF receptor to other proteins led to the 
discovery that it was 99.4% homologous with the mannose-6-phosphate (M-6-P) 
receptor, which recognises M-6-P moieties on acid hydrolases and other proteins, and 
targets them to lysosomes. The binding site for M-6-P is distinct from that for IGF-II, 
with binding of one ligand, decreasing the affinity for the other (Braulke et al., 1988;
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Waheed et al., 1988). The finding that the receptors are one of the same, raised the 
obvious question, as to whether the receptor mediated any of the effects of IGF-II. 
The answer however, has not been that simple, with conflicting data arguing for and 
against a role in IGF-II signalling. H35 hepatoma cells, that express both IR and type 
2 IGF receptor at the same level, need 1000 times the concentration of IGF-II as 
insulin for stimulation of DNA synthesis (Massague et al., 1982; Koontz, 1984). This 
suggested therefore, that IGF-II was acting via the IR, which has a lower affinity for 
IGF-n, and Mottola and Czech (1984), went on to show that IGF-II-stimulated DNA 
synthesis was not affected by antibodies against the type 2 IGF receptor, again 
suggesting that the response was not through this receptor. Several other studies have 
analysed potencies of the IGF’s, and the effect of blocking specific receptors, and 
generally concluded that the response to IGF-II is not mediated through the type 2 
IGF receptor.
Although the majority of evidence is against a mitogenic role for the type 2 IGF 
receptor, a few studies have indicated that some effects may be mediated via this 
receptor. Evidence for a proliferative signal, comes from K562 human 
erythroleukemia cells, which are stimulated to grow by both IGF-I and II, but contain 
no detectable type 1 IGF receptors (Blanchard et al., 1988). However, the 
measurement of receptor levels, using binding and cross-linking studies, provided no 
indication of receptor number and may not have been able to detect low levels of type 
1 IGF receptor. The results are difficult to interpret due to cross-reactivity of the 
ligands for the receptors, and the presence of binding proteins in the membrane, that 
can bind radiolabelled ligand. The evidence provided against the presence of type 1 
IGF receptors, was the low binding of 125i_igf-I to membrane preparations. 
However, the low binding of radiolabelled-insulin led the group to suggest that cells 
do not contain detectable levels of IR, whereas other groups have shown that the same 
cells contain IR (Tang et al., 1983). The high affinity of IGF-I for the type 1 IGF 
receptor, means that it is of paramount importance to determine whether these cells 
actually contain small amounts of receptor, to confirm a role for the type 2 IGF
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receptor, or other studies, such as blocking the type 2 IGF receptor with antibodies or 
other ligands (e.g. cathepsin D), must be performed.
In breast cancer cells, the mitogenic effect of both IGF-I and II on a range of cell lines 
has been investigated (discussed in more detail in Section 1.3.2), with both growth 
factors showing extreme potency (Karey and Sirbasku, 1988). Studies investigating 
the response to these growth factors have shown that most of the mitogenic effect of 
IGF-II can be blocked by a-IR3, an antibody to the type 1 IGF receptor, suggesting 
that the response is mediated via this receptor (Arteaga and Osborne, 1989). 
However, a number of these studies have been at high concentrations of IGF-II, when 
it is known to elicit a response through the type 1 IGF receptor. Mathieu et al. (1990) 
have shown that by using lower concentrations of IGF-II (0.5nm), whereby it is all 
cross-linked to the type 2 IGF receptor, a-IR3 has no effect on the response, and that 
cathepsin D, another ligand for the receptor, can block the effect of IGF-II, suggesting 
a role for the receptor in eliciting a mitogenic response.
Several papers have suggested that IGF-II signalling is coupled to G-protein 
pathways. IGF-II can increase inositol triphosphate production in renal basolateral 
membranes, which do not have insulin or type 1 IGF receptors (Rogers and 
Hammerman, 1988; Rogers et al., 1990). IGF-II can also mobilise Ca^+ in EGF 
primed Balb/3T3 cells, which can be blocked by pertussin toxin, suggesting that a G- 
protein is involved in signalling (Nishimito et al., 1987). Further studies by this 
group have shown that a Gi-2 protein is involved (Nishimito er al., 1989), and that 
there is a specific recognition sequence in the intracellular domain of the type 2 IGF 
receptor (Okamoto et al., 1990). When purified type 2 IGF receptor and G protein are 
incubated together in phospholipid vesicles, GTPys reduces the affinity of the 
receptor for IGF-II, whereas, IGF-II increases the binding of GTPys to the G protein.
Furthermore, IGF-II can stimulate phospholipase C-mediated production of inositol 
phosphate, which is increased by GDPyg, but unaffected by GTPys. Several reports
therefore suggest a role for the type 2 IGF receptor in mediating a response to IGF-II,
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and that it may be by signalling pathways involving G-proteins. This would, 
however, be the only G-protein coupled receptor to be a single transmembrane 
protein, and not the classical seven transmembrane spanning receptor.
1.2.4.3 Hybrid receptors
Mutant receptors consisting of chimeras of both insulin and type 1 IGF receptor, 
arising naturally or engineered, have provided a great deal of information on the 
specificity of the two IGF receptors for their respective ligands, and their methods of 
signalling. Andersen et al. (1990), recombinantly produced a chimeric IR, that had 
the first 295 N-terminal amino acids replaced with the corresponding amino acids 
from the type 1 IGF receptor. The chimeric receptor had similar IGF-I binding 
properties to normal type 1 IGF receptors, and Gustafson and Rutter (1990) went on 
to produce a series of chimeras of IR with sections of type 1 IGF receptor, and found 
that amino acids 223-274 determine the specificity for binding IGF-I. Workers have 
discovered mutant receptors, occurring naturally, which can transduce a signal 
(Stumpo and Blackshear, 1991), however, these mutant receptors are often inactive 
(Treadway et al., 1991) and may be responsible for a certain number of genetic 
conditions where the IR is mutated with type 1 IGF receptor, leading to reduced 
insulin and IGF-I binding, possibly resulting in leprechaunism (Van Obberghen- 
Schilling et al., 1981) and insulin-resistance (Frattali et al., 1992).
1.2.5 Insulin-like growth factor binding proteins (IGFBP)
The regulation of growth factor activity usually occurs by a number of mechanisms. 
A few of these are; 1) levels of growth factor, 2) levels of specific receptor, 3) 
presence of signal transduction pathway. The identification and purification of 
specific high affinity insulin-like growth factor binding proteins (IGFBP) has 
highlighted another level of regulation, whose complexity may provide as much 
control of IGF action as all three points above. The existence of IGFBP was 
suspected for many years, by a series of observations that could not be solely
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explained by the IGF's. Daughaday and Kipnis (1966) found that under neutral 
conditions, the somatomedins eluted with a high molecular weight, and Burgi et al. 
(1966) estimated the activity in serum to be between 75 and 150kDa, which could be 
reduced to approximately lOkDa by acid treatment of the serum. The existence of a 
carrier protein for IGF's in serum, was also consistent with work by Daughaday et al. 
(1968), who showed that in hypophysectomised rats, somatomedin activity took 
longer to disappear than insulin. The purification and characterisation of IGFBP's has 
enabled the cloning of six distinct peptides (Table 1.4), which all arise from different 
genes, and share little overall homology (Baxter and Martin, 1989; Krywicki and Yee, 
1992). Crucially, all forms do share homology in the position and number of cysteine 
residues, all human forms having 18 conserved cysteines (12 N-terminal, 6 C- 
terminal), except for IGFBP-4 that has cysteines in the middle portion, and IGFBP-6 
that has 16 cysteines (two less at N terminal). All forms vary in their glycosylation 
and phosphorylation, and some contain RGD amino acid sequences near their 
carboxy-terminus, which may mediate cell-attachment (Table 1.4).
The family of IGFBP's, can be regulated by a number of factors, and are found at 
varying levels in a number of tissues, suggesting that each may have different 
functions, the complexity of which has been highlighted when the effect of the 
IGFBP's on IGF action have been analysed. IGFBP-1 expression can be decreased by 
insulin (Suikkari et a l, 1988), increases with fasting (Busby et al., 1988), diabetes 
(Brismar et al., 1988) and markedly during pregnancy (Drop et al., 1984). IGFBP-2 
on the other hand, is increased by diabetes, fasting and IGF-I, but is not affected by 
insulin (Ooi et al., 1990; Zapf et al., 1990). IGFBP-3 shows interesting regulation, 
different to IGFBP-1 and 2, in that growth hormone can induce IGFBP-3 expression, 
and the level is raised in patients with acromegaly (Baxter and Martin, 1986). 
Expression of IGFBP-3 can be increased by a number of growth factors (insulin, 
vasopressin, bombesin, platelet-derived growth factor, epidermal growth factor), and
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reduced by steroids (Corps and Brown, 1991). The expression of IGFBP in breast 
cancer cells and tissue is discussed in Section 1.3.5.
1.2.5.1 Biological activity
Studies on the effect of IGFBP on IGF activity, has received much attention since 
their purification and cloning, but has highlighted a complex number of interactions, 
with binding proteins being either stimulatory, by presenting IGF to the receptor, 
inhibitory, by sequestering IGF from the receptor, or simply increasing the half-life of 
the growth factor.
The simplest form of regulation by binding proteins, sequestration of the growth 
factor, resulting in a decreased activity, has been shown by a number of workers, with 
preparations of IGFBP-1 and 3 blocking association of IGF-I with the receptor in a 
number of cell lines, and reducing IGF-I mitogenic (Liu et a i, 1991) and anabolic 
effects (Ritvos et a i, 1988). Further support for this type of regulation of IGF 
activity comes from the production of mutated IGF-I peptides, that have lower 
affinities for binding proteins, whereby loss of the first three amino acids of IGF-I 
results in decreased affinity for IGFBP, and increased activity compared to native 
IGF-I (Ross et a i, 1989).
Studies have also shown, however, that IGFBP can potentiate the action of IGF's, 
with both IGFBP-1 and 3 increasing the mitogenic activity of IGF-I on human 
fibroblasts, and IGFBP-1 accentuating IGF-I mitogenic activity nearly 10-fold in a 
range of cell lines (Elgin et a i, 1987; Blum et a i, 1989). The most probable 
explanation for this activity, lies in the RGD sequence present in these binding 
proteins, which enables association with cell membranes, and so presentation of the 
IGF-I to the type 1 IGF receptor. IGFBP-3, however, does not have a RGD sequence, 
but is glycosylated, and so presumably associates with the cell membrane via a 
carbohydrate interaction.
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Two more pieces of evidence indicate the complex regulation of IGFBP action, and 
the difficulty in interpretation of results. De Mellow and Baxter (1988) found that 
IGFBP-3 could either inhibit or potentiate the effects of IGF-I depending upon the 
conditions chosen, and Elgin et al. (1987) stressed the importance of additional 
serum-derived factors when they saw potentiation via IGFBP-1. Interestingly, 
another level of regulation has been discovered by Jones et al. (1991), with 
phosphorylation of IGFBP-I increasing its affinity for IGF-I 6-fold.
1.2.6 IGF's in human disorders
1.2.6.1 Endocrine/paracrine effects
Two disorders of IGF-I secretion indicate its role in mediating growth hormone (GH) 
effects, namely acromegaly and dwarfism. In acromegaly, GH secreting tumours 
result in increased serum IGF-I levels (Hall and Sara, 1984), whilst in Laron dwarfs, a 
defect of the GH receptor leads to reduced serum IGF-I concentrations (Zapf et al., 
1981). Several other disorders result in a lowering of serum IGF-I concentration, 
such as malnutrition, insulin deficiency and liver disease (Zapf and Froesch, 1986). 
A number of tumours such as Wilm's, neuroblastoma, hepatoblastoma, 
pheochromocytoma, leiomyoma etc. (reviewed in Cullen et al., 1991), synthesise 
IGF-II mRNA constitutively, however, as with IGF-I, the endocrine and autocrine 
effects of this growth factor are poorly understood.
In one interesting example of IGF-II expression, Daughaday has shown the endocrine 
effects of IGF-n, and highlighted the importance of analysing both IGF-II mRNA and 
the nature and sizes of secreted IGF-II peptide. Patients with leiomyosarcoma, 
fibrosarcoma, haemangiopericytomas and hepatomas, often suffer from extra- 
pancreatic hypoglycaemia, with suppressed levels of both GH and serum IGF-I 
(Daughaday et al., 1988; Daughaday et al., 1990). Although most of these tumours 
express high levels of IGF-II mRNA, measurement of serum IGF-II by 
radioimmunoassay (RIA) often indicated no change or only a slight increase in IGF-II
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levels (Zapf et al., 1981). An important step in the understanding of the development 
of non-islet cell tumour hypoglycaemia (NICTH), came from Daughaday et al. (1988) 
who described a patient with leiomyosarcoma and hypoglycaemia, whose serum IGF- 
II level was normal by RIA, but by gel fractionation, existed mainly (70%) in a large 
form, termed big IGF-II. Removal of the tumour reduced the serum concentration of 
big IGF-n, with concomitant loss of hypoglycaemia. Elucidation of the mechanism 
whereby big IGF-II causes hypoglycaemia, came from studies by Daughaday (1988), 
who showed that big IGF-II preferentially bound to IGFBP-2 in a 50kDa complex, 
whereas normal serum IGF-II circulated in a complex with IGFBP-3, and an acid 
labile subunit, with a total mass of 150kDa. Baxter and Daughaday (1991) concluded 
that the IGFBP-3 bound to big IGF-II can not form the 150kDa complex, but data of 
(Zapf et al., 1992), suggest that it is the oversecretion of IGF-II that causes a decrease 
in the production of IGFBP-3 and the acid labile subunit, that leads to the formation 
of big IGF-II with IGFBP-2 (Figure 1.9). The final outcome, is that the 50kDa 
complex is able to pass across capillary membranes, is more available to target 
tissues, and so exerts an insulin-like action resulting in hypoglycaemia. The role of 
different forms of IGF-II, binding proteins, and endocrine/paracrine effects, highlights 
the problems associated with determining the role of IGF's in several disorders.
1.2.6.2 Autocrine/paracrine effects
Both IGF-I and II have been implicated in autocrine and paracrine mediated 
proliferation of a number of tumours. IGF-I is present in higher amounts in primary 
lung tumours, than in normal lung tissue (Minuto et al., 1986), and studies of a human 
lung cancer cell line (CALU-6) have indicated that cells respond to exogenous IGF-I, 
and an antibody to the type 1 IGF receptor can block autocrine-mediated proliferation 
via secreted IGF-I (Minuto et al., 1988). IGF-II has been studied in a number of 
embryonal tumours, where its mRNA is greatly upregulated (Scott et al., 1985). 
Established neuroblastoma cell lines secrete IGF-II that can act in an autocrine 
manner through the type 1 IGF receptor (El Badry et al., 1989).
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Oversecretion of big IGF-II by tumour
I
Elevation of total and free serum IGF-II 
(transient, first symptom hypoglycaemia?)
I
Supression of 
-GH 
-In
- IGF-II
Decreased production of
- IGFBP-3
- IGF-I
- acid labile subunit
Increased production of
- IGFBP-2
- (IGFBP-1?)
Sequestrationof IGFBP-3 into 50kDa complex 
and reduction of 150kDa complex
Shift of IGF-II (mainly big) to 50kDa complex
Increased bioavailability of IGF-II
Supression of
- hepatic glucose production
- lipolysis
HYPOGLYCAEMIA
Figure 1.9 Suggested mechanism for the development of non-islet cell tumour
hypoglycaemia (adapted from Zapf et al., 1992).
36
The role of IGF-I in paracrine mediated proliferation of tumours was discussed in 
Section 1.1.6.2, with reference to the effect of PDGF on IGF-I synthesis in stromal 
cells, which can then in turn stimulate proliferation of breast epithelial cells.
1.3 INSULIN-LIKE GROWTH FACTORS IN BREAST CANCER
1.3.1 Introduction
In the last five years, a growing body of evidence has linked the IGF's with both 
oestrogen action, and breast cancer (Westley and May, 1991; Yee, 1992), but research 
has been hampered, by technical difficulties in measuring both IGF peptide and 
mRNA, and then interpreting results, with cross reactivity between two ligands, two 
receptors, and effects of up to six binding proteins. Initial observations of IGF-like 
immunoreactivity in conditioned media (CM) of breast cancer cells were compounded 
by the presence of binding proteins, that could bind the radiolabelled ligand, in RIA. 
The development of a standard technique for the removal of binding proteins prior to 
RIA, subsequently indicated that no breast cancer cell lines investigated secreted IGF- 
I. Analysis of IGF-I mRNA, has also proved difficult, but the inability to detect any 
by RNase protection in a range of breast cancer cell lines, seem to confirm the lack of 
secreted IGF-I
Together with technical difficulties in analysis of the IGF's, the interpretation of data 
is extremely difficult, because if all factors are considered, including the ability for 
autocrine, paracrine, or endocrine mediated effects, cross-reactivity between ligands 
and receptors and the effect of binding proteins, the possibility of interactions is vast. 
However, this may provide a clue as to their importance, because any growth factor 
with such an crucial role in the proliferation of normal and neoplastic cells, which is 
such a potent mitogen, would be expected to be under strict regulatory control. The 
discovery that oestrogen can alter IGF peptide, receptor and binding protein levels, 
provides a strong argument for a role in oestrogen action (summarised in Table 1.5).
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1.3.2 IGF peptides
IGF-I and II are both potent mitogens for a range of breast cancer cells (Karey and 
Sirbasku, 1988), with increased proliferation al picomolar to nanomolar 
concentrations in vitro. In MCF-7 cells, oestrogen increases the effect of IGF-I 
(Stewart et al., 1990), due to induction of the type 1 IGF receptor mRNA and protein, 
whilst anti-oestrogens inhibit the response (Wakeling et al., 1989). A monoclonal 
antibody to the type 1 IGF receptor, a-IR3, can block the mitogenic response to IGF- 
I, suggesting that proliferation is signalled via this receptor, and this antibody also 
blocks most of the effects of IGF-II (Arteaga and Osborne, 1989). Retinoic acid can 
also inhibit IGF-I action, which may be mediated by increased secretion of binding 
proteins, that can then sequester the growth factor from the receptor (Fontana et al.,
1991).
The low levels of IGF secreted by breast cancer cells, and the presence of binding 
protein, have made measurement of both growth factors difficult. Early reports of 
IGF-I-like immunoreactivity in MCF-7 conditioned media, performed by RIA, with 
no acid-ethanol extraction were due to binding proteins interacting with the 
radiolabelled ligand (Ahmed et al., 1989). However, acid chromatography by Huff et 
al. (1986), indicated a 13kDa immunoreactive IGF-I-like peptide, and other groups 
also detected an immunoreactive species that comigrated with IGF-I (Minuto et al., 
1987; Karey and Sirbasku, 1988). The inability to detect IGF-I mRNA in any breast 
cancer cell lines (Ahmed et al., 1989), would seem to confirm the lack of IGF-I 
detected in conditioned media from breast cancer cells. However, the detection of 
IGF-I-like peptides has yet to be explained, with the possibility that authentic IGF-I is 
secreted, but at levels that are significantly lowered following the removal of binding 
proteins, and so difficult to detect by RIA.
IGF-II peptide has only been detected in a small number of breast cancer cells such as 
T47D and MCF-7 (Osborne et al., 1989). Again, detection of IGF-II peptide has 
proved difficult due to the presence of secreted binding proteins, but IGF-II mRNA
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has also been discovered in these cell lines (Yee et al., 1988; Osborne et al., 1989). 
The data for IGF-II peptide levels are controversial, as generally 50% of the peptide is 
lost through IGFBP removal, and the resulting level of peptide (rarely >100ng IGF- 
n/ml conditioned media) is at the limit of confident detection by RIA. Consistent 
with these technical difficulties, no studies have been performed on the sizes of the 
IGF-II secreted.
Clearly, with the IGF's being such potent mitogens, at such low concentrations, 
measurement of the peptide is essential. Due to the difficulties encountered in cell 
lines, no studies have yet been performed on IGF peptide levels in tumours.
1.3.3 IGF mRNA expression
Initial investigation of IGF-I mRNA expression in breast cancer cell lines, gave 
confusing results, with multiple hybridising bands, that were not present in normal 
liver (Yee et al., 1989). Analysis by RNase protection, indicated that none of the 
breast cancer cell lines contained detectable levels of IGF-I mRNA (Ahmed et al.,
1989). IGF-II is expressed by only a minority of breast cancer cell lines such as 
MCF-7 and T47D (Yee et al., 1988; Osborne et al., 1989). The rare expression of 
IGF-I and II in established breast cancer cell lines is in stark contrast to the clinical 
situation, whereby IGF-I is detectable in nearly all breast tumour specimens (Yee et 
al., 1989). The reason for this anomaly, is the site of expression of IGF-I, being 
mainly stromal, and not epithelial. The same situation exists for IGF-II expression, 
although rare in breast cancer cell lines, it can be detected in most breast tumour 
specimens (Yee et al., 1988), again with expression mainly confined to breast stromal 
cells and higher in fibroblasts from malignant lesions, than benign (Singer et al.,
1992). IGF-II mRNA has been detected by in situ hybridisation in epithelial cells in 
breast tumour specimens (Paik, 1992).
Oestrogen and progestins can upregulate IGF-II mRNA in both T47D and MCF-7 
cells (Yee et al., 1988; Osborne et al., 1989; Papa et al., 1991), with increased
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secretion of IGF-II resulting in downregulation of the type 1 IGF receptor (Papa et al., 
1991). No studies have shown oestrogen effects on the level of secreted IGF-II 
peptide. The most recent evidence for oestrogen regulation of IGF-II mRNA 
expression, comes from xenograft studies by Brunner et al. (1992), who has shown 
that oestrogen can regulate IGF-II mRNA expression in ER-positive MCF-7 
xenografts, without having an effect on the high constitutive expression by ER- 
negative MDA-231 xenografts.
1.3.4 IGF receptors
De Leon et al. (1988) indicated that the majority of breast cancer cell lines have type 
1 and 2 IGF receptors. However, this study was performed by ligand-binding and 
cross-linking studies, which are difficult to interpret, due to the cross-reactivity of the 
two receptors, (Section 1.1.2.3) and also the presence of membrane-bound IGFBP, 
that can bind radiolabelled ligand (Section 1.1.2.5). To eliminate this problem, 
Cullen et al. (1990) studied IGF receptor mRNA in breast cancer cells and tissue. 
Nearly all breast cancer cell lines examined contained detectable levels of type 1 IGF 
and 2 IGF receptors, along with IR. In agreement with this observation, most breast 
tumour specimens also contained both IGF receptor mRNA (Cullen et al., 1990). 
Two other studies have also shown the presence of type 1 IGF receptors in malignant 
breast tissue (Pollack et al., 1987; Peyrat et al., 1988).
Oestrogen can regulate both protein and mRNA levels of type 1 IGF receptor 
expression in MCF-7 cells (Stewart et al., 1990), which was confirmed by (Freiss et 
al., 1990), who also showed that 4-hydroxytamoxifen could decrease the level of type 
1 IGF receptor in two ER-positive cell lines (T47D and MCF-7), but had no effect in 
an ER-negative cell line (BT-20). Papa et al. (1991), indicated that progestins could 
decrease IGF-I receptor levels in T47D cells, but this was not only a result of 
decreased mRNA expression, but also due to increased IGF-II production, which 
downregulated the type 1 IGF receptor. The effects of oestrogen on type 1 IGF 
receptors in cell lines, is paralleled in the clinical situation, by a positive correlation
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between ER-status and type 1 IGF receptor levels (Pekonen et al., 1988; Peyrat et al., 
1988).
Oestradiol down-regulates both type 2 IGF receptor protein and mRNA, in MCF-7 
cells (Mathieu et al., 1991). The authors suggest that this is due to increased 
secretion of both IGF-II and pro-cathepsin D, two ligands for the type 2 IGF receptor.
1.3.5 IGFBP
The presence of IGFBP in CM was discovered when measurement of IGF-I showed 
that IGF-immunoreactivity often migrated at high molecular weights. De Leon et al. 
(1988) demonstrated that four breast cancer cell lines secreted different binding 
proteins, with ER-positive cells (MCF-7 and T47D) secreting a 27kDa BP, whilst ER- 
negative cells (MDA-231 and HS578T) secreted a 24kDa BP. Clemmons et al. 
(1990) also showed ER-status dependent IGFBP expression in a range of breast 
cancer cells, with ER-positive cells secreting 24 and 34kDa BP, and ER-negative 
cells secreting 24, 29 and 43kDa BPs. Yee et al. (1991) have analysed mRNA 
expression of IGFBP in a range of breast cancer cell lines, to confirm the previous 
cross-linking studies, and the results are presented in Table 1.6.
A recent report by Figueroa et al. (1993), examining IGFBP mRNA expression in 
human breast tumour specimens would seem to substantiate the data obtained from 
cell lines. IGFBP 2-6 mRNA were found in all of 40 tumours, with a lack of any 
IGFBP-1 mRNA. Furthermore, IGFBP-3 was higher in ER-ve tumours, whilst 
IGFBP 4 and 5 were higher in ER+ve specimens, confirming the pattern seen in 
breast cancer cell lines. This group also performed the important verification of 
performing ligand blot analyses on the tumour specimens, to indicate that mRNA 
levels were predictive of IGFBP protein expression.
Although there is little data on the regulation of IGFBP expression by oestrogen, the 
data so far indicates differential regulation throughout the BP's. Clemmons et al. 
(1990) first indicated that IGFBP 2 and 4 were upregulated by oestradiol in MCF-7
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cells, which was confirmed by Figueroa et al. (1993) who also showed oestradiol 
induction of BP 2,4 and 5, and that, 4-hydroxytamoxifen caused a decrease in IGFBP 
3 mRNA expression. However, the significance of these results is lessened by the 
fact that two other groups have not been able to show oestrogen-regulation of IGFBP 
(Ahmed et al., 1989; Kim et al., 1991). These differences may be due, however to 
different techniques used for IGFBP detection and cell culture conditions.
1.3.6 Conclusion
Clearly, a growing body of evidence is emerging that oestrogen can alter the 
expression of several components of the IGF repertoire, with several indications that 
observations in cell culture are paralleled in the clinical situation. However, the 
number of different regulatory factors, and pathways for a mitogenic signal, makes 
any deduction of a role for the IGF's in oestrogen mediated proliferation and breast 
cancer difficult.
Complicating this are the problems associated with analysing the IGF's. The 
development of more sensitive and specific techniques has enabled identification of 
IGF-II and IGF-I-like peptides in breast cancer cells. Analysis of the peptide and 
mRNA levels, are important not only due to the potency of the growth factors, but 
also from indications of the role of IGF-II in other malignancies. For instance, in 
Wilm's tumour, IGF-II mRNA is dramatically increased, but there are only modest 
increases in levels of IGF-II peptide, whilst in contrast, in some tumours IGF-II 
mRNA is relatively constant with an increase in IGF-II peptide levels (Haselbacher et 
al., 1987). The importance of measuring the size and nature of IGF-II peptide has 
already been discussed (Section 1.2.6.1).
IGF-II expression has also highlighted the problems with drawing conclusions from 
experiments performed on established cell lines in culture. Osborne et al. (1987) 
clearly indicated clonal variation in oestrogen sensitivity of the MCF-7 cell line held 
in different laboratories. Furthermore, the recent report by Brunner et al. (1992), of
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hormonal responsive IGF-II mRNA expression in breast tumour xenografts did 
indicate that MDA-231 cells expressed mRNA, whilst earlier reports from the same 
laboratory showed no expression (Yee et al., 1988). The cells have therefore either 
changed phenotypically, or cell culture conditions affected IGF-II mRNA expression.
Two further experiments have strengthened the link between IGF-II, the type 1 IGF 
receptor, oestrogen action and breast cancer. Firstly, transfection experiments with 
IGF-II cDNA, have shown that a single growth factor, can increase the growth rate, 
and reduce steroid sensitivity of breast cancer cells. Daly et al. (1991) transfected 
oestrogen-dependent MCF-7 cells with the IGF-II gene, under the control of the 
human metallothionein HA promoter, and by switching on IGF-II mRNA, with heavy 
metal ions, were able to increase proliferation, to that of parent cells in the presence 
of oestradiol, and render the transfected cells virtually hormone-independent. This 
proliferative effect could be blocked by a-IR3, indicating that secreted IGF-II was 
acting in an autocrine manner through the type 1 IGF receptor. As seen by other 
workers, measurement of the levels of secreted IGF-II proved difficult, and no 
analyses were performed on the nature of the secreted IGF-II. Cullen et al. (1992) 
confirmed this result, by transfection of MCF-7 cells with IGF-II cDNA under the 
control of the constitutive cytomegalovirus promoter. The same reduction in steroid 
sensitivity was seen, but this group also noted changes in anchorage-dependent 
growth, and colony formation in soft agar, indicating a more aggressive phenotype.
Secondly, Arteaga et al. (1989) provided the first and only indication that blockade of 
a growth factor pathway may reduce breast tumour growth, by using an antibody to 
the type 1 IGF receptor (a-IR3) to inhibit growth of oestrogen-unresponsive MDA- 
231 cells in vivo, and so decrease tumour size and number. However, in the same 
experiment, growth of oestrogen responsive MCF-7 cells was not affected, which 
may be due to several in vivo factors. Oestrogen may have induced other factors in 
the MCF-7 cell line, that do not act through the type 1 IGF receptor (e.g. TGFa), or 
induced high levels of secreted IGF-II that could overcome the antagonist effect.
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Additionally, since this experiment, data on the effect of oestrogen on secretion of 
binding proteins, and the complex number of interaction they can perform has arisen, 
and these were not taken into account.
1.4 SUMMARY
Breast cancer is the largest cause of death from cancer in women in England, with 
25,000 new cases a year, and 15,000 deaths. The high death rate, is partly attributable 
to the inevitable progression of breast cancer from a hormone sensitive to hormone- 
independent state. This is a major clinical problem, with several treatments for 
hormone-sensitive cancers (antioestrogens, aromatase inhibitors, leutrophin releasing 
hormone agonists), but no successful treatments for the hormone-independent cancer, 
that will inevitably kill the host, if not through the breast tumour, then by metastatic 
cancer. The role of oestrogen in the progression of breast cancer was implicated as 
long ago as 1896, however, it was not until the discovery of the ER and the cloning of 
the cDNA, that workers have finally started to understand how oestrogens can elicit 
such a wide array of effects. One of those effects, regulation of growth factor 
secretion, has gained the most interest, with a large amount of research now finally 
starting to indicate how a transmembrane receptor can trigger cell proliferation. 
Phosphorylation now seems the most important signalling mechanism within the cell, 
with specific tyrosine phosphorylations playing an important role in receptor 
pathways.
The intense research into the growth factors that are controlled by oestrogen still 
leaves us with no indication of how oestrogen mediates proliferation in cell lines, and 
highlights the problem that breast cancer research is now facing. For whilst there is 
gaining evidence indicating how growth factors signal mitogenic responses (MAP 
kinase etc.), the study of single growth factors and receptors, in oestrogen action, has 
not been entirely fruitful. Evidence for synergism both between growth factors and 
hormones indicates the need for better models of the in vivo situation (Stewart et al., 
1990; Stewart et al., 1992). The IGF's with their complex number of interaction
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between ligands, receptors and binding proteins may have a role to play, and will 
most probably be the first 'anti-growth factor' strategy tested in the treatment of breast 
cancer.
1.5 AIMS OF THE STUDY
There is no data on the level of IGF-I or II peptide in human breast tumours, and data 
in cell lines is controversial and contradictory. Furthermore, although oestradiol 
induces IGF-II mRNA in certain breast cancer cell lines, no data exists on increased 
levels of peptide. This all results from the downfalls of RIA. The general aims of 
this thesis were therefore as follows;
1 To develop and optimise a sensitive and specific immunoblotting technique 
for analysis of IGF-II peptide levels and the nature and size of the peptide.
2 Examine IGF-II secreted by MCF-7 cells transfected with IGF-II cDNA.
3 Characterise forms of IGF-II secreted by transfected cells.
4 Determine significance of transfected cells by analysing levels of IGF-II in 
other breast cancer cell lines, together with the effects of oestradiol.
5 Generate a polyclonal antibody to phosphotyrosine, perform affinity 
purification and characterisation of the antibody, and then study tyrosine 
phosphorylation of the type 1 IGF receptor in breast cancer cells.
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CHAPTER 2 MATERIALS AND METHODS
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2.1 MATERIALS
2.1.1 General chemicals
Unless otherwise stated, all general laboratory chemicals were supplied by BDH 
Chemicals Ltd., Poole, England, or by Fisons pic, Loughborough, England, and all 
other chemicals and biochemicals by Sigma Chemical Co., Poole, England.
2.1.2 Acrylamide
Protogel (30% (w/v) acrylamide and 0.8% (w/v) bisacrylamide solution) was supplied 
by National Diagnostics, Atlanta, Georgia, USA.
2.1.3 Radioactivity
All radiochemicals were supplied by Amersham International pic, Buckinghamshire, 
England, except for [32p]-orthophosphate (Na3(P0 4 )2) which was supplied by ICN 
Flow, Buckinghamshire, England.
2.1.4 Antibodies
A rabbit polyclonal antibody to phosphotyrosine was a gift from Dr M Fry, Institute 
for Cancer Research, Sutton, England. A mouse monoclonal antibody to rat IGF-II 
was purchased from Sera-Lab, Crawley Down, Sussex, England. Peroxidase-labelled 
and biotinylated secondary antibodies were supplied by Dako Ltd, High Wycombe, 
Bucks, England. A mouse monoclonal antibody to IGF-I was a gift from Dr S 
Hampton, University of Surrey, Guildford, England.
2.1.5 Tissue Culture Products
2.1.5.1 Imperial Cancer Research Fund, London, England.
Dulbecco's modified eagle's medium (DMEM) containing phenol red (1%); 
Glutamine (200mM); lOxPBS (1.7M NaCl, 30mM KCl, lOmM Na2HP0 4 , 18mM
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KH2PO4); Trypsin (0.038%(w/v) KCl, 0.01%(w/v) Na2HP0 4 , 0.01%(w/v) dextrose, 
0.3%(w/v) tris-HCl pH7.7, 0.25%(w/v) trypsin, 0.01%(w/v) streptomycin and 
lOOU/ml penicillin with 1% phenol red in PBS); Versene (0.02%(w/v) EDTA with 
1% phenol red in PBS)
2.1.5.2 Life Technologies, Irvine, Scotland.
14cm, 9cm, 5cm, 3cm nunc tissue culture plates; RPMI without phenol red and 
glutamine; RPMI without phosphate; Foetal calf serum (FCS); 
Penicillin/streptomycin (10,000 units/ml); G418 sulphate
2.2 GENERAL METHODOLOGY
2.2.1 Protein determination
This was determined using either Pierce (Pierce, Illinois, U.S.A) or Biorad (Biorad, 
Hertfordshire, England) assay kits. If proteins were in a denaturing buffer (e.g. SDS, 
Triton), the bichionic acid (Pierce) method was used, as it is not affected by 
denaturing agents. A standard curve was prepared with bovine serum albumen 
(BSA), at 10-80pg, and the reaction performed for 30 minutes at 37'C. Absorbance 
was read at 562nm on a LKB ultrospec II.
All other protein determinations were performed by the coomassie blue method using 
a Biorad assay kit. A standard curve was set up as in Sect. 2.2.1 and the reaction 
performed according to the manufacturers instructions (10  min at room temperature 
(R.T.), absorbance read at 595nm).
2.2.2 DNA determination
A modification of the method of Burton (1955) was used. DNA pellets were 
suspended in 1ml of 0.5M PC A, centrifuged at 4000rpm for 5 min, washed with 1 ml 
of 0.5M PGA with recentrifugation, resuspended in 1 ml 0.5M PCA and incubated at 
70“C for 15 min. Samples were cooled on ice for 10 minutes, centrifuged as above.
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supernatants transferred to glass stoppered vials, 2ml of DNA reagent (0.3g 
diphenylamine, 20mls glacial acetic acid, 0.3 ml conc. H2SO4  and 1.6mg/ml 
acetaldehyde) added, and incubated overnight in the dark at R.T. Absorbance was 
read at 595nm and DNA content calculated from a standard curve prepared with calf 
thymus DNA (O-lOOpg).
2.2.3 Tissue collection and storage
Breast cancer tissue was routinely collected on solid CO2 from the Pathology 
Department of the Royal Surrey Hospital, Guildford, and stored in liquid nitrogen.
2.3 TISSUE CULTURE
2.3.1 Routine stock
For information on cell lines see Table 1.1. Stock cells were maintained as 
monolayer cultures in 9cm plates. Steroid-sensitive cells (ZR-75, McG, KO, T47D) 
were grown in DMEM containing 5% FCS and lO'^M oestradiol. Unresponsive 
breast cancer cell lines (HBL-100, MDA-231) and all other lines (A431, NR6+) were 
grown in DMEM and 5%FCS. The transfected breast cancer cell lines MN2, MI5 
and MI7 were routinely grown in DMEM, 5%FCS, IQ-^M oestradiol and 100p.g/ml 
G418 sulphate.
2.3.2 Passage of cells
After washing with 2ml of prewarmed trypsin/versene (1:4) mix, the cells were 
incubated with another 2ml, and incubated at 37“C until the cells detached and 
formed a single cell suspension. Trypsin was inactivated by transferring to 2ml of 
DMEM + 5% FCS, pelleted by spinning at 800rpm in a Heraeus Labofuge M for 3 
min, and resuspended in 5ml of growth medium. Cells were counted by 
haemocytometer (Section 2.3.4) and seeded with fresh medium at an appropriate 
dilution.
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2.3.3 Freezing and thawing of stock cultures.
Cells, after trypsinisation, were resuspended in 1ml freezing mixture (0.8ml DMEM, 
0.1ml dimethyl sulphoxide (DMSO) and 0.1ml FCS), stored at -70*C overnight in a 
polystyrene container, and then transferred to liquid nitrogen for long term storage.
Frozen cells were rapidly thawed in a 37^C water bath, and seeded in two 9cm plates 
with DMEM and 10% FCS. The next day the media was changed to DMEM and 5% 
FCS to remove dead cells and DMSO.
2.3.4 Counting cells
Cell number was calculated using a haemocytometer or a Coulter Counter. For the 
haemocytometer, cells were trypsinised, and then counted in quadruplicate. A 
conversion factor of 1x10  ^was used to calculate the number of cells/ml.
For Coulter counting, a 9cm plate was washed with PBS at 4“C, lysed with 2ml of 
O.OIM N-2-hydroxyethylpiperazine-2'-2-ethanesulfonic acid (HEPES) and 1.5mM 
MgCl% buffer, with 4 drops of Zaponin (Coulter Electronics, Harpenden, England). 
Cells examined for lysis microscopically, transferred to 8ml of Isoton (Coulter 
Electronics) and nuclei counted in triplicate on a Model ZBl Coulter Counter.
2.3.5 MTT proliferation assay
The method of Twentyman and Luscombe (1987) was used. Cells were seeded at I- 
2x1 (P cells per well in 96 well culture plates and the next day MTT assay performed 
(Day 0) and media changed. On appropriate days, 20pl of MTT (5mg/ml in PBS) was 
added to each well, incubated for 4 hours at 37 “C, carefully aspirated, and the 
formazan solubilised with 200pl of DMSO + 2.5% RPMI. Plates were shaken for 10 
min, DMSO sucked up and down by pipette, and absorbance read on a Multiskan 
MCC at 540nm. All time points were performed either in triplicate or quadruplicate.
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2.3.6 Steroid-free experiments
For experiments involving the analysis of steroid effects, cells were grown in RPMI 
1640 medium containing no phenol red. Phenol red has oestrogenic effects as shown 
in Figure 2.1. 5% DCFCS (Section 2.3.7), 2mM glutamine and penicillin/
streptomycin (50 units/ml) were added to the RPMI prior to use.
2.3.7 Dextran charcoal stripped foetal calf serum (DCFCS)
FCS (500ml) was stripped of steroid by dextran charcoal. Charcoal was adsorbed to 
dextran by mixing 5g of activated charcoal, 0.5g dextran T-40, O.OIM Tris/HCl pH7.4 
and O.lmM EDTA in 500ml water. This was centrifuged at 2000xg for 20 min, the 
liquid aspirated, serum added to the pellet, and incubated in a shaking water bath at 
55"C for 30 min. Charcoal was removed by centrifugation as above, and the stripped 
serum filter sterilised through a 0.45pM filter and then a 0.22pM filter (Nalgene, 
Rochester, U S A). Serum was tested for growth potential on oestradiol-dependent 
cells (for example see Fig 2.1), and then stored in aliquots at -20“C.
2.3.8 Pulse labelling of cells with [%]-thymidine
[%]-thymidine (ImCi/ml) was diluted 1 in 10 with distilled water and 10|il added per 
ml of RPMI + 5% DCFCS. 5cm plates were washed with RPMI, and then incubated 
with 5ml RPMI + 5% DCFCS containing pH]-thymidine for 1 hr. Plates were 
washed with PBS at 4°C, fixed with 5% TCA for 20 min, washed with 5% TCA, then 
70% ethanol and allowed to air dry. Cells were dissolved in 1ml lysis buffer (O.IM 
NaOH, 2% Na2COs and 1% SDS) and 0.75ml added to 10ml Optiphase. The 
scintillant was left for 30 min and then counted for 2 hr on a LKB 1217 Rackbeta 
counter. All time points were performed in quadruplicate.
2.3.9 p2p]-orthophosphate labelling of cells
Cells were grown in DMEM and 5% FCS to the required density and then incubated 
overnight in DMEM +1% FCS. They were then washed with phosphate-free RPMI
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Figure 2.1 Effect of phenol red, lO'^M oestradiol (E2) and FCS on proliferation
of ZR-75 breast cancer cells. Cells plated at 1000 cells/well in a 96 
well plate, incubated in RPMI + 5% DCFCS for 3 days and then media 
changed as above. MTT assay performed after 3 days, values 
representing quaudruplicate wells ± S.E.M.
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and labelled with 300pl of phosphate-free RPMI containing ISOpCi [^^Pj-Nag (P04)2 
for 4 hr at 37“ C. After washing with RPMI, the cells were stimulated with growth 
factor dissolved in RPMI, for the required time, and then lysed (Section 2.6).
2.3.10 Preparation of conditioned media (CM)
This was performed by the method of Daly et al. (1991). Cells (MN2, MI5, MI7) 
were grown in DMEM + 5% FCS, lO'^M oestradiol and G418 Sulphate, to 
subconfluence and incubated in RPMI +1% DCFCS for 24 hr. If appropriate, cells 
were incubated with 5x1 O^M ZnCl2 (zinc) to stimulate IGF-II production. Plates 
were washed three times with RPMI, incubated in serum-free media (SFM - RPMI, 
lOmM HEPES pH7.4, Ijig/ml transferrin and 0.75 pg/ml fibronectin) and after the 
required time conditioned media (CM) was collected, spun at lOOOrpm for 3 min to 
remove dead cells and debris, and aprotinin added to a final concentration of 0.2  
trypsin inhibitor units/ml (1% v/v). Media was stored at -70“C.
2.4 CONCENTRATION OF CONDITIONED MEDIA
2.4.1 PD-10 column
2ml of CM was diluted with 0.5ml of distilled water, loaded onto a PD-10 desalting 
column (Pharmacia, Buckinghamshire, England), eluted with 10ml of water and 1ml 
fractions collected. Protein content of the fractions was measured by absorbance at 
280nm and the fractions of interest pooled, frozen at -70“C and lyophilised.
2.4.2 Dialysis
Dialysis tubing (Medicell International, London, England) was prepared by boiling 
for 5 min in 0.2M sodium bicarbonate and 0.05M EDTA, washing with distilled 
water and then boiling for another 5 min in the same buffer. After washing with 
distilled water, tubing was autoclaved and stored in distilled water. Dialysis of CM 
was against 3 litres of distilled water at 4“C for 2 days with 2 changes of water. CM 
was then frozen at -70“C and lyophilised.
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2.4.3 C3 concentrator
CM was desalted using a C3 concentrator (Amicon, Gloucestershire, England). 2ml 
was centrifuged over a membrane at 7500xg for 3 hr and the concentrate (~50pl) 
diluted in 2ml water and recentrifuged, and then frozen at -70"C and lyophilised.
2.5. ELECTROPHORESIS AND IMMUNOBLOTTING
2.5.1 Slot blot technique
Analysis of proteins on nitrocellulose, without first performing electrophoresis, was 
performed using a slot blot apparatus (Schleicher & Schuell, Kingston-upon-Thames, 
England). Two pieces of 3MM whatman filter paper were wet with distilled water 
and placed on the apparatus. A sheet of nitrocellulose (Schleicher & Schuell) was 
wet with water, placed on top of the 3MM, the apparatus assembled, and protein 
applied to the nitrocellulose under vacuum. After blotting, the apparatus was 
dismantled, and nitrocellulose blocked with PBS/0.05% TWEEN20 (PBST).
2.5.2 SDS-PAGE
Proteins and markers (Table 2.1) were electrophoresed by a modification of the 
method of Laemmli (1970). Polyacrylamide gels (15%) were run, using a Hoefer 
SE400 electrophoresis system, at 20 mA constant current for 3 hours until the 
bromophenol blue front was l-2cm from the bottom of the glass plates. The gel was 
either stained for protein (Section 2.5.3), exposed to x-ray film (Section 2.5.4) or 
transferred to PVDF (Section 2.5.5).
2.5.3 Staining proteins
If low levels (ng) of protein were to be detected, a silver staining kit (Sigma), was 
used. After electrophoresis, gels were fixed in 30% ethanol/10% acetic acid for 2 hr, 
washed with water for 3x10 min, distilled water for 10-20 sec and incubated in 
developer solution for 5-8 min until bands could be seen. The gel was
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HIGH M.Wt. (kDa) LOW M.Wt. (kDa)
Myosin 200,000 Ovalbumen 45,000
Phosphorylase b 97,400 Carbonic anhydrase 30,000
BSA 69,000 Trypsin inhibitor 21,500
Ovalbumen 45,000 Lysozyme 14,700
Carbonic anhydrase 30,000 Aprotinin 6500
Trypsin inhibitor 21,500 Insulin (b) chain 3400
Lysozyme 14,700 Insulin (a) chain 2350
Table 2.1 Amersham rainbow molecular weight (M.wt.) markers
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then transferred to water for 3x10 min, incubated in reducing solution for 10-20 
seconds and washed for 1 min with water. Gels were dried as in Section 2.5.4.
All other staining of gels was performed by the quick and simple method of 
coomassie blue staining. Gels were fixed and stained in a 0.05% coomassie blue 
solution in 40% methanol/7 % acetic acid overnight and then destained in 40% 
methanol/7% acetic acid until background staining was removed.
2.5.4 Drying and autoradiography of polyacrylamide gels.
Polyacrylamide gels were fixed and stained (Section 2.5.3), and then dried. A wet 
sheet of 3MM paper was placed on the gel, two sheets of dry paper, and dried on a 
Biorad 483 slab drier at 80"C for 60 min. Radiolabelled proteins were visualised by 
exposure to x-ray film at -70* C for the required time.
2.5.5 Electrophoretic transfer of proteins to PVDF
This was performed by the method of Towbin and Gordon (1984). Transfer to PVDF 
(Millipore, Hertfordshire, England), was at 20v/cm overnight (4“C) in a Transblot cell 
(Biorad) with 3 litres of buffer (50mM Tris-HCl, 192mM glycine and 20% methanol). 
If the IGF-II antibody was to be used for immunoblotting, no SDS was added, but in 
all other cases, 0.1% SDS was included to improve transfer of high molecular weight 
proteins. After transfer, membrane was blocked with PBST for 1 hr at R.T.
2.5.6 Detection of total protein on PVDF membrane
To check efficiency of transfer, proteins were visualised by a reversible stain. 
Ponceau S. Membrane was washed with distilled water and incubated in 0.2% 
Ponceau S/2% TCA for 5 min, and destaining performed with distilled water. Stain is 
reversible by incubation of the blot in PBS. If a permanent stain was needed, the 
membrane was washed with PBST for 3x10 min and then incubated with a solution of 
Pelikan India Ink (l|il ink/ml PBS) overnight, and then destained with distilled water.
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2.5.7 Immunodetection by enhanced chemi-Iuminescence (ECL)
Membranes were blocked as in Section 2.5.5, put in a Hybaid tube, and incubated 
with an appropriate dilution of primary antibody. Membrane was washed 6 x 5  min 
with PBST, incubated with a 1:1000 dilution of biotinylated anti mouse antibodies 
(DAKO), washed as before, and incubated with a 1:1000 dilution of extravidin 
peroxidase (Sigma) for 1 hr. After washing, detection was performed by ECL 
(Amersham International PLC, Buckinghamshire, England), according to the 
manufacturer's instructions, exposing the membrane to Hyperfilm-ECL (Amersham) 
for the required time. Optimisation of the protocol is detailed in Chapter 3.
2.6. PREPARATION OF CYTOSOLS AND LYSATES
2.6.1 Breast cancer tissue
Tissue was partially thawed, cut into small pieces, weighed, and put in a Teflon 
container with a tungsten ball. This was put in liquid nitrogen for 2 hr, vibrated on a 
Mikro dismembrator II (Braun, Germany) for 45 sec, and tissue transferred to 8 
volumes of T/E buffer (Tris/HCl 50mM pH7.4, ImM EDTA, ImM DTT and ImM 
PMSF). Homogenate was centrifuged at 45,000xg at 4“C for 30 min, the supernatant 
aliquoted, protein determined (Section 2.2.1) and stored at -70"C. Pellets were stored 
for DNA analysis (Section 2.2.2).
2.6.2 Cell lysates
2.6.2.1 Tris/EDTA lysis
Confluent plates were washed with cold PBS and harvested by scraping into 1.5ml 
eppendorf tubes. 500jil of T/E buffer was added, sonicated for 15 seconds, and 
centrifuged at 14000xg for 10 mins at 4"C. Supernatant was removed, protein 
determined (Section 2.2.1), aliquoted and stored at -70"C. The DNA content of the 
pellet was determined as in Section 2,2.2.
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2.6.2.2 Triton lysis
Cells were harvested as in section 2.6.2.1 and 1ml of Triton buffer added (50mM 
HEPES pH7.4, 50mM NaCl, ImM EDTA, ImM PMSF and 1% Triton). DNA was 
sheared by sonication for 3x5 seconds, and lysate centrifuged at 14000xg for 10 min 
at 4’C. Supernatant was removed, protein determined (Sect. 2.2.1) and aliquots 
stored at -70"C. In experiments where tyrosine phosphorylation was studied, the lysis 
buffer included ImM NagVO^ to block phosphatase action.
2.6.2.3 RIPA lysis
Cell lysis with RIPA buffer (150mM NaCl, 1% NP-40, 0.5% DOC, 0.1% SDS, 
50mM Tris pH 8.0) was performed as in Section 2.6.2.2.
2.7. CHROMATOGRAPHY
2.7.1 Cation-exchange
Cation-exchange chromatography was performed for separation of insulin-like growth 
factor-II (IGF-II) by a modification of the method of Hudgins et al. (1992). 7g of 
Sephadex C-25 SP (Pharmacia) was swollen in 50ml of 0.5M NaCl for 5 min, and 
washed with starting buffer (2M acetic acid/0.075M NaCl pH 2 8 ) by pouring the 
swollen gel over a buchner funnel with whatman filter paper. Swollen gel was 
suspended in starting buffer, incubated at 90"C for 2 hrs to complete swelling and 
degas the buffer, and then washed as before to end with a 70% slurry. Gel was 
poured into a column (5x1 5cm), washed through with 2 column volumes of starting 
buffer and connected to a Beckman LKB 7000 Ultrorac fraction collector at 4^C. 
The flow rate was calculated to be ~0-5ml/min.
21 mg (lOOjil) of CM (previously concentrated 100-fold), was diluted to 1ml with 
starting buffer and loaded onto the column. The column was washed with 3 column 
volumes of; starting buffer, buffer 2 (2M acetic acid, 04M NaCl pH 2 8) and buffer 3 
(0.5M Tris-HCl and 2M NaCl pH 8 0). Column fractions (1ml) were collected and
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absorbance read at 280nm. Protein peaks were pooled, dialysed against 3 litres of 
water for 2 days at 4*C, and lyophilised. Samples were reconstituted in 50pl water, 
and 5|Xl analysed by gel electrophoresis followed by staining with coomassie blue 
(Section 2.5.3), or immunoblotting for IGF II (Section 2.5.7).
2.7.2 Blue sepharose
Blue sepharose, a gift from Dr Tony Knowles (ICRF, London, England), was swollen 
in distilled water and washed over a glass fibre filter for 15 min with distilled water. 
1ml samples were incubated with 300pl of a 75% slurry of blue sepharose (1.5 ml 
eppendorf), shaken for Ihr at 4°C, centrifuged at 7000xg for 1 min and the 
absorbance of the supernatant read at 280nm. IGF II was analysed after dialysis, 
freeze drying and immunoblotting as in Section 2.5.7.
2.7.3 Blue Silica
Blue Silica was a gift from Dr Piotr Kwasowski (University of Surrey, Guildford, 
England). Beads were suspended in water, and batch chromatography performed as 
in Section 2.7.2.
2.7.4 C l8 reverse phase chromatography
This was performed by a modified method of Hsu and Hammond (1987). A Sep Pack 
C l8 column (Millipore) was prewashed with 5ml methanol, 5ml propan-2-ol and 
10ml of 4% acetic acid, the sample loaded onto the column, and washed with 10ml of 
acetic acid. Elution was performed with 5ml of 87.5% acetonitrile/12.5% IM HCl, 
and the eluent dialysed, lyophilised and analysed for IGF II activity by 
electrophoresis and immunoblotting (Section 2.5.7).
2.7.5 FPLC
This technique was performed with the help of Mr Arcardio Garcia de Castro (School 
of Biological Sciences, University of Surrey, England), on a Pharmacia system
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comprising of a P-500 pump, LCC500 controller, UV-M monitor and a FRAC-100 
fraction collector. A column of Sephacryl S-100 was poured (25x1.5cm), set up on 
the machine, and equilibrated with PBS/4% v/v acetic acid for 24 hours. lOOjil of 
conditioned media (previously concentrated 100-fold), was diluted to 1ml with 
PBS/4% v/v acetic acid, loaded, and the column run at a rate of 0.5 ml/min. Eluate 
was collected in 5ml fractions, protein content measured by absorbance at 280nm, 
and IGF-n analysed by dialysis, freeze drying and immunoblotting as in Section
2.5.7. Pure protein standards were run for calibration (Figure 5.9), which were 
alcohol dehydrogenase, bovine serum albumen (BSA), carbonic anhydrase and a- 
lactoglobulin.
2.8 GENERATION OF AN ANTIBODY TO PHOSPHOTYROSINE
2.8.1 Conjugation of phosphotyrosine (PY) to a hapten
Phosphotyrosine was coupled to either BSA or haemocyanin (HC) by l-ethyl-3-(3- 
dimethylaminopropyl) carbodiimide hydrochloride (EDAC) using a modified method 
of Harlow and Lane (1988). 123|ig of PY was dissolved in 1.2ml water and 
concentrated NaOH added to pH 5.7. 20|ig of hapten and 90|ig of EDAC were added 
and the pH maintained at pH 5.7 with concentrated NaOH for 2 hr until it stabilised. 
Conjugate was rocked at 4°C for 24 hr, and then dialysed against 3 litres of 50mM 
Tris-HCl and 150mM NaCl for 48 hr at 4°C with 3 changes of buffer.
2.8.2 Injection of peptide
All injections were kindly carried out by Mr Del Watling (ICRF, Hertfordshire, 
England). A prebleed was taken from a rabbit, and it was then injected with 1.5pg 
conjugate mixed with an equal volume of Freud's incomplete adjuvant. Rabbits were 
boosted at weeks 3, 6 and 9 with 1.5}ig of conjugate and test bleeds taken 1 week 
after boosting. The rabbits was bled-out at week 10.
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2.8.3 Monitoring antibody generation
Specific antibodies in the test bleeds were measured by ELISA. 96 well plates were 
coated with serial dilutions of BSA-PY conjugate for 1 hour, blocked with PBST + 
3% BSA overnight and incubated with lowering dilutions of serum from the test 
bleeds, followed by incubation with an anti-rabbit peroxidase labelled antibody. 
Substrate was prepared by dissolving 50mg of orthophenylene diamine (OPD) in 
100ml of buffer (1.42g Na2HPO4/0 .35g citric acid adjusted to pH 5 with concentrated 
HCl), and 20ml of H2O2 (lOOvols) added prior to use. Each well was incubated with 
200pl of substrate for 10 min in the dark, and the reaction stopped by addition of 50pl 
of IM sulphuric acid (2.8ml conc. sulphuric acid (SG. 1.84) in 100ml water). 
Absorbance was read at 492nm. All dilutions were performed in triplicate.
2.8.4 Ammonium sulphate precipitation of immunoglobulins
15ml of a saturated solution of ammonium sulphate was slowly added dropwise to 
30ml of serum, and then stirred at 4"C for 6 hr. Precipitated protein was centrifuged 
at 3000rpm for 10 min, the supernatant collected, 15ml of ammonium sulphate slowly 
added dropwise and the serum stirred overnight at 4"C. Protein was centrifuged at 
3000rpm for 10 min, resuspended in 15ml of distilled water, and dialysed against 3 
litres of PBS for 2 days at 4"C with four changes of buffer.
2.8.5 Affinity purification of anti-phosphotyrosine antibodies.
Specific antibodies against phosphotyrosine (a-PY) were purified by passing serum 
over a column of PY coupled to sepharose beads (a gift from Dr M Fry). The column 
was regenerated with 1 column volume of 6M urea and then washed with PBS until 
the eluate reached neutrality. Serum was loaded onto the column, washed with 3 
column volumes of PBS, 5mM phosphoserine (PS), 5mM phosphothreonine (PT) and 
1 column volume of PBS in succession. Antibodies to PY were specifically eluted 
(1ml fractions) by 40mM phenylphosphate, protein content measured by absorbance 
at 280nm and fractions of interest were pooled. An equal volume of 4M NaCl was
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NaCl was added for 1 hour, dialysis performed against 3 litres of 2M NaCl/O.lmM 
EDTA for 2 days at 4"C with 3 changes of buffer, then overnight against sodium 
bicarbonate.
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CHAPTER 3 CHARACTERISATION OF AN ANTIBODY TO
INSULIN-LIKE GROWTH FACTOR II (IGF-II)
65
3.1 INTRODUCTION
To study IGF-II secreted by a breast cancer cell line transfected with the IGF-II gene, 
the techniques of electrophoresis and immunoblotting were chosen. These techniques 
allow the analysis of different forms of IGF-II whilst eliminating the problems 
associated with RIA of insulin-like growth factors (removal of binding proteins). 
Detection of nanogram levels of growth factor were possible by the commercial 
availability of a mouse monoclonal antibody to rat IGF-II that has 100% homology 
with human IGF-II, and a very high specificity. Primary antibody was then detected 
using an avidin-biotin amplification step, and enhanced chemi-luminescence (ECL) 
performed (Figure 3.1).
Information supplied with the antibody related only to it's use in RIA. Therefore, the 
conditions needed for analysis with immunoblotting had to be determined. As ECL 
was not being performed in the laboratory, this was optimised at the same time.
3.2 OBJECTIVES
1 Calculate the intensity of light to preflash film before exposure to ECL.
2 Determine the dilution of reagents and antibodies for optimal antigen 
recognition using ECL.
3 Investigate the effect of denaturing agents on antibody recognition of 
IGF-II.
4 Examine cross reactivity of antibody with other growth factors.
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3.3 RESULTS
3.3.1 Preflashing of autoradiography film
To increase the sensitivity of autoradiography film, and linearise the response to 
signal, a preflash unit was purchased (Amersham). Data supplied with it, indicated 
that the optimum absorbance for preflashing autoradiography film is 0.15 absorbance 
units. The intensity of light needed for the preflash was calculated by exposing film 
to light of lowering intensity (Figure 3.2), by moving the light source away from the 
film, and the signal analysed on a densitometer by measuring the absorbance at 
550nm (Figure 3.3). From this, 68 cm was chosen as the distance to preflash all 
further films, where stated.
3.3.2 Optimum dilution of biotinylated anti-mouse antibodies for ECL
Serial dilutions of anti-IGF-II mouse antibody (Ipg-lng) were blotted onto 
nitrocellulose, using a slot blot apparatus, and detected with lowering dilutions of 
biotinylated anti-mouse antibodies (1:10^-1:10^) in PBST. Extravidin peroxidase 
was diluted 1:1000, and ECL performed (Figure 3.4). Increasing the dilution of 
secondary antibody clearly reduced the detection of primary antibody. 1:1(X)0 was 
chosen as the dilution of secondary reagent for all further experiments.
3.3.3 Optimum dilution of extravidin-peroxidase for ECL
Serial dilution of biotinylated antibody (1 :10^-1:10^) were blotted onto 
nitrocellulose, and detected with lowering dilutions of extravidin peroxidase (Figure 
3.5). Dilutions of 1:100 to 1:1000 of extravidin peroxidase did not significantly affect 
the detection of biotinylated antibody, whereas increasing dilutions did, however, fail 
to detect a 1:10"^  dilution of biotinylated antibody. For this reason, 1:1000 was 
chosen as the dilution for the tertiary reagent, and was used for all further 
immunoblotting involving ECL.
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Figure 3.2 Effect of light-source distance (cm) on pre-flashing of autoradiography film.
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Figure 3.4 Optimal detection of anti-IGF-II antibody with biotinylated rabbit anti- 
mouse antibodies. Serial dilutions of anti-IGF-II antibody were 
applied to nitrocellulose, immunoblotted with lowering dilutions of 
biotinylated anti-mouse antibodies, a 1:1000 dilution of extravidin 
peroxidase and ECL performed.
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Figure 3.5 Optimal detection of biotinylated anti-mouse antibodies with
extravidin peroxidase. Serial dilutions of biotinylated anti-mouse 
antibodies were applied to nitrocellulose, immunoblotted with 
dilutions of extravidin peroxidase, and ECL performed.
3.3.4 Optimal detection of IGF-II
Having chosen a 1:1000 dilution of biotinylated anti-mouse antibody, and extravidin 
peroxidase, the optimum dilution of primary antibody was analysed. 100 and lOng of 
IGF-n peptide were blotted onto nitrocellulose, alongside lOOng BSA, and detected 
with 3 dilutions of anti-IGF-II antibody (Sera Lab). Primary antibody was then 
detected with a 1:1000 dilution of secondary and tertiary reagent, and ECL performed 
(Figure 3.6). Under these conditions, both concentrations of IGF-II were detectable 
by all three dilutions, with no detection of BSA. To ensure a low background when 
immunoblotting, and for cost reasons, a 1:1(X)00 dilution was chosen for all further 
experiments.
3.3.5 Incubation of antibody with IGF-II prior to immunoblotting
10 mis of antibody diluted in PBST (O.lpg/ml) was incubated with lp.g of IGF-II for 
1 hour at 40(Z. Antibody that had been blocked with IGF-II gave a very faint 
response to 200 and lOOng of IGF-II that was not detectable by densitometry, 
indicating efficient blocking (Figure 3.7).
3.3.6 Cross-reactivity of the IGF-II antibody with other growth factors
To assess the cross-reactivity of the antibody with other growth factors (insulin, IGF-I 
and EGF), detection was performed alongside IGF-II. The three growth factors (200 
and lOOng) were applied to nitrocellulose alongside dilutions of IGF-II (200, 100, 50, 
10, 5, and Ing), immunoblotted (Figure 3.8), and analysed by densitometry (Figure 
3.9). Neither EGF nor insulin showed any cross reactivity, whilst IGF-I showed a 
small amount with detection of 200ng being about 10% of that with 200ng IGF-II. 
Data supplied with the antibody also indicates 10% cross-reactivity with IGF-I in 
RIA.
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Figure 3.6 Optimal detection of IGF-II. Pure IGF-II and BSA (control) were 
applied to nitrocellulose, immunoblotted with lowering dilutions of 
anti-IGF-n antibody, a 1:1000 dilution of biotinylated anti-mouse 
antibodies and extravidin peroxidase, then ECL performed.
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Figure 3.7 Specific blocking of anti-IGF-H response. A 1:10000 dilution of anti- 
IGF-II antibody was incubated with Ipg IGF-II prior to 
immunoblotting.
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Figure 3.8 Cross-reactivity of anti-IGF-II antibody with IGF-I, insulin and EGF.
Peptides were applied to nitrocellulose, immunoblotted with a 1:10000 
dilution of anti-IGF-II antibody and ECL performed.
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Figure 3.9 ECL detection of IGF-II (Figure 3.8). Absorbance (550nm) expressed 
as arbitary units, and corrected for background value.
3.3.7 Effect of denaturing agents on the detection of IGF-II
3.3.7.1 Sodium dodecyl sulphate (SDS)
IGF-II was denatured by boiling in sample buffer for 3 minutes, and blotted onto 
nitrocellulose. Native IGF-II was diluted in distilled water and blotted as a control. 
Dénaturation of the peptide destroyed IGF-II detection, whereas native IGF-II still 
gave a signal (Figure 3.10).
3.3.7.2 Dithiothreitol (DTT)
IGF-II (50 and lOng) was incubated with DTT (100, 10 and OmM), applied to 
nitrocellulose and immunoblotted (Figure 3.11). lOmM DTT reduced the detection of 
IGF-II, whilst lOOmM destroyed the signal for both dilutions of IGF-II. Absorbance 
was measured by densitometry (Figure 3.12).
3.3.8 Analysis of IGF-II by non-denaturing electrophoresis
Due to the effect of denaturing agents on antigen recognition (Section 3.3.7), non­
denaturing electrophoresis was performed. IGF-II was electrophoresed, and then 
transferred to polyvinylidenedifluoride (PVDF) membrane (Immobilon-P, Millipore) 
and immunoblotted (Figure 3.13). Molecular weight markers did not separate in the 
gel, and when the membrane was immunoblotted, IGF-II was detected as a smear 
from ~45-7kDa (estimated molecular weights, as markers did not separate). The same 
effect was seen with IGF-I (blotted with a 1:5000 dilution of a-IGF-I antibody).
3.3.9 Analysis of IGF-H by SDS-PAGE
IGF-II was denatured by boiling in sample buffer for 3 minutes, and separated by 
electrophoresis. Transfer was performed overnight at 4^0, but crucially without SDS 
in the transfer buffer. Under these conditions IGF-II was detectable as a single band 
with an estimated molecular weight of 7kDa (Figure 3.14). If transfer was performed 
in the presence of SDS, IGF-II was not detectable (data not shown).
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Figure 3.10 Effect of SDS on detection of IGF-H. Peptide was denatured by 
boiling in sample buffer for 3 min, applied to nitrocellulose and 
immunoblotted with dilutions of anti-IGF-II antibody.
Control (NATIVE IGF-H) represents peptide dissolved in distilled 
water.
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Figure 3.11 Effect of DTT on detection of IGF-II. Peptide was incubated with 
DTT, applied to nitrocellulose, and immunoblotted with a 1:10000 
dilution of anti-IGF-II antibody.
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Figure 3.12 Densitometric analysis of Figure 3.11. Absorbance (550nm) expressed 
as arbitary units.
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Figure 3.13 Non-denaturing electrophoresis of IGF-I and II. 200ng of both 
peptides were boiled in sample buffer (without SDS) and 
electrophoresed. After transfer overnight to PVDF, the membrane was 
probed with antibodies to the respective peptides (anti-IGF-I antibody 
at 1:5000 dilution and anti-IGF-II at 1:10000), and ECL performed.
7 kDa
Figure 3.14 SDS-PAGE analysis of IGF-II. Electrophoretic transfer overnight in 
the absence of SDS, and immunoblotted as above for IGF-II.
3.4 CONCLUSIONS
The final conditions for SDS-PAGE and immunoblotting are summarised in Figure 
3.15. ECL was chosen for immunoblotting, using an avidin-biotin amplification step 
(Figure 3.1). To measure the absorbance of the signal on autoradiography film, 
preflash must first be performed, to amplify and linearise the response. By flashing 
film with different intensities of light, the optimum intensity was calculated to be 
when the light source was 68cm from the film. Optimum dilutions of secondary and 
tertiary reagents for use in ECL were determined using the slot blot technique to blot 
either primary mouse antibody or biotinylated antibody onto nitrocellulose. A 1:1(XX) 
dilution of both reagents gave a good signal to background ratio, was cost effective, 
and proved a convenient dilution to use.
Having selected the conditions for ECL analysis, a set of experiments were performed 
to examine the effect of various factors on IGF-H detection. Treatment of IGF-II with 
denaturing agents (SDS and DTT) destroyed antibody recognition of the peptide, and 
so the adverse effect of denaturing agents led me to investigate the possibility of 
using non-denaturing electrophoresis for the separation and detection of IGF-II. 
When IGF-II was electrophoresed on a non-denaturing gel, and immunoblotted, it 
was detected as a smear from 45 to 7kDa, however, when IGF-II was separated by 
SDS-PAGE, and transfer performed overnight without SDS in the buffer, IGF-II was 
detected as a single band at 7kDa.
Cross-reactivity of the antibody with structurally related growth factors (In, IGF-I), 
other growth factors (EGF), and other proteins (BSA) confirmed the specificity of the 
antibody for IGF-II. The antibody had little cross-reactivity with IGF-I (10%), whilst 
insulin, EGF and BSA gave no signal. Preincubation of the antibody with l^ig of 
IGF-II completely blocked antigen recognition.
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Figure 3.15 Optimised conditions for analysis of IGF-H by SDS-PAGE and 
immunoblotting using ECL.
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3.5 DISCUSSION
A sensitive and specific method for analysis of IGF-II by immunoblotting has been 
developed and optimised. This is important, as this method now allows the 
examination of the size and nature of the peptide, and does not have the major 
downfall of RIA i.e. removal of binding proteins. The recent development of chemi- 
luminescent technology allows the visualisation of results on a hard copy 
(autoradiogram), and permits quantitation.
The effect of denaturing agents on IGF-II did provide an obstacle. The effect was not 
due to any residual SDS or DTT denaturing the primary antibody, as the membrane 
was washed with PBST before incubation, but the inability of the antibody to 
recognise denatured peptide, suggest that the antibody has probably been raised to a 
conformational epitope, such as a pocket, that is disrupted upon dénaturation, with 
DTT suggesting that this conformation is held together by disulphide bonding. As 
mature IGF-II contains 6 cysteine residues this would seem feasible.
Analysis by non-denaturing electrophoresis, however, was not possible. With this 
method, proteins are not denatured by SDS, and so do not run solely due to molecular 
mass, as in SDS-PAGE, but due to the overall ionic charge. As the gel is run at 
pH8 .8 , we would expect most proteins to be fully charged, however, IGF-I and II 
have p i’s of 8.8 and 6.8  respectively, and so may not have been fully charged, 
resulting in differential mobility in the gel, and a smear upon immunoblotting. This 
may have also been due to impurity of the recombinantly produced peptide, with 
different forms having slightly different pi's.
The phenomena of renaturation of proteins after dénaturation has been investigated 
(Szewczyk et al., 1988), with the finding that even enzyme activity can be restored in 
certain circumstances. For this reason SDS-PAGE and transfer without SDS was 
tested, resulting in the detection of recombinant mature IGF-II as a single band at 
7kDa. This result agrees with the earlier data suggesting that proteins can renature, as
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long as transfer is performed overnight and in the absence of SDS. Presumably, SDS 
simply dissociates from the peptide which can then reform it’s tertiary structure. The 
extent of renaturation was not calculated, but detection of native IGF-H on a slot blot 
was always comparable with detection of the same amount of peptide separated by 
SDS-PAGE and immunoblotted.
Having determined the conditions for optimal IGF-H detection, the antibody was then 
used to analyse IGF-II secretion in breast cancer cell lines.
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CHAPTER 4 DETECTION OF INSULIN-LIKE GROWTH
FACTOR II IN A TRANSFECTED BREAST 
CANCER CELL LINE
83
4.1 INTRODUCTION
The involvement of growth factors in oestrogen-stimulated proliferation of breast 
cancer cells has attracted much interest, with a special emphasis on autocrine pathways 
related to loss of oestrogen-sensitvity (Osborne et al., 1990). Recent evidence suggests 
that the IGF family of ligands and receptors may have an important role to play 
(Chapter 1).
To examine the role of IGF-II in oestrogen-mediated proliferation of breast cancer cells, 
a cell line devoid of any IGF-II mRNA (MCF-7 McGrath) was chosen for study 
(Darbre and Daly, 1990). These cells are dependant on oestrogen for growth, whilst 
another variant of this cell line, KO, is oestrogen-responsive (Osborne et al., 1987), 
and has detectable levels of IGF-II mRNA (Darbre and Daly, 1990). MCF-7 McGrath 
cells were transfected stably with the IGF-II gene under the control of the 
metallothionein IIA promoter (Daly et al., 1991), which gave an inducible system 
whereby the IGF-II expression could be switched on by heavy metal ions. 
Upregulation of IGF-II mRNA by zinc (5xlO'^M ZnCl2 ) stimulation resulted in an 
increase in basal growth rate in the absence of oestrogen, and rendered the cells 
virtually independent of oestrogen for growth. This increase in growth rate was 
partially blocked by an antibody to the IGF-I receptor (a-IR3), suggesting that IGF-II 
was acting in an autocrine manner through this receptor. Another clone, MI5, had 
detectable levels of IGF-II mRNA, that was inducible by zinc, but no peptide was 
detected by RIA (Daly et al., 1991). MN2 cells, transfected with vector but without 
IGF-II cDNA, retained oestrogen-dependence, and contained no detectable IGF-II 
mRNA.
The measurement of IGF-II levels in CM of cells stimulated by zinc proved difficult 
due to the extremely low levels of growth factor (nanograms/10^ cells), and the 
presence of binding proteins in the media, which have to be removed, before 
performing RIA (Section 1.3.2). MI5 cells were stimulated to grow by zinc, but had
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no detectable IGF-II in CM. This chapter describes the measurement of IGF-II peptide 
levels in MN2, MI5 and MI7 cells, using the specific and sensitive immunoblotting 
technique developed and optimised in Chapter 3.
4.2 OBJECTIVES
1 Establish that MN2, MI5 and MI7 cells have transfected vector, that is 
functional by measuring growth in the presence of zinc.
2 Detect levels of IGF-II in CM by slot blot analysis.
3 Examine forms of IGF-II secreted, by SDS-PAGE and immunoblotting.
4 Show that forms of IGF-II in CM are not due to cell death or damage.
5 Examine time course of secretion in MI5 and MI7 cells.
6 Determine the effect of cell density of levels of IGF-II
6 Analyse intracellular IGF-II
85
4.3 RESULTS
4.3.1 Proliferative effect of zinc and oestradiol on transfected cells
Control MN2 cells transfected with vector but no IGF-II cDNA showed the classical 
steroid dependent phenotype (Figure 4.1 A), which was identical with growth curves 
obtained for the stock MCF-7 McGrath cells (data not shown). MN2 cells grown in 
phenol red-ftee RPMI and in the absence of oestradiol, resulted in no difference in cell 
number after 13 days. The addition of zinc (SxlO’^M ZnCl2) also had no effect on cell 
proliferation, whereas oestradiol (10"^M) significantly increased cell number after 5 
days, and prolonged exposure to the hormone resulted in continual exponential growth. 
The MI7 cell line, in contrast, showed an oestrogen-responsive phenotype with 
proliferation in the absence of any steroid (Figure 4.IB), resulting in a significant 
increase in cell number after 13 days. Oestradiol further increased cell growth to that of 
MN2 cells grown in the presence of oestrogen. Crucially, the addition of zinc also 
resulted in an increase in cell proliferation to approximately that of cells grown in the 
presence of oestrogen. This data is consistent with that of Daly et al. (1991), and 
confirms the presence of functional vector in the transfected cell lines.
4.3.2 Slot blot analysis of IGF-II in CM of MN2 and MI7 cells
MN2 and MI7 cells were grown to sub-confluence in the presence or absence of zinc, 
and CM collected (section 2.3.10). CM from one 9cm plate (3ml) was applied to 
nitrocellulose using a slot blot apparatus, in lOOpl aliquots. The flow through the 
membrane slowed appreciably as the final aliquots were added, suggesting that either 
the membrane was saturated with protein or that other factors or debris in the media 
were clogging it up. Having passed all the media through the apparatus, the 
nitrocellulose was blocked and immunoblotted (Section 2.5) with the antibody to IGF- 
II (Fig 4.2A).
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Figure 4.1 Proliferative effect of zinc and oestradiol on transfected MCF-7 ceils.
Control MN2 (A) and MI7 (B) cells plated at 500 cells/well in 96 well 
plates and grown in the presence of phenol red-free RPMI (nothing), 
or with 10‘^M oestradiol (E2) or 5xlO‘^M ZnCl2 (Zn). Cell number 
was assessed by MTT assay with points representing quadruplicate 
wells ± SEM. No error bars are shown if values were too small for 
visual display.
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Figure 4.2A Slot blot analysis of IGF-II in CM from MN2 and MI7 cells grown in 
the presence (+ zinc) or absence (-zinc) of 5xlO'^M ZnCl2 - Media 
from one 9cm plate (3ml) was applied to nitrocellulose and 
immunoblotted with a 1:10000 dilution of anti-IGF-II antibody. Pure 
IGF-II (100, 50, lOng) immunoblotted as a positive control.
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Figure 4.2B Densitometric analysis of autoradiograph in Figure 4.2A. Absorbance 
obtained at 55()nm expressed as arbitrary units.
CM from the MN2 cell line either in the presence or absence of zinc showed little or no 
detectable IGF-II, whilst the MI7 cell line, in contrast, exhibited a small amount of 
immunoreactive IGF-II in the absence of zinc, and a three-fold induction in the amount 
of detectable IGF-II when cells were incubated with zinc (Figure 4.2B)
4.3.3 SDS-PAGE analysis of CM from transfected cells
Electrophoresis was performed on lOOpl of CM from a total of 1ml taken from a 9cm 
plate, proteins transferred to PVDF overnight and the membrane immunoblotted 
(Figure 4.3A). 20ng of recombinant IGF-II gave a strong signal indicating a relative 
molecular mass of 7kDa. IGF-II was not detectable in conditioned media from MN2 
cells (as with the slot blot data), however, conditioned media from MI7 cells contained 
two immunoreactive forms with approximate masses of 22 and 15kDa. A longer 
exposure (Figure 4.3B), indicated trace amounts of a 7kDa form, which comigrated 
with recombinant mature IGF-II. The specificity of the three bands, shown by the 
absence of any immunoreactive forms in the MN2 conditioned media and the increase 
in signal upon zinc stimulation of MI7 cells, was also confirmed by first blocking the 
antibody before immunoblotting (Section 3.3.5), which resulted in no detection IGF-II 
(data not shown).
4.3.4 Proof that high molecular weight forms of IGF-II are not in conditioned media 
due to cell death or damage
4.3.4.1 Cell number
This was calculated, using a Coulter Counter, over a 24 hour conditioning period 
(Figure 4.4) for both MN2 and MI7 cells in the presence or absence of zinc. Cell 
number for both cell lines stayed relatively constant for the conditioning period 
suggesting minimal cell death.
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Figure 4.3A Immunoblot analysis of CM from MN2 and MI7 cells grown in the 
absence (-) or presence (+) of zinc for 48 hours (CM collected for last 
24 hours). lOOpl (from a total of 1ml) electrophoresed and 
immunoblotted with a 1:10000 dilution anti-IGF-II antibody. 20 ng 
pure IGF-II ran as positive control. Molecular weight markers 
(Marker) are indicated on the right.
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Figure 4.3B A longer exposure of the immunoblot in Figure 4.3A
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Figure 4.4 Effect of conditioning period on MN2 and MI7 cell number, grown in 
the presence or absence of zinc. One 5cm plate counted at each time 
point with a coulter counter.
91
4.3.4.2 Cell viability
This was calculated for MN2 and MI7 cells before and after the conditioning period by 
trypan blue exclusion. Before conditioning, cells were 96±2% viable after 
trypsinisation, whilst after 24 hr in CM, 92±7% of cells were viable, confirming that 
the conditioning period had not affected the majority of cells.
4.3.4.3 Immunoblot analysis of a cytosolic protein.
CM from MN2 and MI7 cells were immunoblotted for a protein confined to the cytosol 
of MCF-7 cells, namely HSP27. This protein was not detectable in the media (data not 
shown), indicating that little or no cell death or damage had occurred over the 
conditioning period.
4.3.4.4 Histology of cells.
Cells were stained with haemotoxylin and eosin before and after conditioning. No 
difference in the cells could be seen after the conditioning period with the majority of 
cells looking normal and healthy (data not shown).
4.3.5 Time course of IGF-II secretion by MI5 cells
MI5 cells were grown to subconfluence in twelve 5cm plates, starved in RPMI +1% 
DCFCS overnight and then changed to SFM at time 0. CM (1ml) either with zinc (6 
plates) or without (6 plates) was collected off plates at 14, 16, 18 and 24 hr after zinc 
stimulation, and lOOpl electrophoresed and immunoblotted (Figure 4.5). In the 
absence of zinc, MI5 cells secreted both mature 7kDa IGF-II and a larger form, present 
as a triplet at -17, 16 and 15kDa. Stimulation of cells with zinc resulted in the 
appearance of a larger form of 22kDa along with the triplet (~16kDa) and mature IGF-II 
(7kDa).
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Figure 4.5 Time course secretion of IGF-II by MI5 cells grown in the absence (-) 
or presence (+) of zinc. Cells grown in 5cm plates, were incubated 
with 1ml SFM, CM collected at the indicated time, and 100|il 
electrophoresed and immunoblotted for IGF-II. 20ng pure IGF-II (I) 
ran as positive control. Molecular weight markers (M) are indicated 
on the left.
4.3.6 Time course of IGF-II secretion by MI7 cells
MI7 cells were grown to subconfluence in twelve 5cm plates, and starved in 1% 
DCFCS overnight and treated as the MI5 cells above (Fig 4.6A and B). In the absence 
of zinc, a linear secretion of 22kDa IGF-II was seen (Fig 4.6C). Cells incubated with 
zinc showed no detectable IGF-II up to 8 hours, i.e. secretion was actually inhibited, 
but from then on IGF-II was detectable, and was secreted at a faster rate than the cells 
in the absence of zinc (Fig 4.6C), until at 19-38 hr a steady state levels was reached for 
both sets of cells. A time course study on the MN2 cell line showed no detectable IGF- 
II at any time point (data not shown).
4.3.7 pH]-thymidine incorporation
4.3.7.1 Optimisation of pH]-thymidine incorporation
To examine whether the inhibition of secretion in the MI7 cell line resulted in reduced 
growth rate, a sensitive method for assessing proliferation was used, namely, pH]- 
thymidine incorporation, as cell number would not change to a large extent over the 
period of suppression of secretion (8hr). To ensure that the level of thymidine is not 
limiting, and so as not to add large amounts of radioactivity that could be damaging to 
the cells, cold thymidine is normally added. The MI7 cell line shows no density 
inhibition, and so as the cells could not be synchronised (only artificially), they were 
pulsed with thymidine for 1 hr. As the cells were only exposed for such a short time, 
the level of thymidine was not limiting, and so the concentration of cold thymidine 
could be reduced, so increasing the incorporation of labelled-thymidine. To determine 
a suitable amount of [^H]-thymidine, MN2 cells grown in the presence or absence of 
10"8m oestradiol for 3 days, were pulsed with different concentrations of [% ]-labelled 
and cold thymidine, and incorporation determined (Fig 4.7). In both the presence or 
absence of hormone, lowering the amount of cold thymidine increased the 
incorporation of pH]-thymidine into DNA. The conditions chosen to study DNA 
synthesis in MI7 cells was lOjiCi [% ]-thymidine and no cold thymidine.
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Figure 4.6A Time course secretion of IGF-II by MI7 cells grown in the absence
(-) or presence (+) of zinc. Cells grown in 5cm plates, were incubated 
with 1ml SFM, CM collected at the indicated time, and lOOjil 
electrophoresed and immunoblotted. 20ng of pure IGF-II (I) ran as 
positive control. Molecular weight markers (M) are indicated on the 
left.
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Figure 4.6C Densitometric analysis of autoradiograph in Figure 4 .te . Absorbance 
obtained at 550nm is expressed in arbitary units.
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Figure 4.7 Effect of increasing specific activity of [^HJ-thymidine (T) on 
incorporation into of MN2 cells grown in the absence (A), or in the 
presence (B) of 10‘^M oestradiol (E2) for 3 days. C represents the 
two sets of data on the same scale. 1) 100p.M cold T + 10|iCi [^H]-T, 
2) ImM cold T + lOO^ tCi 3) lO^M cold T + lO^Ci [%]-T, 4)
lOjiCi [^H]-T + no cold T. Incorporation determined from one plate 
as in Section 2.3.8.
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43.1.2 pH]-thymidine incorporation into MI7 cells
To measure the proliferative effect of the IGF-II produced by MI7 cells, pH ]- 
thymidine incorporation was measured in cells with and without zinc over a time 
course. Cells were grown to subconfluence and at the specified times after zinc 
stimulation (0, 3, 7, 12, 23, 32, 48 hr), cells were incubated in media containing pH]- 
thymidine for 1 hr. [^H]-thymidine incorporation was determined as in Section 2.3.8 
(Figure 4.8). At 3 hr zinc-stimulation there was a small but not statistically significant 
decrease in incorporation. After 13 hours there was a significant increase (p<0.05) in 
[^H] thymidine incorporated, that was maintained throughout the experiment. This 
increase in growth rate directly correlated with the time course of IGF-II secretion 
(Figure 4.6C).
4.3.8 Effect of cell density on IGF-II secretion and processing
During several experiments, it was noticed that the level and types of IGF-II varied. A 
possible explanation for this was the difference in cell number and viability when CM 
was collected. To examine how the three major forms of IGF-II changed, two 
variables were analysed, different cell densities (sparse, sub-confluent and over­
confluent), and the time the cells were incubated in SFM (1,2 or 3 days). Therefore, 
MI7 cells were plated in 6 well plates (Falcon) at 2x10^ (sparse), 1x10^ (sub 
confluent) and 2x10^ (over confluent) cells/ well in duplicate, and CM immunoblotted 
for IGF-n (Figure 4.9). Cells incubated in SFM for one day secreted mainly the large 
22kDa form of IGF-II with the sparse cells plated in the absence of zinc not secreting 
detectable levels. The pattern of secretion did not seem to alter greatly over the three 
days, but was checked by densitometry of the large form (Figure 4.10). This 
demonstrated that for cells plated at a sparse density, and in the absence of zinc, IGF-II 
was not detectable after 3 days of incubation, but in the presence of zinc secreted small 
amounts of IGF-II, which accumulated over the 3 days. The same pattern of secretion 
was seen for cells plated at subconfluence, but with higher levels of IGF-II. When
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Figure 4.8 Effect of zinc on [^H]-thymidine incorporation in MI7 cells. Cells 
were grown with or without zinc, and at the indicated time, pulsed 
with lOOjiCi [^H]-thymidine, and incorporation determined. Control 
represents incorporation in MI7 cell without zinc. Values represent 
average of triplicate plates ± S.E.M. Students t-test performed to show 
significance. * p<0.05. **0.01<p<0.001
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Figure 4.9 Effect of cell density on secretion and processing of IGF-II. MI7 cells 
plated in RPMI + 5% DCFCS at sparse (1x10^), sub-confluent (1x10^) 
and over-confluent (2x10^) densities in 6 well plates, and after 24 hr, 
incubated with SFM in the absence (-) and presence (+) of zinc, in 
duplicate. CM (1ml) collected after 1, 2 or 3 days, and l(X)|il 
electrophoresed and immunoblotted for IGF-II.
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Figure 4.10 Densitometric analysis of immunoblots in Figure 4.9. Absorbance at 
550nm (arbitary units) is on the 22kDa form of IGF-II either in the 
absence (A) or presence (B) of zinc.
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cells were over confluent, however, a completely different picture was seen. The large 
form of IGF-n was secreted at a high concentration on the first day, but interestingly, 
conditioned media collected after 2 and 3 days had less present. The decrease in IGF-II 
in over-confluent cells is concominant with an increase in the 15kDa form of the growth 
factor (Figure 4.9). Dividing the absorbance by cell number, to give a value of IGF-II 
secretion/cell (Figure 4.11), we can see that in the presence of zinc, secretion per cell 
does not alter greatly between the different confluencies, with a hint of decreased 
secretion at high confluency. In the absence of zinc, however, density-dependant 
secretion was seen, as a dramatic increase in secretion occurred between the cells plated 
at sub confluency, to those that were plated over-confluently.
4.3.9 Intracellular IGF-II in MN2 and MI7 cells
To determine the types of IGF-II associated with cells secreting IGF-II, cell lysates of 
MN2 and MI7 cells grown in the presence and absence of zinc for 48 hours were 
prepared. Lysates were prepared in three different buffers (T/E, Triton, RIPA) as in 
Section 2.6.2, protein content estimated, and 50pg of protein from each cell line 
electrophoresed and immunoblotted for IGF-II (Figure 4.12). Cells lysed with T/E 
showed no immunoreactive IGF-II, but lysed with Triton or RIPA, MI7 cells grown in 
the presence of zinc had two IGF-II species of 24 and 22kDa. As equal amounts of 
protein were analysed, the T/E sample represents a higher proportion of the lysate (due 
to a lower protein yield), highlighting the lack of IGF-II.
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Figure 4.11 Densitometric analysis from Figure 4.10, corrected for cell number.
Data represents IGF-II (absorbance in arbitary units) secreted/cell for 
CM collected on each day in the absence (A) or presence (B) of zinc.
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4.4 CONCLUSIONS
MI7 cells transfected with the IGF-II gene, secrete three forms of IGF-II with 
approximate masses of 22, 15 and 7kDa, the latter comigrating with recombinant 
mature IGF-II. Secretion was apparent in the absence of zinc, but was inducible three 
fold by stimulation with zinc. MI5 cells, transfected with IGF-II cDNA, that had lower 
levels of IGF-II mRNA, secreted only the 15kDa form (triplet of 17, 16, and 15kDa), 
and mature 7kDa IGF-II. Stimulation by zinc resulted in the appearance of the 22kDa 
form seen in the MI7 cell line. Examination of the cells after removal of the CM 
confirmed their viability, proving that the large forms were specifically secreted and not 
in the media due to cell death or damage.
The 22kDa form of IGF-II, was present in the highest amount, often accounting for up 
to 80% of the total IGF-II. Upon zinc stimulation of MI7 cells, an initial suppression 
of IGF-II secretion was seen up to 8-10 hours, but continual exposure induced 
secretion at a faster rate than in the absence of zinc. Densitometric analysis of the large 
form showed that cells in the absence of zinc secreted the large form at a constant rate 
until at 19-38 hours the level reached steady state. The same time was taken to reach 
steady state levels in the cells stimulated with zinc, but the final level was higher. 
When MI7 cells were stimulated with zinc, two more form appeared, of 24 and 19kDa. 
Cellular IGF-II, detectable only in detergent buffers, appeared as a 24 and 22kDa form.
Studies on the proliferative effect of the secreted IGF-II on [^H]-thymidine 
incorporation, showed an initial decrease when MI7 cells were stimulated with zinc, but 
was followed by a significant increase, which was concominant with the increase in 
IGF-n secretion seen in the time course experiment. Density, and the confluency of the 
cells both affected the rate of secretion and processing of the IGF-II, with a decrease in 
the 22kDa form when cells were incubated in SFM for longer periods, and only when 
cells were at over-confluence
105
4.5 DISCUSSION
Daly et a/. (1991) indicated that transfection of full length IGF-II cDNA (815 bp) into 
MCF-7 McG cells resulted in increased basal growth rate and zinc-stimulated growth, 
that reduced the oestrogen-sensitivity of the cells. By blocking the effect with a 
monoclonal antibody to the IGF-I receptor (a-IR3), they concluded that IGF-II was 
acting in an autocrine manner through this receptor. Detection of IGF-II by 
radioimmunoassay (RIA) proved difficult and inconclusive.
Analysis of IGF-II by a different method, electrophoresis and immunoblotting 
(optimised in Chapter 3), detected IGF-II in three forms of 22, 15 and 7kDa. They are 
related to IGF-II as judged by ; 1) specificity of the antibody for IGF-II (Chapter 3), 2) 
blocking signal by incubation of antibody with mature IGF-II prior to immunoblotting,
2) absence of any signal in the MN2 cell line, 3) inducible signal in the MI7 cell line. 
As all forms show immunoreactivity, they must all contain the epitope present in mature 
IGF-II, needed for antibody recognition, suggesting that they may represent large 
precursors peptides, with the size of the largest form being similar to the predicted 
molecular weight (21kDa) of the translation product of the full length IGF-II cDNA 
(Bell et al.y 1984). This is further discussed in Chapter 5 where the three forms are 
partially characterised. These forms may arise therefore, by saturation of the 
processing machinery involved in cleaving prepro-IGF-II to the mature growth factor.
Analogous results were seen be Gentry et al. (1987), when Chinese hamster ovary 
(CHO) cells were transfected with Type 1 transforming growth factor p (TGFP). The 
growth factor was secreted in large precursor forms, together with the mature form. 
Gentry suggested that these forms arose due to saturation of processing machinery, and 
this would seem tenable, as their transfection system used dihydrofolate reductase 
amplification for high level expression of TGFp. However, even when cells were 
secreting low levels of TGFp, it still appeared as large precursor forms, suggesting that 
saturation of processing was not the only answer. In our transfected cells, the secretion
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of IGF-n, mainly in the large 22kDa form, may also be due to saturation of processing. 
However, as was the case with Gentry et al. (1987), when MI7 cells were not 
stimulated with zinc, and secreting low levels of IGF-II, nearly all of the secreted 
growth factor was in the large 22kDa precursor form. Another cell line, MI5, may 
provide the answer, however, as the large 22kDa form only appeared upon zinc 
stimulation, suggesting that the increase in transcription and translation of the cDNA 
directly resulted in the incomplete processing and secretion of pro-IGF-II.
The appearance of two more forms of IGF-II (24 and 19kDa) when MI7 cells were 
stimulated with zinc (Figure 4.6B) may provide further evidence for saturation of 
processing. The largest form secreted (24kDa) is of a similar weight to prepro-IGF-II 
detected in the BRL-3A cell line by Yang et al. (1985a), with the 2kDa increase over the 
22kDa form correlating with the predicted size of the signal sequence (Bell et al., 
1984). This would mean, however, that the peptide would have to be secreted with 
this sequence intact, but this is possible, as evidence exists for the secretion of proteins 
with an internal sequence (Lingappa et al., 1979), and secretion of mutated proteins 
where cleavage could not occur (Pavla et al., 1982). We can not rule out, however, the 
possibility that these two forms are a result of posttranslational modification of the 
precursors as seen with TGFP (Sha et al., 1989).
Analysis of cytosolic IGF-II, possible only in denaturing buffers, also detected a 24 
and 22kDa form of IGF-II, that were membrane bound. These sizes again suggest that 
prepro and pro-IGF-II are detected, having been translated from the mRNA, the peptide 
being present in the endoplasmic reticulum and golgi, before being sorted towards a 
secretory vesicle (Steiner et al., 1980).
The secretion of IGF-II in the absence of zinc was not detectable by Daly et al. (1991) 
using RIA, but was clearly visible by this method, and is linked to the increased basal 
growth rate of the MI7 cell line. The secretion, referred to by Daly as being due to a 
'leaky promoter' is presumably due to basal level enhancer present in the promoter 
(Figure 4.13). Haslinger et al. (1985) observed that the metallothionein promoter often
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produces high basal expression in transfection systems, and this was also seen when 
MCF-7 cells were transfected with TGFa under the control of the metallothionein 
promoter (Clarke et al., 1989). The promoter has a complex number of regulatory 
elements including two basal level enhancers (BLE), and four metal regulatory elements 
(MRE) which provide the response to heavy metal ions . A proposed model for the 
action of heavy metal ions on the promoter involves a metal regulatory factor (MRF), 
that in the presence of zinc can bind limiting factors in the nucleus, that binds to the 
MRE which can act upon the BLE and induce transcription (Figure 4.13) (Karin et al., 
1987). Deletion analysis indicates that the BLEs are crucial for both the basal level, and 
also zinc-induction. The basal level in the MI7 cells, may be due to the action of the 
BLE, but we cannot, however, rule out the possibility that the low level of secretion is 
due to heavy metal ions present in the stripped serum. Certain heavy metal ions are 
present, but levels are not known (personal communication, GIB CO). The method of 
collecting CM from the cells i.e. removal of serum, suggests that the basal level is 
probably due to the former reason.
The stimulation of MI7 cells with zinc initially lowered the level of IGF-II secreted, but 
after 10 hours, marked stimulation was seen. The initial inhibition, may be due to the 
complex mechanism whereby heavy metal ions can cause induction of transcription. It 
is possible that the suppression of IGF-II synthesis is due to a delay in transcription, as 
the complex described above forms. Time may be needed for factors to be recruited, or 
the DNA to rearrange its quaternary structure to a conformation whereby the MRF, 
MRE and BLE can act in synergy (Figure 4.13). Either of these situations may result 
in a delay in transcription, which would reduce the mRNA available for translation, and 
so result in a decrease in IGF-II secretion. The decrease in IGF-II present in the media 
of cells suggests that the mRNA present at time 0 has a short half life, or that there were 
such low levels that detectable levels of IGF-II were not translated. The decrease may, 
however, simply represent the cells being 'shocked' by the addition of heavy metal 
ions, which could have affected secretion of a range of proteins. The lack of detection
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of IGF-II mRNA in cells in the absence of zinc, despite detection of peptide hinders 
elucidation of this phenomenon.
Experiments performed on the proliferative effect of the secreted IGF-II, showed that 
the initial suppression of IGF-II synthesis did not significantly affect [^H]-thymidine 
incorporation in MI7 cells, but that when secretion started, cells in the presence of zinc 
synthesised DNA at a significantly faster rate than those in its absence. The large form 
of IGF-n, present in the highest amount, may be causing part of this increase in DNA 
synthesis, as could the 15kDa form. This possibility is further investigated in Chapter 
5.
The levels of IGF-II varied between experiments, the most likely reason being variation 
in cell density in the so-called sub-confluent monolayers. Analysis of the effect of 
density on the secretion of IGF-II highlighted a complex number of interactions. For 
cells grown in the absence of zinc, there was a large induction of secretion of the 22kDa 
peptide from cells plated at sub-confluence to those plated at over-confluence with the 
possibility of interactions between cells in the overconfluent state. Another possible 
explanation, that unfortunately can’t be measured due to low levels of IGF-II, is the 
fact that in the sparse and subconfluent cells, there may have been more efficient 
processing of the large form to the mature growth factor. This density effect was not 
so apparent in the cell stimulated with zinc, with IGF-II production per cell declining 
when cells were plated at higher densities.
The effect of increasing the incubation time in SFM, also indicated complex 
interactions. At sparse and subconfiuent densities a steady increase in the large form of 
IGF-II was seen. However, at over-confluency, a decrease in IGF-II was seen over 
the three days. This could be due to several reasons: 1) The large form of IGF-II is 
processed to the 15kDa form in the media, by proteolytic enzymes either secreted by the 
cells, or released from dying cells. This is backed up by an increase in the 15kDa form 
as cells were incubated for longer periods. 2) The large form is being internalised by 
cells. This would agree with data concerning interactions of other purified large forms
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of IGF-II with the same receptor (Section 1.2.3.3). 3) IGF-II is being degraded at a 
rate faster than secretion.
Having detected IGF-II in the three forms, they are further purified and characterised in 
the next chapter to confirm their partially processed nature, and their similarity to other 
forms present in the literature.
I l l
CHAPTER 5: ANALYSIS OF HIGH MOLECULAR
WEIGHT FORMS OF IGF-II SECRETED BY 
MI7 CELLS
112
5.1 INTRODUCTION
The discovery of large forms of IGF-II in the last ten years (Section 1.2.3.2) has led to 
research into their significance in IGF-II action, but has also provided insight into the 
processing of prepro-IGF-II to the mature growth factor. The size of the three forms of 
IGF-II secreted by the MI7 cell line suggests that they may represent precursor forms, 
with the smallest form (7kDa) comigrating with pure recombinant mature IGF-II. The 
largest form, 22kDa, is of a similar molecular weight to pro IGF-II detected by Yang et 
al. (1985a) from a cell free translate of BRL-3A mRNA. The 15kDa form of IGF-II 
secreted by MI7 cells may have structural homology with 15kDa pro-IGF-II discovered 
by Gowan et al. (1987), which has been purified and consists of mature IGF-II with a 
21 amino acid extension (lOkDa of protein) and 5kDa of O-linked glycosylation 
(Hudgins et al., 1992). The heterogeneity of the 15kDa form seen in MI5 and MI7 
cells in Chapter 4 suggests that these may also be posttranslationally modified.
Purification of these different forms would allow analysis of their sequence and 
biological activity, however, in the past this has proved a difficult task due to; 1) low 
amounts of IGF-II, 2) the presence of high affinity binding proteins and 3) the small 
differences in molecular weight and structural properties. This chapter describes the 
concentration of IGF-II in CM, and purification by a variety of size fractionation 
methods.
5.2 OBJECTIVES
1) Concentrate IGF-II - determine methods
2) Separate different forms - FPLC
- cibracon blue
- ultrafiltration
3) Characterisation of forms - acidification
- ion-exchange chromatography
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5.3 CONŒNTRATION OF IGF-H IN CONDITIONED MEDIA
5.3.1 Introduction
To increase the amount of IGF-II that could be electrophoresed and immunoblotted, 
CM was lyophilised and reconstituted in distilled water. However, after reconstitution, 
the salt was at a saturating concentration which made reconstitution difficult, and 
interfered with subsequent electrophoresis. Therefore, several methods were tested for 
their ability to remove the salt, but not affect the levels and types of IGF-II in CM.
5.3.2 PD-10 column
2.5mls of CM was passed over a PD-10 column (Pharmacia), and macromolecules 
eluted with distilled water (Section 2.4.1). The eluate showed an initial peak of protein 
(Figure 5.1), but also a second peak where we would expect the salt to elute. The 
fractions of interest (4-6) were pooled, freeze dried and immunoblotted for IGF-II 
(Figure 5.2). Comparison of the eluate (lane 2), with the same amount of CM that had 
not been concentrated (lane 1), indicated loss of the 22 and 15kDa forms of IGF-II, 
with an increase in the 7kDa mature form.
5.3.3 CIS reverse phase chromatography
A common method for separating binding proteins from IGF's in CM is reverse phase 
chromatography. Chromatography was performed with a CIS column (Section 2.4.2), 
but resulted in complete loss of IGF-II (Figure 5.2, lane 3). The method was not 
evaluated further to examine whether IGF-II had bound, due to the difficulties 
encountered with removing the acetonitrile from the eluate before performing SDS- 
PAGE.
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Figure 5.1 Elution profile of 2.5 mis of CM passed over a PD-10 desalting 
column. Fractions 4-6 pooled, and lyophilised.
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MI7 CM concentrated 
Immunoblotting of CM after concentration, indicating the effect of 
various desalting methods on the levels of IGF-II. lOOjil of CM 
electrophoresed in lane 1, whilst lanes 2-6 represent electrophoresis of 
l|il CM concentrated 100-fold by the indicated methods. For the C3 
membrane, proteins were either retained (R) or passed through (E).
5.3.4 C3 amicon.
Concentration of 2mls of CM with a C3-3000 M.Wt cut-off membrane (Section 2.4.3), 
resulted in desalting of CM, with the membrane retaining (R, lane 4) all the IGF-II, 
leaving none detectable in the eluate where the salt was found (E, lane 5). However, 
comparison of the desalted IGF-II (lane 4), with CM that had not been concentrated 
(lane 1) indicated a small loss of the 22kDa from of IGF-II. This fact, and the long 
times needed for centrifugation (up to 6 hours), and the small volumes that could be 
treated (maximum of 2 mis per column), made this method unsuitable.
5.3.5 Dialysis.
CM was dialysed against distilled water overnight at 4“C, and immunoblotted for IGF- 
II (Figure 5.2, lane 6 ). A small loss of 15kDa IGF-II occurred, with an apparent 
increase in the 22 and 7kDa forms. The differences between CM before and after 
concentration may be due to the fact that these samples had to be electrophoresed on 
different width gels, and large volumes of samples often produce diffuse signals. The 
large volume of CM that was not concentrated that had to be loaded to obtain a signal 
(lOOjil) may therefore be the reason, as for CM that had been concentrated only l|j.l 
was analysed.
5.4 SEPARATION OF LARGE FORMS OF IGF-II
5.4.1 Introduction
Concentration of IGF-II in CM was best performed by dialysis, lyophilisation, and 
reconstitution. Although a time consuming method, dialysis did not substantially affect 
the level and type of IGF-II, and this method could also handle large volumes. In most 
cases, CM was concentrated between 100-1000 fold, often resulting in up to 50pg 
immunoreactive IGF-II/ml CM. However, many other proteins were present 
accounting for a total protein content of up to 20mg/ml. Analysis of the largest amount 
of protein by SDS-PAGE (lOOpg) could detect IGF-II by immunoblotting, but not by
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silver staining, as in lOOpg of protein, IGF-II was at a concentration of less than 50ng. 
The separation of IGF-II from other contaminating proteins would allow more IGF-II 
to be analysed by SDS-PAGE, and so permit either separation of the forms by 
electroelution from the gel, or sequencing from nitrocellulose. Separation of the three 
forms was attempted by a number of different methods; 1) cibacron blue, 2 ) 
ultrafiltration, 3) FPLC
5.4.2 Removal of albumen from CM.
Despite the preparation of CM in serum-free conditions (section 2.3.10), the major 
protein after electrophoresis was a protein of approximately 70kDa (Figure 5.8), which 
is presumably residual albumen, accounting for up to 60% of the total protein present. 
This represents trace amounts of albumen compared to the levels in FCS, but are high 
in relation to the concentration of IGF-H. The contaminating albumen could probably 
be reduced by incubating the cells with another volume of serum-free media, however, 
cells started to die when this was performed, resulting in the release of other proteins 
into the media. For this reason, methods were evaluated for separation of BSA from 
the three forms of IGF-H in CM.
5.4.2.1 Cibacron blue.
A common method for removal of albumen from biological samples is the dye cibacron 
blue, which when bound to a matrix such as sepharose, has a relatively low affinity 
(lO'^M) for albumen, but an extremely high capacity (>10mg BSA/ml blue sepharose). 
Initial experiments performed with a column of blue sepharose or blue silica, resulted in 
albumen passing through the column (data not shown). Batch chromatography on the 
other hand, with CM in the presence of dye for up to 1 hour, resulted in the removal, 
and allowed the analysis of a number of different conditions.
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5.4.2.2 Optimum conditions for albumen binding.
BSA was dissolved at a concentration of 1 mg/ml in six buffers of different ionic 
strength, blue sepharose or blue silica (200pl) added, rocked for 1 hour, centrifuged at 
7000xg to remove beads, and the absorbance of the supernatant read at 280nm. In 
Figure 5.3, the absorbance when no gel was added (column 1), represents the 
absorbance of BSA dissolved in water (Img/ml). Under these conditions, blue 
sepharose removed approximately 50% of the BSA, whilst blue silica bound very little 
(column 2), however, raising the ionic strength of the buffer that BSA was dissolved 
in, greatly increased the ability of blue sepharose and blue silica to bind BSA. The 
higher affinity in the presence of salt, was not affected by tris buffer (O.IM pH 7.4), 
but tris alone was also able to increase the ability of blue sepharose and blue silica to 
bind BSA. To ensure that the BSA had not been simply trapped by the beads upon 
centrifugation, and so removed from the supernatant, BSA was eluted by incubation of 
beads with 2M NaCl for 1 hour (Figure 5.4). The lower absorbances in columns 1 and 
4, reflect reduced binding under these conditions seen in Figure 5.3. Interestingly, 2M 
NaCl resulted in less than 10% elution of BSA from blue silica. For further 
experiments, O.IM NaCl was chosen as the optimum condition for BSA binding.
5.4.2.3 Separation of BSA from IGF-II
BSA (Img) and IGF-II (200 ng) were diluted in 1ml of O.IM NaCl, and the 
absorbance read at 280nm (Figure 5.5, column 1). Blue sepharose and silica were 
added, incubated for 1 hour with shaking, centrifuged, supernatant aspirated, and the 
absorbance read (column 2). Comparison of the absorbance before and after incubation 
with blue sepharose and silica, indicated binding of approximately 80% of the BSA by 
both gels (Figure 5.5). Increasing the ionic strength of the wash buffer eluted BSA 
from blue sepharose in a non-specific manner with ~ 10-20% of the BSA per fraction. 
For blue silica, however, httle elution occurred even with a buffer of high ionic strength 
(2M NaCl), which confirms the data seen in section 5.4.2.2. To examine whether the 
cibacron blue bound IGF-II, and if so whether it was eluted by salt, fractions were
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Figure 5.3 Effect of ionic conditions on the binding of BSA by blue sepharose and 
blue silica. BSA (Img/ml) was disolved in water and the absorbance 
read at 280nm (1). BSA (Img/ml) that had been dissolved in water (2), 
O.IM NaCl (3), O.OIM NaCl (4), O.IM NaCl + lOOmM tris pH 7.4 (5), 
O.OIM NaCl + lOOmM tris pH 7.4 (6) and lOOmM tris pH 7.4 (7), was 
incubated with blue sepharose or blue silica, beads removed by 
centrifugation, and the absorbance of the supernatant read at 280nm.
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Figure 5.4 Elution of BSA from blue sepharose and blue silica. Beads that had 
previously bound BSA in different buffers (see legend for Figure 5.3), 
were incubated with 2M NaCl for 1 hour, removed by centrifugation, 
and the absorbance of the supernatant read at 280nm.
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Figure 5.5 Elution of BSA from blue sepharose and blue silica. BSA (Img/ml) 
and IGF-II (200ng) were dissolved in O.IM NaCl (1), gel added, 
removed by centrifugation, and absorbance of the supernatant read at 
280nm (2). Beads were then washed in succession with buffers of 
increasing ionic strength; O.IM NaCl (3), 0.5M NaCl (4), IM NaCl 
(5), 2M NaCl (6), and absorbance of the supernatant read each time.
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Figure 5.6 Immunoblot analysis of IGF-II in eluate from blue sepharose (a) and 
blue silica (b). Eluate (described in Figure 5.5), was dialysed, 
lypohilised and reconstituted in lOOjil of distilled water. l()|il was 
analysed by SDS-PAGE and immunoblotted. 20ng IGF-II (1) ran as a 
positive control.
dialysed to remove salt, freeze dried, reconstituted and immunoblotted (Figure 5.6). 
Both blue sepharose and blue silica bound all the IGF-II (lane 2 and 3) but the 
appearance of IGF-II from blue sepharose paralleled that of BSA, with non-specific 
elution throughout the washes, indicating no separation from BSA. The total IGF-II 
eluted was comparable to the same amount ran as a positive control (lane 1) 
Interestingly, there was no elution of IGF-H from blue silica, even under the strongest 
ionic conditions, as with BSA (Figure 5.6). Both methods were therefore unsuitable 
for removal of IGF-H from BSA.
5.4.3 Molecular weight cut off membranes.
After centrifugation of MN2 and MI7 CM over CIO and C30 membranes, the volume 
above the membrane (retentate), and the volume that went through (eluate) were 
lyophilised, and reconstituted with 50pl water. 25pl was electrophoresed and stained 
with coomassie blue (Figure 5.7), whilst the other 25pl was immunoblotted for IGF-H 
(Figure 5.8). Staining for total protein indicated that the main contaminants of CM, 
were retained (retentate) by both the CIO and C30 membrane, however, it was 
noticeable that both membranes retained nearly all the protein, as there was little 
staining in the eluate. Immunoblotting for IGF-H (Fig 5.8), showed that none was 
present in the MN2 conditioned media, as would be expected, but all three forms of 
IGF-H in the MI7 CM were retained by both the CIO and C30 column. Both columns 
were therefore unsuitable for separation of IGF-H from BSA.
5.4.4 FPLC.
This was performed with the help of Mr Arcardio Garcia de Castro. Pure protein 
standards were run over the column, eluted with PBS at a rate of 0.5 ml/min, and a 
calibration curve obtained (Figure 5.9). CM was acidified with 4% (v/v) acetic acid 
prior to chromatography, to dissociate binding proteins, and lOOjil of conditioned 
media (2mg total protein), diluted to 1ml with PBS/4% (v/v) acetic acid and loaded onto 
the column. Elution was performed with PBS/4% (v/v) acetic acid at a rate of
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Figure 5.7 Ultrafiltration of MN2 and MI7 CM, with CIO and C30 membrane (E 
eluate and R - retentate). 2ml of CM (0. Img/ml) passed over the 
membrane, and E and R lyophilised and recondtituted in 50|il of 
distilled water. Duplicate 25|il aliqouts were analysed by SDS-Page 
and stained with coomassie blue or immunoblotted for IGF-II (Figure 
5.8).
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Figure 5.8 Immunoblot analysis of lGF-11 in eluate (E) and retentate (R) alter
centrifugation over a CIO or C30 membrane.
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Figure 5.9 Standard curve for FPLC column (sephacryl S-100, 25x1.5 cm).
Protein standards (alcohol dehydrogenase, 150kDa; bovine serum 
albumen, 69kDa; carbonic anhydrase, 30Da; a  lactoglobulin, 14kDa) 
were all run individually at a rate of 0.5ml/min, and eluted with PBS.
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0.5ml/min. Fractions were dialysed, freeze dried, electrophoresed and either silver 
stained (Figure 5.10), or immunoblotted for IGF-H (Figure 5.11). Staining for total 
protein revealed separation of different molecular weight proteins throughout the 
fractions, however, immunoblotting for IGF-H indicated that the three forms of IGF-H 
had not separated to a large degree, and the bands were now much more diffuse, 
suggesting protein degradation. Comparison of MI7 CM that had not been subjected to 
FPLC (2% of that loaded on column), indicated a large loss of all forms of IGF-H. 
This method was not successful for separation and purification of different forms of 
IGF-H.
5.5 CHARACTERISATION OF LARGE FORMS OF IGF-H.
5.5.1 Introduction
Separation of IGF-H from other components in CM, especially BSA, proved difficult, 
due to the similar binding properties of the proteins (cibacron blue), inadequate 
differences in molecular weight (ultrafiltration, FPLC), and the low amount of starting 
material (FPLC columns resulted in a large dilution factors). Despite this, 
characterisation of the three forms was attempted by first showing that the high 
molecular weight was not due to binding proteins, and that the 15kDa form could be 
separated from the 22 and 7kDa form by cation-exchange chromatography, as 
performed by Hudgins et al. (1992) who indicated the presence of 15kDa pro-IGF-H in 
serum.
5.5.2 Acidification of media
Most breast cancer cells secrete high affinity binding proteins for the insulin-like 
growth factors, which can in turn, regulate their action (Section 1.3.5). The MCF-7 
cell line can secrete four of these, and so as to ensure that the large molecular weight of 
the IGF-H was not due to binding proteins not dissociated by SDS-PAGE, CM was 
acidified prior to electrophoresis (Figure 5.12). Concentration of IGF-H had no effect 
on the levels of IGF-H (lanes 1 and 2, versus 3 and 4), whilst acidification also had no
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Figure 5.10 Silver stain of eluate from FPLC column. Fractions were dialysed (to 
remove acid), lyophilised and reconstituted in distilled water before 
SDS-PAGE.
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Figure 5.11 Immunoblot of eluate from FPLC column. 20ng IGF-II and 2p.l of 
MI7 CM ran as positive controls. Molecular weight markers.(M) are 
indicated on the left.
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Figure 5.12 Effect of concentration and acidification on the level of IGF-II in CM 
from MI7 cells in the absence (2, 4, 6) and presence (3, 5, 7) of zinc. 
20ng IGF-II (lane 1) ran as a positive control. 100|il CM treated as 
follows: A) no concentration, B) CM acidified with 4% v/v acetic acid 
and then dialysed and lyophilised, C) CM dialysed, lyophilised and 
reconstituted with PBS/ 4% v/v acetic acid, which was neutralised with 
2p,l IM tris pH 8.8, and all samples analysed by SDS-PAGE and 
immunblotted for IGF-II.
effect (lanes 5 and 6). This shows, therefore, that SDS-PAGE separates IGF-II from 
binding proteins efficiently.
5.5.3 Cation-exchange chromatography
A method for separation of a high molecular weight form of IGF-II in serum was 
performed by Hudgins et al. (1992), which was a development of a method first used 
for purification of mature IGF-I by Svoboda et al. (1987). IGF-II binds strongly to a 
cation-exchange column and can be separated from other proteins, but Hudgins also 
noted that the large form of IGF-H in human serum purified by Gowan et al. (1987) 
bound weakly to the column. Cation-exchange chromatography of the large forms of 
IGF-H from MI7 cells, was performed according to Section 2.7.1. lOOpl of CM 
(concentrated 100 times), that contained approximately lOpg of total immunoreactive 
IGF-H, was diluted with SOOpl of starting buffer (2M acetic acid with 0.075M NaCl) 
and loaded onto a column (5cm x 2.5cm) of SP-Sephadex C-25.
Following removal of weakly bound proteins (Figure 5.13) by washing with starting 
buffer (peak 1), elution was performed with 0.4M NaCl (peak 2), and then 2M NaCl 
(peak 3). Fractions in peaks 1,2 and 3 were pooled, dialysed to remove salt and acid, 
lyophilised and reconstituted in 50pl of water. 5pl was analysed by SDS-PAGE and 
immunoblotting (Fig 5.14). Lane 5 represents 2pl of conditioned media before 
chromatography, and lane 4, 20ng of IGF-H, as positive controls. The wash through 
the column (peak 1, lane 1), contained no immunoreactive IGF-H, whilst increasing the 
ionic strength of the buffer to 0.4M NaCl resulted in the selective elution of the 15kDa 
form of IGF-H (peak 2, lane 2). This was clearly separated from the other two forms 
of IGF-H of 22 and 7 kDa, which coeluted under the strongest ionic conditions (peak 
3, lane 3).
Comparison of media before and after chromatography, indicated a recovery of about 
10% of IGF-H, and electrophoresis of the concentrated eluate, and staining with 
coomassie blue showed that the loss was not only with IGF-H, but for all proteins.
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Figure 5.13 Elution profile from cation-exchange column. 100|il of CM 
(concentrated 100 fold) from MI7 cells grown in the presence of zinc 
was diluted in starting buffer (2M acetic acid and 0.075M NaCl), 
loaded onto the column (5 x 2.5cm), washed with three column- 
volumes each of starting buffer, then buffer 2 (2M acetic acid and 
0.4M NaCl) and then buffer 3 (2M NaCl and 0.5M Tris/HCl pH7.4). 
Protein elution was monitored by absorbance at 280nm, fractions of 
interest were pooled, dialysed against 3 litres of distilled water at 4°C 
overnight and freeze dried.
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Figure 5.14 Immunoblot of eluate from cation-exchange column. Fractions were 
pooled into peaks 1, 2 and 3 (Figure 5.13), dialysed, lyophilised and 
reconstituted in 100|il water. lOp.1 was electrophoresed and 
immunoblotted for IGF-II (lanes 1-3). Lane 4 represents 20ng IGF-II 
and lane 5, 2|il conditioned media prior to chromatography.
Treatment of the column with 2M NaOH, resulted in elution of the remaining protein 
(data not shown). Although concentration of the forms was not successful due to such 
large losses, the separation of 15kDa IGF-II from 7kDa mature IGF-II, however, 
paralleled that seen by Hudgins et al. (1992).
5.6 BIOLOGICAL ACTIVITY OF LARGE FORM OF IGF-H
5.6.1 Introduction
Although puriHcation of the large forms of IGF-H had proved difficult, determination 
of their biological activity was attempted, by comparing the proliferative effect of 
recombinant mature IGF-H with the total immunoreactive IGF-H secreted by MI7 cells.
5.6.2 Preparation of CM
CM was collected from four 9cm plates of MN2 and MI7 cells grown with and without 
zinc (total 16 plates), concentrated and reconstituted in 200|il of water. CM was 
collected from two separate experiments on 10/2/93 and 14/2/93.
5.6.3 Levels of total immunoreactive IGF-H in CM
Pure IGF-H was immunoblotted (Figure 5.15) and analysed by densitometry (Figure 
5.16), producing a standard curve, with a linear response from 5 to 200ng. Lowering 
volumes of concentrated CM from 10/2/93 (Figure 5.17) and 14/2/93 (Figure 5.18) 
were immunoblotted, and the amount of IGF-H present calculated from the standard 
curve (Table 5.1). MN2 CM from both experiments had no detectable IGF-H, whilst 
MI7 CM from 10/2/93 had 2.6p.g and 17.4fi,g/ml IGF-H, and on 14/2/93 had 4.4 and
15.6 |ig/ml IGF-H in the absence and presence of zinc respectively. When cell number 
was taken into account, on both occasions, MI7 cells in the absence of zinc secreted an 
average of 22  ng IGF-H/10^ cells/24 hours, and in the presence 104 ng IGF-H/10^ 
cells/24 hours.
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Figure 5.15 Pure IGF-II applied to nitrocellulose, by slot blot apparatus, and 
immunoblotted.
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Figure 5.16 Densitometric analysis indicating a linear response to IGF-II (Figure 
5.15). Absorbance (550nm) expressed in arbitary units.
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Figure 5.17 Immunoblot of CM prepared from cells on 10/2/93. CM (10, 5, 1, 
0.5pl) applied to nitrocellulose by slot blot apparatus, and
immunoblotted for IGF-II.
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Figure 5.18 Immunoblot of CM prepared from cells on 14/2/93. CM (10, 5, 1, 
0.5pl) applied to nitrocellulose by slot blot apparatus, and 
immunoblotted for IGF-II.
Conditioned Media -10/2/93
Cell Number 
(4x9cm plates)
ng IGF-IVpl ng IGF-n/106
cells/24 hrs
Total IGF-II 1 
(ng)
MN2-Zn 2.7x107 ND ND ND
MN2 + Zn 2.6x107 ND ND ND
MI7 - Zn 3.6x107 3 14 520
MI7 + Zn 2.8x107 17 124 3480
Conditioned Media -14/2/93
Cell Number 
(4x9cm plates)
ng IGF-IVpl ng IGF-II/106  
cells/24 hrs
Total IGF-II 
(ng)
MN2-Zn 2.5x107 ND ND ND
MN2 + Zn 2 .8x10? ND ND ND
MI7 - Zn 3.0x10? 4 29 880
MI7 + Zn 3.7x107 16 84 3120
Table 5.1 Secretion of total immunoreactive IGF-II by MN2 and MI7 cells in 
two independent experiments. Amount of IGF-II calculated by 
densitometry of slot blot (Figure 5.17 and 5.18), and estimation from 
standard curve for pure IGF-II (Figure 5.16). Cell number was 
calculated with a Coulter counter. ND - IGF-II not detectable.
10/2/93
14/2/93
IGF-n (ng)
Volume CM 20pl 2pl 0 .2pl 0 .02pl
M I7-Zn 52 5.2 0.52 0.052
M I7+Zn 348 34.8 3.48 0.348
M I7-Zn 88 8.8 0.88 0.088
MI7 + Zn 312 31.2 3.12 0.312
Table 5.2 Total immunoreactive IGF-II (ng) present in CM added in proliferation 
assay.
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5.6.4 SDS-PAGE analysis of IGF-II in CM
Two volumes of CM from MI7 cells (5 and lOpl) were electrophoresed and 
immunoblotted (Figure 5.19). As mentioned in Section 4.3.8, the conditioned media 
from these two experiments had a different pattern of IGF-II secretion compared to 
most other experiments. In this case, the large form of 22kDa was still in the greatest 
abundance, but there were higher levels of the two other forms (15 and 7kDa). The 
biological activity of the CM was then measured by assessing the effect on proliferation 
of MCF-7 McG oestrogen-dependent cells.
5.6.5 Proliferative effect of CM on MCF-7 McG cells
MCF-7 cells were plated in 96 well plates, and incubated in RPMI with 5% DCFCS for 
7 days, to remove any steroid, and reduce proliferating to basal rate. Cells were then 
exposed to serial dilutions of recombinant IGF-II, and lowering volumes of CM for 4 
days and cell growth assessed by MTT assay. For pure IGF-II, control represents 
absorbance after 4 days with no stimulant (Figure 5.20), whilst the control for MI7 
CM, is the absorbance after cells were exposed to the same volume of MN2 CM. In 
the absence of any mitogen (0), there was no proliferation of MCF-7 cells, confirming 
their oestrogen-dependant phenotype. IGF-II was a potent mitogen, with an increase in 
cell number at lOng/ml and maximal response at lOOng/ml. CM prepared from MI7 
cells in the absence of zinc caused no proliferation, whilst CM prepared from cells in 
the presence of zinc stimulated growth. CM from 14/2/93, gave a similar response, 
however, CM from cells grown in the absence of zinc was mitogenic. Having 
estimated the amount of IGF-II present in the CM (Table 5.1), the amount of total 
immunoreactive IGF-II added to the proliferation assay can be calculated (Table 5.2). 
CM from MI7 cells (14/2/93) in the presence and absence of zinc had similar activities 
(Figure 5.21), but both were lower than for pure IGF-II, with a decrease in the slope of 
the dose response curve, and a shift to the right.
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Figure 5.19 Immunoblot of CM from MI7 cells grown in the absence (-) and 
presence (+) of zinc.
C M . 10/2/93
500 -1
400 -
« ê  300-  
§ 8
200 -
(20)
100
(0.2)(0.02)
100 1000100 1
-Q—-  Pure IGF n  
■o—  MI7-Zn 
-#—  MI7+Zn
0 volume of CM added
Pure IGF-II (ng/ml) 
CM -14/2/93
500 1
400 -
(20)
300 -
200 -
100 f
(0.02) (0.2)
1000100101O
 Q—  Pure IGF n
 O—  MI7-Zn
• —  MI7+Zn 
0  volume of CM added
Pure IGF-II (ng/ml)
Figure 5.20 Proliferative effect of pure IGF-II (1000, 100, 10, 1 and 0 ng/ml), and 
lowering volumes of CM from MI7 cells (20, 2, 0.2, 0.02 p.1). MCF-7 
cells exposed to stimulant on day 0 and counted by MTT assay on day 
4. Control for IGF-II represents absorbance on day 4 with no 
stimulant and MI7 CM, after 4 days with a corresponding volume of 
MN2 CM. Each point represents the mean value of quadruplicate 
wells±S.E.M. Where no bars are shown, errors were too small for 
visual display.
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Figure 5.21 Proliferative effect of pure IGF-II and CM from MI7 cells. Amount of 
IGF-II in CM calculated by immunoblotting (Table 5.1 and 5.2).
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5.7 CONCLUSIONS.
IGF-II was concentrated by dialysis, to remove salt from the medium, and then 
lyophilised and reconstituted. This method allowed the processing of large volumes of 
CM, which may have affected the levels and types of IGF-II, but to not the same extent 
as other methods that were tested.
Separation of albumen from CM was attempted by both size fractionation, and specific 
adsorption. All techniques performed (ultrafiltration, cibacron blue and FPLC) failed to 
separate BSA from IGF-II, and all techniques had their own downfalls. Cation- 
exchange chromatography, however, was able to specifically separate the 15kDa form 
of IGF-II from the 22kDa form and mature IGF-II. Unfortunately, a large proportion 
of the protein (-90%), bound to the column in a non-specific, and was only eluted in 
2M NaOH. This technique, therefore was useful for characterisation of this large form, 
but was not suitable for purification, suffering great losses of IGF-II.
Determination of the biological activity of the large forms was attempted, by analysing 
the proliferative effect of CM and pure IGF-II on MCF-7 cells. Pure IGF-II was a 
potent mitogen, as was CM from MI7 cells, but when the amount of IGF-II was 
estimated in the CM, the proliferative response was reduced compared to the same 
concentration of pure IGF-II. The CM is, therefore, biologically active, but the effect 
of the large forms can not be assessed.
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5.8 DISCUSSION
Separation and purification of the three forms of IGF-II is essential for analysing their 
structural and biological properties, also giving some insight into how these forms have 
been processed from prepro-IGF-II to the mature form (presumably via cleavage at 
pairs of basic amino acids). Initially, several methods were evaluated for concentration 
of IGF-II in CM. As the growth factor is secreted at such low levels (ng IGF/mls 
CM), concentration was essential, to allow more IGF-II to be analysed by 
electrophoresis and immunoblotting. Three fast methods for desalting (PD-10, C3, 
CIS) all resulted in loss of IGF-II or degradation of the three forms, and the method of 
dialysis and lyophilisation was chosen. The large precursor forms of IGF-II have 
several protease susceptible sequences (Section 1.2.3.1), that allow processing to the 
mature form, and so a protease inhibitor was added to the CM before and after dialysis. 
ITie level and types of IGF-II altered to a small degree, over the concentration period.
Having concentrated CM, it was hoped that more IGF-II could be electrophoresed, and 
so separated by removal from the polyacrylamide gel by electro-elution. However, 
when concentration had been performed, the limiting factor for SDS-PAGE analysis 
now (previously the volume of media) was the amount of contaminating protein. The 
majority of this was albumen, most probably left over from the serum the cells were 
routinely grown in. Three methods were chosen to try to separate the albumen from the 
IGF-II. Ultrafiltration showed the wide range of sizes a molecular weight cut off 
membrane will retain. Even with a 30kDa cut off membrane, the three forms of IGF-II 
(22,15,7kDa) were retained with the albumen, when they should have passed through 
the membrane. One possible explanation for this, however, was that the CM was not 
acidified prior to ultrafiltration, and so the IGF-II may have been bound in high 
molecular weight binding protein complexes.
Cibacron blue is a common dye used for the removal of albumen from biological 
samples. With a thorough examination of the conditions needed for optimum albumen
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binding, however, IGF-II either coeluted with BSA (blue sepharose), or did not elute 
under the most stringent conditions (blue silica). The final method, FPLC, was 
successful at size fractionation of proteins in CM, but this did not occur with IGF-II, 
with the three forms eluting across all the fractions, particularly with the BSA. The 
diffuse bands suggest that also some protein degradation had occurred.
A final method for purification and separation of the forms was attempted by cation- 
exchange chromatography, previously performed by Hudgins et al. (1992) for 
purification of a 15kDa pro-form of IGF-II from serum. Following their method 
exactly, we were also able to specifically separate 15kDa IGF-II from the mature 7kDa 
and 22kDa form. However, this method resulted in a loss of approximately 90% of the 
protein loaded, as it bound non-specifically and non-ionically to the matrix, and would 
only be eluted with 2M NaOH. The most probable reason for the strong binding is the 
strong acidic conditions used for loading the sample (pH 2.8), and washing the 
column. Data available on the column indicates a working range of pH 2-11. Hudgins 
et al. (1992) recovered 64% of the large form of IGF-II, using exactly the same 
method, which had been labelled with indicating that losses did occur, but not to 
the same extent as we encountered.
Hudgins et al. (1992) used an antibody raised to the first 21 amino acids of the carboxy 
terminal extension (Arg^S to LysSS), to show that the large form of IGF-II, represents 
mature IGF-II with this 21 amino acid extension, accounting for lOkDa of protein, and 
the increase in molecular weight was found to be due to 5kDa of 0-linked glycosylation 
on Thr^^, which is in the carboxy-terminal extension (Section 1.2.3.2). As yet, the 
significance of this glycosylation on the processing or biological activity of the large 
form of IGF-II is unknown, but this form of posttranslational modification has been 
shown to be present and important in secretion of large forms of TGFp (Gentry et al 
1987). The 15kDa form detected in the MI7 cells line often showed heterogeneity, 
suggesting posttranslational modification, and this was more evident in the MI5 cell 
line, with the detection of three distinct forms of 16,15 and 14kDa.
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Although separation of the large forms of IGF-II from the mature form could not be 
performed, biological activity was examined, by analysing the proliferative effect of 
CM prepared from MN2 and MI7 cells. Total immunoreactive IGF-II was successfully 
measured by slot blot and densitometry, with a linear standard curve. Pure IGF-II was 
a potent mitogen, with stimulation of proliferation at lOng/ml, and a maximal response 
at lOOng/ml, which is in accordance with other observations (Stewart et al. 1990). CM 
also caused proliferation, but did not stimulate growth of cells to the same extent as 
recombinant IGF-II and by comparing immunoreactive equivalents of IGF-II, a lower 
response was seen for CM than pure IGF-II. When the amount of mature IGF-II in the 
CM was estimated, the same decrease was seen (data not shown), suggesting that other 
factors in CM may have been affecting the response of the MCF-7 cells to the IGF-II. 
This may be due to several reasons, resulting from the inability to separate and purify 
the three forms. Firstly, there may be other components in the conditioned media that 
were inhibiting cell proliferation, such as inhibitory growth factors (e.g. TGFp), or 
toxins secreted by the MI7 cells, that may have been concentrated on collection of CM. 
If these were of a low molecular weight, then we would have expected them to be 
removed by dialysis, but this would have not occurred with TGFp. Secondly, the 
large forms may have antagonised the effect of mature IGF-II, by competing for the 
Type 1 IGF receptor (Perdue et al., 1991), and eliciting a reduced response (Zumstein 
et al., 1985). Thirdly, a possible reason for the decrease in proliferation, is the effect 
of insulin-like growth factor binding proteins (IGFBP) secreted by the MCF-7 cells 
(Section 1.2.5.1). MCF-7 cells can secrete up to four binding proteins; IGFBP 2, 3, 4 
and 5 (Yee et al., 1991) but the role of the binding protein in regulation of IGF action is 
unclear. Studies have shown that the binding proteins can be either stimulatory (Blum 
et al. 1989), presumably by presenting the growth factor to the receptor, or inhibitory 
(McGuire, et al., 1992), by sequestration of the growth factor. We can say therefore, 
that the CM is biologically active, but assessment of the role of the various forms of 
IGF-II is not possible. Purification and separation of the large forms of IGF-II, has so 
far proven difficult, and will clearly be essential for further analysis.
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In conclusion, this chapter shows the difficulties involved in purification of insulin-like 
growth factor-n. Although purification of the three forms of IGF-II was not achieved, 
separation by ion-exchange chromatography, supports the theory that they are large 
precursor forms of IGF-II, and they most probably arise by saturation of the 
processing machinery normally involved in the processing of prepro IGF-II to the 
mature growth factor (discussed in Chapter 4).
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CHAPTER 6 THE LEVELS AND NATURE OF IGF-II IN
A RANGE OF CANCER CELL LINES
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6.1 INTRODUCTION
IGF-II is a potent mitogen for a number of breast cancer cell lines, but has only been 
detected in a few of these, such as T47D and MCF-7, which is in contrast to the clinical 
situation, whereby IGF-II mRNA is easily detectable in nearly all breast tumour 
specimens (Section 1.3.2). This apparent rarity of expression in breast cancer cell 
lines, may however, be a result of the inherent technical difficulties in measurement of 
low levels of IGF-II peptide and mRNA, with RIA producing false positive results 
with binding proteins, and failing to provide any information on the types and nature of 
the secreted IGF-II. Large forms of IGF-II have been shown to have an important role 
in the formation of extra-pancreatic hypoglycaemia, with pro-IGF-II preferentially 
binding to different binding proteins than mature IGF-II (Section 1.2.6.1). Together 
with the importance for measuring the forms of IGF-II secreted by tumours, the level 
of peptide, often not measured due to the difficulties with RIA is also important, as in 
Wilm's tumour, mRNA can be upregulated, with no increase in peptide, and in certain 
sarcomas IGF-II peptide can be substantially increased, with only a moderate induction 
of IGF-II mRNA (Section 1.2.6.2).
Due to this clear need to analyse both the level and type of IGF-II secreted by tumours 
and cancer cells, and to determine the relevance of large forms of IGF-II secreted by the 
MI7 cell lines, this chapter describes the identification of IGF-II peptide in a range of 
breast and ovarian cancer cells lines.
6.2 OBJECTIVES
1 Analyse mitogenic effect of oestradiol and IGF-II on breast cancer cell hnes.
2 Examine the level and type of IGF-II in four human breast cancer cell, 
lines, and determine the effect of oestradiol upon secretion.
3 Investigate IGF-II in CM from two ovarian cancer cell lines (PE04 and 
PE014).
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6.3 PROLIFERATIVE EFFECT OF IGF-II ON BREAST CANCER CELLS
The mitogenic effect of oestradiol and recombinantly produced mature IGF-II on seven 
breast cancer cell lines was performed by MTT assay. ZR-75 and MCF-7 McG are 
oestrogen-dependant, MCF-7 KO oestrogen-responsive, and MDA-231 and HBL-lOO 
oestrogen-unresponsive cell lines (Table 1.1), whilst the T47D variants have been 
previously produced by long-term withdrawal of steroid (Darbre and Daly, 1990). All 
seven breast cancer cell lines were seeded at 1000 cells/well in 96 well plates and 
incubated in RPMI + 5% DCFCS for 3 days, to remove any steroid and reduce 
proliferation to basal rate. Cells were exposed to no mitogen, 10"^M oestradiol, 1000, 
1(X), or 10 ng/ml IGF-II for 4 days and MTT assay performed (Figure 6.1). The two 
unresponsive cell lines (MDA-231 and HBL-lOO), both grew at a faster rate than all the 
other cell lines, with little effect of oestradiol. The T47D unresponsive clones did show 
a small effect of oestradiol upon proliferation, whilst the responsive clones had a more 
oestrogen-dependant phenotype. This is most probably due to experimental variation. 
The oestrogen-responsive cell line, MCF-7 KO, proliferated in the absence of 
hormone, but was stimulated to grow by oestradiol, whilst oestrogen-dependent cells 
(ZR-75 and MCF-7 McG), did not proliferate in the absence, but grew exponentially in 
the presence of oestradiol. This all confirms, therefore, the expected steroid- 
responsiveness of the cells, and converting the data to percentage increase in 
absorbance at 540nm, using the absorbance at Day 0 for control, a much simpler effect 
of IGF-II is seen (Figure 6.2). IGF-II was a potent mitogen for oestrogen responsive 
or dependant cell lines with increased proliferation at 10 and 100 ng/ml, and maximal 
proliferation at approximately lOOOng/ml. There was little effect on oestrogen- 
unresponsive cells, with a small decrease in proliferation at low levels of IGF-II. The 
response to IGF-II never equalled that of oestradiol, and was highest in T47D and 
MCF-7 cells, and so IGF-II peptide levels were analysed in these cell lines.
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6.4 LEVELS OF IGF-II IN HUMAN BREAST CANCER CELLS
6.4.1 Preliminary analysis of three breast cancer cell lines
To examine whether the method of immunoblotting (Chapter 3), was sensitive enough 
to detect IGF-II in non-transfected human breast cancer cell lines, CM was collected 
from three cell lines (T47D, MCF-7 McG and KO), grown in the presence or absence 
of 10"^M oestradiol. Equal amounts of CM (50p.g protein) were electrophoresed and 
immunoblotted (Figure 6.3A), indicating that the MCF-7 McG and KO both secreted 
IGF-n in a 15kDa form, with a small amount of the mature 7kDa growth factor, whilst 
the T47D cell line, in contrast, secreted only mature 7kDa IGF-II (6.3B, longer 
exposure). The large form of IGF-II, in the MCF-7 variants, was heterogeneous in 
molecular weight, with three distinct bands at approximately 17, 16 and 15kDa. In 
MCF-7 cells (KO and McG), oestradiol reduced the level of the 15kDa form of IGF-E, 
with no obvious effect on mature IGF-II, whilst in T47D cells there was a decease in 
the amount of mature IGF-II. Unfortunately, cell number was not counted when CM 
was collected, and so the reduction in IGF-II in both cases may simply represent an 
increase in total protein present in CM collected from cells in the presence of oestradiol. 
To examine the effect further, a more detailed experiment with four breast cancer cell 
lines was performed.
6.4.2 Effect of oestradiol on IGF-H secretion by breast cancer cells
Two 9 cm plates of HBL-lOO, MDA-231, T47D and MCF-7 McG cells, were grown in 
the presence or absence of 10"^M oestradiol for 4 days, CM collected, concentrated and 
protein content estimated. Cell number was counted from one plate, and the other lysed 
with T/E buffer, and the amount of protein and DNA estimated (Table 6.1). 25jlg of 
CM from each cell line was immunoblotted for IGF-H (Figure 6.4), indicating that all 
cells secreted predominantly mature 7kDa IGF-II with trace amounts of a large 15kDa 
form. A longer exposure indicated lower amounts of a 22kDa form (data not shown), 
with both of the large forms comigrating with those seen in the MI7 cell line. To
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15
T47D McG KO T47D
Figure 6.3 Immunoblot of three breast cancer cell lines exposed to lO’^M
oestradiol (E2) for 3 days. CM was concentrated 50-fold and 50^ig of 
each cell line analysed by SDS-PAGE. B is a longer exposure of the 
immunoblot
22kDa
15kDa
7kDa
15kDa
IGF-II MI7 MDA-231 T47D MCF-7McG HBL-lOO 
- +  -  +  +  -  +
77 89 45 100 24 87 124 124
7kDa
lO'^M E2
units IGF-II/10^ cells
Figure 6.4 Immunoblot of two oestrogen-sensitive (MCF-7 McG and T47D) and 
two unresponsive (MDA-231 and HBL-lOO) cells exposed to 10"*M 
oestradiol (E2) for 4 days. CM (4ml) from two 9cm plates was 
concentrated 100-fold, and 25|ig each cell line analysed by SDS- 
PAGE and immunoblotted for IGF-II. Units IGF-II (arbitary)/10  ^
cells calculated from the protein content of CM, cell number, and 
densitometry of the signal for mature IGF-II (Table 6 .1).
cell number 
(xlO-7) 
2x9cm plate
Protein in lOOpI 
concentrated 
CM ( i^g)
Total protein 
from plate (p.g) 
lx9cm plate
Total DNA I 
from plate (|ig) 1 
lx9cm plate
MCF-7 McG -E2 0.95 80 400 20
MCF-7 McG +E2 1.03 300 1220 40
T47D -E2 1.16 l i s 2335 52
T47D +E2 1.52 340 3165 68
MDA-231 -E2 0.80 250 1200 36
MDA-231 +E2 0.97 250 1470 40
HBL-lOO -E2 0.67 350 1400 64
HBL-lOO +E2 0.85 450 1380 68
Table 6.1 Cell number and protein content of CM taken from two 9cm plates of 
four breast cancer cell lines. One plate counted by coulter counter, the 
other lysed with T/E buffer then protein and DNA content estimated.
Cell line Cell number 
(xl07)
Densitometry 
(arb. units)
Units IGF-II 
/lO^ cells
MCF-7 McG -E2 0.39 73 24
MCF-7 McG +E2 1.03 75 88
T47D -E2 1.16 108 46
T47D 4-E2 1.52 112 100
MDA-231 -E2 0.80 62 78
MDA-231 +E2 0.97 87 90
HBL-lOO -E2 0.67 59 124
HBL-lOO +E2 0.85 59 124
Table 6.2 Effect of lO'^M oestradiol (E2) on secretion of IGF-II (arbitary units) 
by breast cancer cells. 25|ig each cell line immunoblotted (Figure 
6.4), and so densitometric value (arbitary units) normalised for cell 
number by knowing the total protein present in CM (Table 6.1).
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estimate the amount of IGF-II secreted by each cell hne, a number of calculations must 
be performed. CM was reconstituted in lOOp.1 of water, and after protein content 
estimation, 25|ig of protein from each cell line was analysed by SDS-PAGE. From the 
cell number on each plate, total protein in CM and densitometric analysis of the signal 
for mature IGF-II, the amount of IGF-II secreted (arbitrary units)/! 0^ cells can be 
calculated (Table 6.2). Oestradiol induced secretion 2 and 4-fold in T47D and MCF-7 
McG cells respectively, but had little effect on the oestrogen unresponsive HBL-lOO 
and MDA-231 cells. The oestradiol-unresponsive cell lines (HBL-lOO and MDA-231), 
secreted higher levels of IGF-H in the absence of oestradiol (124 and 77 arbitrary units 
IGF-II/10^ cells respectively), than the oestradiol-responsive cell lines (24 and 45 
arbitrary units IGF-II/10^ cells, MCF-7 McG and T47D respectively).
6.5 ANALYSIS OF IGF-H IN OESTROGEN-INDEPENDENT MCF-7 CELLS
6.5.1 Introduction
In collaboration with Dr Roy Bicknell (ICRF, Institute of Molecular Medicine, 
Oxford), IGF-II peptide levels were analysed in MCF-7 cells that had been turned 
oestrogen-independent. Oestrogen-responsive MCF-7 cells, that were previously 
growth-inhibited by tamoxifen, were transfected with a mixed cDNA library from a 
variety of cell lines (U937 lymphoma; endotoxin, interleukin-1 and tumour necrosis 
factor-a activated human umbilical vein endothelial cells and proliferating (fibroblast 
growth factor stimulated) bovine adrenal capillary endothelial cells), known to secrete a 
number of growth factors. Oestrogen-independent clones were then selected by growth 
in increasing concentrations of tamoxifen, eventually resulting in the generation of two 
clones (clone 3 and 9), that they propose are tamoxifen resistant and oestrogen 
-independent (Dr M Toi, unpublished observations). CM from clone 9 was stimulatory 
for wild-type MCF-7 cells suggesting that an autocrine loop could account for the 
hormone-independent growth. To test this hypothesis, IGF-II levels were analysed in 
CM from wild-type, clone 3 and clone 9 cells.
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6.5.2 Immunoblotting of CM from transfected MCF-7 cells
CM was prepared from non-transfected control cells (wt) and transfected cells (Clone 3 
and 9) by Dr Bicknell (ICRF, Oxford), according to Section 2.3.10, sent to our 
laboratory, and immunoblotted for IGF-II (Figure 6.5). Clones 3 and 9 cells both 
contained 3 forms of IGF-II (22, 15 and 7kDa), whilst the control cells (wt) had no 
detectable IGF-II. To repeat this observation cells were to be sent to our laboratory, 
but unfortunately they suffered contamination, and it was several months before cells 
could be sent, resulting in the generation of late-passage cells, that had not been grown 
in selection media (either G418S or tamoxifen). Therefore, before CM was prepared 
from these cell lines, growth curves were performed to analyse the oestrogen- 
independence and anti-oestrogen resistance.
6.5.3 Effect of tamoxifen on Clone 9 MCF-7 cells
Clone 9 MCF-7, MN2 and MI7 cells were plated at 1000 cells/well in 96 well plates, 
incubated in RPMI + 5% DCFCS for 3 days and MTT assay performed for Day 0. 
Cells were then incubated in RPMI + 5% DCFCS containing serial dilutions of 
tamoxifen (lO'^M to lO'^M) and MTT performed after 10 days (Figure 6 .6). MI7 and 
Clone 9 cells were stimulated to grow by lO'^M tamoxifen and MN2 cells at lO'^M. 
All cells, however were growth-inhibited by lO'^M and 10"^M tamoxifen. In other 
growth assays. Clone 9 cells were oestrogen-independent, similar to the MI7 cells line, 
but were clearly not tamoxifen-resistant.
6.5.3 Immunoblotting of Clone 9 MCF-7 cells
CM was prepared from Clone 9 MCF-7 cells (late passage sent to our laboratory) and 
immunoblotted for IGF-II (Figure 6.7), indicating that the majority of IGF-H existed in 
a 15kDa form, with a small amount processed to the mature growth factor (lane 4). 
The 15kDa form comigrated with the large form of IGF-H seen in MI7 cells (lane 3). A 
cell lysate of clone 9 cells, produced with RIPA buffer, contained an 18kDa from of 
IGF-H , with small amounts of the 15kDa form.
154
22
15
IGF-II Clone 9 WT Clone 3
Figure 6.5 Immunoblot of CM from MCF-7 variants. CM (2ml) concentrated 10- 
fold, protein estimated, and 100|il analysed by SDS-PAGE and 
immunoblotted for IGF-II. 20ng pure IGF-II ran as a positive control.
Figure 6.6
1.4
MN2 
MI7 
Clone 91.0
I^
 0.6
0.4
0.2
0.0
Tamoxifen (M)
Effect of tamoxifen on the growth of three MCF-7 variants. Cells 
were plated at 1000 cells/well, incubated in RPMI + 5% DCFCS for 3 
days, and then media changed to RPMI -+- 5% DCFCS containing serial 
dilutions of tamoxifen. MTT proliferation assay performed on day 10. 
Values represent the mean of quadruplicate wells ± S.E.M. Where no 
bars arc shown, errors were too small for visual display.
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Figure 6.7 Immunoblot of Clone 9 CM and cell lysate. Lysate was prepared in 
RIPA buffer, protein content estimated, and 50(ig electrophoresed. 
CM (2ml) was prepared from two 9cm plates, concentrated 50-fold, 
and lOp.1 analysed. 20 ng IGF-II (I) and 2|il MI7 CM ran as positive 
controls. Molecular weight markers (M) are indicated on the left.
6.6 INVESTIGATION OF IGF-E IN OVARIAN CANCER CELL LINES
6.6.1 Immunoblotting of two ovarian cancer cell lines
In collaboration with Dr Simon Langdon (ICRF Medical Oncology Unit, Edinburgh) 
CM was prepared from two ovarian cancer cell lines, PE04 and PE014 (Langdon et 
al., 1990) by Miss Gill Hirst (Section 2.3.10). Cells were grown in RPMI + 5% 
DCFCS and then cells incubated in SFM, or RPMI + 5% DCFCS for 3 days, CM 
dialysed and concentrated 25-fold, and sent to our laboratory. 10)il of each sample was 
electrophoresed and immunoblotted for IGF-II (Figure 6.8). PE04 cells secreted no 
detectable IGF-II in SFM, but in the presence of 5% DCFCS, 15 and 7kDa IGF-II 
were apparent. PEG 14 cells secreted low levels of a 22kDa from of IGF-II in SFM, 
but 5% DCFCS there were easily detectable levels of IGF-II with of 22, 15 and 7kDa 
forms. These three forms all comigrated with the IGF-II seen in the MI7 cell line (lane 
1).
6.6.2 IGF-II in serum
To ensure that the signal from both cell lines did not arise from the serum, RPMI and 
RPMI + 5% DCFCS, that had seen no cells, were concentrated as above, and lOjil 
immunoblotted together with PEG 14 CM (Figure 6.9). As seen above, PEG 14 cells 
only contained detectable levels of IGF-II when CM was prepared in the presence of 
serum, but immunoblotting of RPMI + 5% DCFCS, indicated that only small quantities 
of IGF-II existed, showing that the IGF-II (Figure 6.8) was actually secreted by the 
cell lines. Interestingly, 5% DCFCS did contain low levels of mature 7kDa IGF-II, but 
also exhibited trace amounts of a 15kDa form that comigrated with the 15kDa form seen 
in the PEG 14 cell lines.
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Figure 6.8
kDa
22
Immunoblot of CM from two ovarian cancer cell lines, PE04 and 
PE014. CM was prepared either with SFM (RPMI), or RPMI + 5% 
DCFCS, concentrated 25-fold and 10|il electrophoresed. MI7 CM 
(2|il) ran as a positive control.
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«
IGF-II M PE014 
a b
M RPMI RPMI + 
5% DCFCS
Figure 6.9 Immunoblot analysis of IGF-II in stripped serum. SFM (RPMI) and 
RPMI + 5% DCFCS, that had seen no cells, were concentrated as 
above. PEG 14 CM was prepared with SFM (a) or RPMI + 5% 
DCFCS (b), and 10|il of each sample electrophoresed. IGF-II (20 ng) 
ran as positive control.
6.6 CONCLUSIONS
IGF-II was a potent mitogen for oestrogen-sensitive breast cancer cell lines, being 
mitogenic at concentrations of lOng/ml and generally giving a maximal response at 
approximately lOO-lOOOng/ml, whilst oestrogen-unresponsive cells were not stimulated 
to grow. Immunoblotting of a range of breast cancer cell lines initially detected large 
forms of IGF-II in the MCF-7 McG and KG cell lines, whilst a more detailed 
experiment indicated that all cell lines investigated (HBL-lOO, MDA-231, T47D, MCF- 
7 McG), contained predominantly mature IGF-II with trace amounts of a 15kDa form, 
that comigrated with the large 15kDa form of IGF-II in the MI7 cell line. Oestradiol 
induced secretion of IGF-II in oestrogen-dependant (MCF-7 McG) and responsive 
(T47D) cells, but had little or no effect on the level of IGF-II in the oestrogen 
unresponsive cell lines (HBL-lOO and MDA-231).
In collaboration with Dr Bicknell (ICRF, Gxford), IGF-II levels were analysed in 
MCF-7 cells rendered oestrogen-unresponsive by transfection with a mixed cDNA 
library. CM from early passage transfected cells (clone 3 and 9) contained IGF-II in 
three forms of 22, 15 and 7kDa, whilst control (wt) cells contained no immunoreacdve 
IGF-n. Late passage clone 9 cells sent to our laboratory at a later date, only secreted 
15 and 7kDa IGF-II. In collaboration with Dr Langdon (ICRF, Edinburgh), two 
ovarian cancer cell lines (PE04 and PEG 14) secreted IGF-II in three large forms, with 
higher levels when CM was prepared with 5% DCFCS compared to SFM. The three 
forms comigrated with those seen in the MI7 cell line. 5% DCFCS alone, contained 
low levels of mature 7kDa with trace amounts of a 15kDa form.
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6.7 DISCUSSION
IGF-II is a potent mitogen for breast cancer cells, with several studies indicating 
mitogenic effects in the nanomolar range (Section 1.3.2). Interestingly, the 
proliferative effect of IGF can be increased by oestradiol treatment of hormone- 
sensitive breast cancer cells, via upregulation of the type 1 IGF receptor (Stewart et al, 
1990). Analysis of the proliferative effect of IGF-II and oestradiol on a range of cell 
lines in our laboratory generally agreed with previously published data (Osborne et al., 
1989; Stewart et al., 1990). All cell lines showed their expected steroid-sensitive 
phenotype in response to 10“ oestradiol, except the T47D variants, where the 
responsive variant was oestrogen-dependant, and the unresponsive was oestrogen- 
responsive. This may have been due to loss of the respective phenotype through 
successive passages, or may have simply been experimental deviance.
The mitogenic response to IGF-II was greatest in oestrogen-sensitive cell lines (ZR-75, 
T47D responsive, MCF-7 McG and KO), with little or no effect in oestrogen- 
unresponsive cell lines (MDA-231, HBL-lOO, T47D unresponsive). IGF-II stimulated 
proliferation at lOng/ml and the response was generally maximal at lOOng/ml, 
confirming previous reports (Stewart et al., 1990). This experiment, having been 
performed in the absence of oestradiol, would suggest that the oestrogen-unresponsive 
cells were growing at their greatest proliferative rate, and so incapable of stimulation by 
an exogenous mitogen. This is substantiated by the fact that the unresponsive MDA- 
231 and HBL-lOO cells grew at a significantly faster rate than the oestrogen-sensitive 
cells, which when grown in the absence of oestradiol are stimulated to proliferate by 
exogenous IGF-II. Oestrogen-unresponsive cells growing faster, is the main event in 
the autocrine hypothesis, with progression to oestrogen-independence occurring by 
cells controlling their own proliferative rate.
However, the fact that the oestrogen-unresponsive cells do not proliferate in response 
to IGF-II may be because they are desensitised to the signal, for T47D unresponsive
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cells grow only slightly faster than their responsive counterparts, but do not respond to 
IGF-II. Desensitisation could occur via a number of mechanisms. Firstly, 
downregulation of the type 1 IGF receptor may have occurred. Due to technical 
difficulties in measurement of accurate receptor numbers (cross-reactivity of ligands 
and receptors), many figures in the past are controversial, however Cullen et al. 
(1989), have indicated that all breast cancer cell lines contain detectable type 1 IGF 
receptor mRNA, and that levels are not significantly different between oestrogen- 
responsive and unresponsive cell lines. This, therefore, argues against the probability 
of downregulation of the receptor. The second mechanism could involve either a 
defective signalling pathway, possibly via IRS-1, or that in oestrogen-unresponsive 
cells, the mitogenic stimuli are using signalling pathways common to the IGFs. This 
has yet to be investigated.
Having determined the effect of exogenous IGF-II on the proliferation of breast cancer 
cells, the level secreted by these cell lines were examined. Two novel and important 
sets of data were revealed. Firstly, all the cell lines (MDA-231, HBL-lOO, T47D 
responsive and MCF-7 McG), secreted mature IGF-II with trace amounts of a 15kDa 
form. Secondly, treatment of the cells with 10"^M oestradiol induced secretion in 
oestrogen-sensitive cells (MCF-7 McG and T47D responsive), but had little or no effect 
on oestrogen-unresponsive cells (MDA-231 and HBL-lOO), which secreted higher 
constitutive levels. Detection of IGF-II in all cell lines contradicts previous publications 
suggesting that IGF-II is only expressed in a limited number of cell lines (Yee et al, 
1988; Osborne et al., 1989), which has led to the main argument against an autocrine 
role for IGF-II in breast cancer cell proliferation. Several reasons may account for the 
differences in expression. All previous studies have been performed by RNase 
protection (mRNA) or RIA (peptide), both techniques fraught with difficulties both in 
performance and with detection limits. The method of immunoblotting employed here 
is sensitive, specific and does not need IGFBP removal before being performed, so 
eliminating the main problem with RIA. The ability to detect IGF-II in all cell lines 
may, therefore, be a result of different techniques and sensitivities. However, caution
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must be taken when conclusions are made from cell lines held in different laboratories, 
for in two instances (one directly related to IGF-II), cell lines have produced spurious 
results. Firstly, Osborne et al. (1987) indicated differences in the oestrogen-response 
of MCF-7 cells from 4 different locations, and Brunner et al. (1992), indicated IGF-II 
mRNA expression in MDA-231 xenografts, where previously they had shown that 
none was detectable (Yee et al., 1988). This suggest that passage number and cell 
culture conditions can affect IGF expression, and that this must be considered when 
taking conclusions from results obtained with cell lines. Expression in all cell lines 
does correlate with IGF-II expression in breast tumour specimens, with Yee et al. 
(1988) having detected IGF-II mRNA in 24 out of 26 specimens.
Oestrogen-induction of IGF-II expression in oestrogen-sensitive cells, and lack of 
effect in unresponsive cells substantiates two sets of data in the literature. Firstly, 
oestrogen upregulation of IGF-II in MCF-7 McG and T47D cells agrees with the data 
on mRNA regulation in these lines (Yee et al., 1988; Osborne et al., 1989). However, 
no data previously existed on the effect of IGF-II peptide, only on the mRNA, due to 
technical difficulties in measurement. The second observation, lack of effect of 
oestradiol on IGF-II peptide secretion by oestrogen-unresponsive cells confirms the 
recent data of Brunner et al. (1992), who has indicated the same effect, but for IGF-II 
mRNA in oestrogen-unresponsive MDA-231 xenografts. This paper also showed 
oestradiol-induction of IGF-II mRNA in MCF-7 xenografts, which agrees with our in 
vitro data. In conclusion, therefore, analysis of IGF-II peptide in breast cancer cells 
has highlighted a possible role for this growth factor in an autocrine regulatory 
pathway in breast cancer cell proliferation, and possibly in oestrogen action, with our 
data substantiating previous mRNA studies.
Having detected mature 7kDa IGF-II in all the breast cancer cell lines, the method of 
immunoblotting also indicated that a small amount existed in the large 15kDa form, 
seen previously in the MI7 cell line, although the levels were much lower in the non­
transfected breast cancer cell lines. The difference in the amount of the 15kDa IGF-II
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between the two experiments, Section 6.3 and 6.4- , may be due to different culture 
conditions when CM was collected. In Chapter 4, the density of cells was seen to have 
a n effect on the level of the 22kDa form of IGF-II in MI7 cells, with less present when 
cells were overconfluent than when subconfluent, with a hint of processing of this form 
to the 15kDa precursor. If density is having such an effect on processing of IGF-II 
(Section 6.2.1 versus Section 6.2.2), shifting the majority to the large 15kDa form to 
mature IGF-II, then this may have large effects on proliferation, if the large form has 
either more or less bioactivity than mature IGF-II.
In collaboration with Dr Bicknell at ICRF in Oxford, the levels of IGF-II were analysed 
in oestrogen-responsive MCF-7 cells that had been made oestrogen-independent, by 
transfection with a mixed cDNA library, and then selection in increasing concentrations 
of tamoxifen (Dr M Toi, unpublished observations). CM was initially prepared by Dr 
Bicknell and sent to our laboratory. Immunoblotting of CM revealed that two 
transfected clones (clone 3 and 9) secreted IGF-II in three forms of 22, 15 and the 
mature 7kDa, the pattern of secretion being the same as in the MI7 cells line, whilst 
control MCF-7 cells (wt) contained no immunoreactive IGF-II. To repeat the 
experiment, the cells were to be sent to our laboratory, but suffered contamination 
problems in Dr Bicknell's laboratory. Clone 9 cells were received several months later, 
when contamination had been eradicated, but now immunoblotting of CM from clone 9 
cells indicated that the cells secreted only 15 and mature 7kDa IGF-II. The lower levels 
of IGF-n and the absence of any 22kDa form, seen in the first experiment, may be due 
to the fact that the cells were not grown in any selection media, and so the transfected 
clone may have been partially lost through several passages, with growth of non­
transfected cells diluting the amount of secreted IGF-II. The secretion of IGF-II by 
clone 3 and 9 cells may indicate the mechanism whereby these cells have gained 
oestrogen-independence, as upregulation of IGF-II secretion, which can then act in an 
autocrine manner, can affect the growth rate and steroid sensitivity of MCF-7 cells 
(Daly et al., 1991; Cullen et al, 1992).
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IGF-II peptide was analysed in two ovarian cancer cell lines, PE04 being oestrogen- 
sensitive, and PEG 14 oestrogen-unresponsive (Langdon et al., 1990). CM prepared 
from PE014 cells by Miss Hirst (ICRF, Edinburgh), contained IGF-II in three forms 
that comigrated with those seen in MI7 cells, the PE014 cells even containing the 
distinct 24kDa form seen only in CM from MI7 cells when they were stimulated with 
zinc. The secretion of only two forms in the PE04 cell line, compared to higher levels 
of the three forms in the PEG 14 cells, may indicate upregulation of expression in the 
oestrogen-unresponsive cells, and so saturation of processing, leading to secretion of 
the 22kDa form (also seen in the MI5 cell line when stimulated with zinc). This may 
indicate how these cells have become oestrogen-unresponsive i.e. upregulation of IGF- 
II expression. The ICRF group in Edinburgh are using antisense-technology to reduce 
the IGF-II secreted by these cells, to see how this affects the proliferation of the cells.
Immunoblotting of serum was performed, to ensure that the large forms of IGF-II, 
seen only in CM prepared in the presence of 5% DCFCS, didn't actually arise from the 
serum. This showed that 5% DCFCS contained low levels of mature IGF-II which did 
not account for the levels of IGF-II seen in CM from PEG4 or PEG 14 cells. The 
increase in IGF-II from SFM to 5% DCFCS, may be due to several reasons. Firstly 
factors present in serum may be inducing the dramatic IGF-II expression. Secondly, 
and conversely to the former reason, is the possibility that the cells incubated in SFM 
have become unhealthy and switched off IGF-II expression. Thirdly, there may be an 
effect of binding proteins in the serum, which may either sequester the growth factor 
from IGF receptors, so stopping internalisation, or simply increasing the half-life of the 
IGF-II. If the first reason is true, and serum (5% DCFCS) can induce IGF-II 
expression in such a dramatic fashion, then this would place previous studies on 
oestrogen action, performed in stripped-serum, into question. Induction of expression 
may explain the data of Arteaga and Gsbome (1989), who found that a-IR3 did not 
inhibit oestrogen-mediated proliferation of MCF-7 cells (in the absence of serum), but 
was able to inhibit basal growth rate in the presence of serum. This group has always 
concluded that this effect is blockade of IGF's from the serum, but as Figure 6.9
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indicates, 5% serum contains little IGF-II, and would suggest that the blockade may be 
of serum-induced IGF-II produced by the cells.
IGF-II was at a low concentration in serum, if we estimate from Figure 6.9 that lOjil 
RPMI + 5% DCFCS contained lOng IGF-II, then as this has been concentrated 25- 
fold, the serum has approximately 40ng IGF-II/ml, consistent with the literature 
(Daughaday, 1988). However, the most interesting observation is the small amounts 
of a 15kDa form, which may be similar to the large 15kDa form of IGF-II purified 
from Cohn fraction IV (Gowan et al., 1987). Immunoblotting may provide a much 
simpler means of measuring the level of the large form of IGF-II in serum of patients 
with extra-pancreatic hypoglycaemia, because at present, all the data in the literature has 
been generated using acid chromatography and RIA (Daughaday and Trivedi, 1992; 
Shapiro et al., 1990; Zapf et al., 1992), a complicated method that can only be used 
with one sample at a time, is known to result in loss of IGF-II and provides no 
reasonable estimate of the size of the precursor. Immunoblotting would allow the 
processing of several samples in a short time, and quantitation by densitometry would 
indicate the level of total immunoreactive IGF-II and the percentage present as big IGF- 
II.
Having shown the presence of IGF-II peptide in a range of cancer cell lines, and shown 
oestrogen induction, the mechanism of IGF-II-mediated proliferation was analysed, by 
first generating an antibody to phosphotyrosine, and then examining phosphorylation 
of the type 1 receptor in breast cancer cells.
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CHAPTER 7 GENERATION OF AN ANTIBODY TO
PHOSPHOTYROSINE, AND EXAMINATION 
OF LEVELS IN BREAST CANCER CELLS
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7.1 INTRODUCTION
The majority of the growth factors implicated in the regulation of cell growth (EGF, 
TGFa, IGF, FGF, PDGF), mediate their action via membrane bound receptors that 
have ligand-inducible tyrosine kinases (Roberts et al., 1988; Ullrich and Schlessinger, 
1990). This type of signal was only discovered just over 10 years ago (Hunter, 
1989a), due to the extremely low levels in the cell, but since the generation of 
antibodies specific for phosphorylation of tyrosine amino acids (Glenney et al., 1988; 
Wang, 1988), there has been a veritable explosion in research not only into the 
mechanism whereby this posttranslational modification can transduce such a pleiotropic 
response (Hunter and Cooper, 1985), often resulting in proliferation, but in the number 
of kinases and phosphatases involved in controlling the signal (Hunter, 1987; Hunter, 
1989b). Due to its critical role in cell growth, the level of tyrosine phosphorylation is 
tightly controlled, accounting for only 0.05% of total phosphorylation in a quiescent 
cell, but often increasing to up to 0.5% in stimulated cells. It is interesting to note, that 
over half of the oncogenes discovered so far, are tyrosine kinases (Hunter, 1989).
This chapter describes the generation of a polyclonal rabbit antibody to 
phosphotyrosine, and the study of tyrosine phosphorylation of the type 1 IGF receptor 
in MN2 and MI7 transfected cells, and also the level in non-transfected breast cancer 
cell lines, when stimulated with either growth factors or oestrogen.
7.2 OBJECTIVES
1 Couple phosphotyrosine to a hapten (BSA or haemocyanin).
2 Raise antibodies in rabbits and detect by enzyme-linked immunosorbent assay 
(ELISA).
3 Concentrate and affinity-purify antibody.
4 Determine specificity of antibody for PY using phosphorylation of the EGFR 
in NR6+ (normal rat kidney cells transfected with EGFR cDNA) cells as a 
positive control.
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5 Examine levels of PY in transfected cells stimulated with IGF-I and H.
6 Analyse PY in non-transfected human breast cancer cell lines stimulated with 
either oestrogen or growth factors.
168
7.3 GENERATION OF AN ANTIBODY TO PHOSPHOTYROSINE
7.3.1 Production of antibody to PY
Rabbit polyclonal antibodies were raised, by injection of a conjugate of 
phosphotyrosine (PY) and haemocyanin (HC). PY was coupled to both HC and BSA 
by l-ethyl-3-(-3-dimethylaminopropyl) carbodiimide hydrochloride (EDAC), which 
couples -NH2 and -COOH residues (example shown in Figure 7.1). Examining bleeds 
from the rabbit by ELISA, using BSA-PY as a substrate (Figure 7.2), the first testbleed 
showed a strong antibody reaction, boosting the rabbit resulted in a moderate increase, 
whilst the bleed-out produced the strongest reaction.
7.3.2 Affinity purification of antibodies to phosphotyrosine
Rabbit serum was first concentrated by ammonium sulphate precipitation, and then PY 
specific antibodies affinity-purified by passing the serum over a column of 
phosphotyramine coupled to sepharose (gift from Dr Fry, Institute for Cancer 
Research, Sutton, Surrey). The column was washed with PBS, 5 mM phosphoserine 
(PS) and 5mM phosphothreonine (PT), and then antibodies specific for PY eluted with 
40mM phenylphosphate. Protein eluted off the column (Figure 7.3), indicated 
antibodies in fractions 3,4 and 5, and these were pooled. Affinity purified antibody (a- 
PY), at a 1:500 dilution, gave a similar response in ELISA against BSA-PY, as an 
antibody received from Dr Fry (Figure 7.4).
7.4 SPECIFICITY OF AFFINITY-PURIFIED ANTIBODIES FOR PY
7.4.1 Competition ELISA
Specificity for PY was determined, by incubating antibodies with increasing 
concentrations of PY, PS or PT, and then ELISA performed against BSA-PY (Figure 
7.5). Antibody reaction could be inhibited (-90%) by 5mM PY and completely
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Figure 7.1 Cojugation between HC/BSA and phosphotyrosine
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Figure 7.3 Protein elution from phosphotyrosine column by 40mM 
phenylphosphate after washing with 5mM PS and PT.
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Figure 7.4 Comparison of affinity purified antibody (a-PY) against an antibody 
received from Dr M Fry. ELISA performed with 200ng BSA-PY as 
substrate, and detected with a 1:500 dilution of each antibody.
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Figure 7.5 Competitive inhibition of antibody recognition of 200ng BSA-PY, by 
incubation of antibody with either PY, PS or PT, for 1 hour prior to 
ELISA.
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abolished by lOmM PY, whereas at 5mM PS and PT both showed 40 and 10% 
inhibition respectively.
7.4.2 Immunoblotting of PY
As a positive control, to test the specificity of the antibody in immunoblotting, PY was 
examined in a rat kidney cell line, NR6+, that had been previously transfected with 
EGF receptor (EGFR) cDNA (Table 1.1). Cells were grown to subconfluence, 
stimulated with 200ng/ml EGF, and cell lysates prepared (RIPA). Immunoblot 
analysis detected a single protein at 175kDa (Figure 7.6), the signal being maximal after 
2 minutes stimulation with EGF, but decreasing thereafter (5 and 10 min).
7.4.3 Immunoprécipitation of PY
NR6+ cells were stimulated with EGF as above, cell lysates (Triton) prepared, and 
immunoprécipitation performed with a-PY and then Protein A coupled to sepharose 
beads. Detection of a 175kDa protein was directly proportional to the amount of 
antibody in the immunoprécipitation, and could be blocked completely by preincubation 
of the antibody with 5mM PY (Figure 7.7). Immunoprécipitation with an antibody to 
the EGFR, confirmed the proteins identity (data not shown).
7.5 TYROSINE PHOSPHORYLATION IN BREAST CANCER CELLS
7.5.1 Transfected MCF-7 cells
MN2 and MI7 cells were grown to subconfluence, stimulated with lOOng/ml IGF-I, 
and cell lysates prepared. Although a number of bands were apparent, no effect of 
IGF-I was seen on tyrosine phosphorylation of any proteins (Figure 7.8) Tyrosine 
phosphorylation of the EGFR in NR6+ cells stimulate with EGF (200ng/ml), was used 
as a positive control.
172
175 kDc
Figure 7.6
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Immunobot of NR6+ cell lysate with 1:100 dilution of a-PY antibody. 
Cells were grown to subconfluence, incubated overnight in RPMI + 
1% DCFCS, and then stimulated with 200ng/ml EGF for the indicated 
time. Cell lysates were prepared in RIPA buffer, protein content 
estimated, and 50p,g analysed by SDS-PAGE.
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Figure 7.7 Immunoprécipitation of NR6+ cell lysate (Triton), with a-PY
antibody. Cells were stimulated with 200ng/ml EGF for 2 min, cell 
lysate prepared and protein content estimated. 500|ig lysate protein 
was incubated with antibody (1,5, 10 and 20|ag), precipitated with 
Protein A, and analysed by SDS-PAGE. 50(ig cell lysate (RIPA) from 
NR6+ and A431 cells stimulated with EGF (lanes 1 and 2) ran as 
positive controls (no immunoprécipitation).
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Figure 7.8 Immunoblot analysis of tyrosine phosphorylation in MN2 and MI7 
cells lysates. Cells grown to sub-confluence in RPMI + 5% FCS, 
incubated in RPMI + 1% DCFCS for 24 hr, and then stimulated with 
IGF-I (lOOng/ml) or IGF-II (500ng/ml) for 0, 2, or 10 min. Rff A 
lysates were prepared, and 50|Xg electrophoresed and immunoblotted 
with a 1:100 dilution of a-PY antibody.
7.5.2 Non-transfected human breast cancer cells
Two breast cancer cell lines (ZR-75 and MDA-231), were grown to subconfluence, and 
stimulated with a mixture of EGF (200ng/ml), In (lOmg/ml) and IGF-I (lOOng/ml). 
Immunoblotting revealed no significant phosphorylations (data not shown), and so a 
more sensitive technique was performed. Cells were prelabelled with [^^P]- 
orthophosphate prior to growth factor stimulation, and then the lysates 
immunoprecipitated with a-PY antibody. NR6+ cells showed phosphorylation of 
EGFR at 175kDa (Figure 7.9), but again, there was no difference when breast cancer 
cells were stimulated with growth factors (Figure 7.9), or oestradiol (data not shown).
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Figure 7.9 Immunoprécipitation from [^^P]-labelled cell lysates with a-PY
antibody. ZR-75 and MDA-231 cells labelled for 4 hours, and then 
stimulated with a mixture of growth factors (EGF-200ng/ml, In- 
10|Xg/ml and IGF-I-lOOng/ml) for 2 min. NR6+ cells stimulated with 
200ng/ml EGF as a positive control. 500^ig cell lysate (Triton), 
incubated with 20|ig a-PY and precipitated with Protein A, performed 
on duplicate plates. No antibody, represents immunoprécipitation with 
Protein A alone
7.6 CONCLUSION
A polyclonal antibody has been successfully raised to phosphotyrosine, by injection of 
a rabbit with HC-PY, as measured by ELISA against BSA-PY. Affinity purification, 
and subsequent validation of specificity, using tyrosine phosphorylation of the EGFR, 
indicated cross-reactivity with PS but very little with PT. Immunoblotting and 
precipitation of NR6+ cells detected a single protein at 175kDa, which was later directly 
identified as the EGFR.
Analysis of tyrosine phosphorylation in breast cancer cells was not successful, even 
when cells were stimulated with levels of growth factor known to elicit a mitogenic 
response. This was also the case when cells were labelled with [^^P] -orthophosphate, 
the most sensitive method for detection. Detection of tyrosine phosphorylation of the 
type 1 IGF receptor was also not possible.
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7.7 DISCUSSION
The generation of antibodies specific for posttranslationally modified amino acids, has 
highlighted the importance of tyrosine phosphorylation in a number of intracellular 
signalling pathways (Ullrich and Schlessinger, 1990). Using this technology, we 
successfully raised an antibody to phosphotyrosine, and performed characterisation, 
using phosphorylation of the EGFR as a positive control. Tyrosine phosphorylation of 
this receptor was maximal after 2 minutes stimulation by EGF, but decreased thereafter, 
presumably due to the effect of phosphatases and down regulation of the receptor 
(Wiley gf a/., 1991). The receptor could be immunoprecipitated after activation, which 
was specifically blocked by preincubation of the antibody with phosphotyrosine. 
However, despite the fact that the antibody could detect tyrosine phosphorylation of the 
EGFR, no detection was possible of activated growth factor receptors in breast cancer 
cells, presumably because even though breast cancer cells proliferate in response to 
IGFs, EGF etc., they generally contain low levels of the respective receptor (Davidson 
etal.^ 1987; Papa era/., 1991).
A more sensitive, but technically difficult method, [^^P]-orthophosphate labelling, also 
failed to detect phosphorylation of growth factor receptors and substrates. This was all 
repeated with two commercially available antibodies (PY-20 Oncogene Science, U S A 
and IG2 Boehringer Mannhein, Sussex, England) were used (data not shown), but 
again failed to detect any tyrosine phosphorylations. In conclusion, growth factor 
receptor levels, and so tyrosine phosphorylation, are too low for detection by direct 
immunoblotting of breast cancer cell lines with anti-phosphotyrosine antibodies.
Reddy et al. (1992) investigated tyrosine phosphorylation of the EGFR in breast cancer 
cells. However, rather than investigating tyrosine phosphorylation of growth factor 
receptors, they investigated whether phosphotyrosine inhibitors affect proliferation of 
breast cancer cells. Although the inhibitor, RG13022, reduced EGF-induced 
proliferation, it also affected insulin, IGF-I, IGF-II, suggesting that the inhibitor is not
177
specific for EGFR phosphorylation, as suggested. Phosphorylation of the EGFR was 
not measured by direct immunoblotting or immunoprécipitation of EGFR by anti- 
phosphotyrosine antibodies, but by initial immunoprécipitation with an antibody to 
EGFR and then immunoblotting with an anti-phosphotyrosine antibody. This suggests 
that in our breast cancer cells we may have been able to detect tyrosine phosphorylation 
of type 1 IGF receptor by first immunoprécipitation with a-IR3. The fact that Reddy et 
al. (1992) were able to reduce oestrogen-mediated proliferation of breast cancer cells by 
this inhibitor, suggests that growth factor receptor tyrosine kinases may be involved, 
but the specificity of the inhibitor must be thoroughly investigated before this can be 
safely concluded.
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CHAPTER 8 SUMMARY OF RESULTS
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CHAPTER 3 - A specific and sensitive immunoblotting technique for IGF-II peptide 
has been developed and optimised, using a commercially available monoclonal 
antibody.
a) Dénaturation of IGF-II, by SDS or DTT, abolished the signal, and so after 
SDS-PAGE (without DTT) electrophoretic transfer was performed overnight 
in the absence of SDS, which resulted in detection of mature IGF-II at 7kDa.
b) The antibody showed no cross-reactivity with insulin, EGF or BSA, but had 
10% cross-reactivity with structurally related IGF-I.
CHAPTER 4 - IGF-II production was analysed in MCF-7 human breast cancer cells 
transfected with prepro-IGF-II (MI7 and MI5) under the control of the 
metallothionein promoter, or with control vector (MN2).
a) Control MN2 cells showed the classical MCF-7 McG oestrogen-dependent 
phenotype, whilst MI7 cells had an oestrogen-responsive phenotype with 
increased basal growth rate. Stimulation by zinc rendered MI7 cells virtually 
oestrogen-independent.
b) Slot blot analysis indicated that CM from MI7 cells had detectable levels of 
IGF-II in the absence of zinc, that were inducible 3-fold by zinc-stimulation. 
Control MN2 cells had little or no IGF-II.
c) SDS-PAGE analysis revealed that MI7 cells secreted IGF-II in three forms of 
22, 15 and 7kDa, the latter comigrating with recombinant mature IGF-II. 
IGF-II levels were again inducible by zinc, and absent in MN2 cells. 
Confirmation of viability of the cells (trypan blue exclusion, haemotoxylin 
and eosin staining), indicated that the three forms of IGF-II were specifically 
secreted, and not in CM as a result of cell death or damage.
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d) A time-course of IGF-II production in MI5 cells indicated that these cells only 
secreted 15 and 7kDa IGF-II in the absence of zinc, the large form being 
heterogeneous in molecular weight. Zinc-stimulation resulted in the 
appearance of a 22kDa form.
e) MI7 cells in the absence of zinc secreted mainly (up to 80%) 22kDa IGF-II at 
a linear rate. Stimulation by zinc inhibited secretion for up to 8 hours, 
thereafter it being secreted at a faster rate than those cells in the absence of 
zinc. Stimulation also resulted in the appearance of two more forms of 24 and 
19kDa.
0 Cellular IGF-II, detectable only in detergent buffers, was seen in MI7 cells
incubated with zinc, and had molecular weights of 24 and 22kDa.
^  Secretion of IGF-II was induced dramatically between cells plated at
subconfluence and overconfluence, in the absence of zinc. Also, if cells were 
incubated in SFM for longer periods, the amount of 22kDa IGF-II increased if 
cells were at subconfluence, but decreased if cells were at overconfluence, 
with a concominant increase in 15kDa IGF-II.
h) Zinc caused a significant increase in [^H]-thymidine incorporation (p<0.01) in
MI7 cells after 13 hours of incubation and at all time points thereafter.
CHAPTER 5 - Concentration and partial characterisation of the three forms of IGF-II
was performed, as individual forms had to be separated for analysis of their structure
and biological activity.
a) The main contaminant of CM, BSA, was bound by cibacron blue sepharose, 
but coeluted with IGF-II, whereas cibacron blue silica bound both BSA and 
IGF-II but did not elute either under strong ionic conditions.
b) All three forms were retained by a 30kDa M.Wt. cut-off membrane (Amicon), 
and not separated from BSA.
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c) FPLC resulted in size fractionation of proteins in CM, but not IGF-II, which
coeluted with BSA and appeared as much more diffuse bands.
4) Cation-exchange chromatography specifically separated 15kDa IGF-II from
22 and 7kDa forms, but large losses of all proteins occurred from non-specific 
interactions with the column.
e) IGF-n levels in MI7 CM were measured, using a slot blot apparatus, by 
producing a linear standard curve with recombinant mature IGF-II, and then 
estimating total immunoreactive IGF-II in CM.
f) MI7 CM was biologically active, causing proliferation of MCF-7 McG cells, 
but the dose response was reduced to equivalent amounts of recombinant 
mature IGF-II.
CHAPTER 6 - The mitogenic effect of IGF-II and oestradiol was measured on a 
range of breast cancer cell lines held in our laboratory, and then IGF-II levels 
analysed in some of these cells. IGF-II levels were also measured, in collaboration 
with two ICRF groups, in oestrogen-independent MCF-7 (9) cells, and two ovarian 
cancer cell lines.
a) Oestradiol (10"^M) stimulated proliferation of oestrogen-sensitive cell lines 
(ZR-75, T47D responsive, MCF-7 KG and McG), whilst having little or no 
effect on oestrogen-unresponsive cells (MDA-231, HBL-100, T47D 
unresponsive).
b) IGF-II caused proliferation of oestrogen-sensitive cells at 10 and lOOng/ml, 
with maximal response at approximately lOOOng/ml, whereas it had little or 
no effect on oestrogen-unresponsive cell lines.
c) CM from four breast cancer cell lines contained mainly mature 7kDa IGF-II, 
with trace amounts of a large 15kDa form. Oestradiol induced secretion of 
mature IGF-II 2 (T47D responsive) and 4-fold (MCF-7 McG), with little or no
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effect on higher constitutive levels in oestrogen-unresponsive cells (MDA-231 
and HBL-100).
MCF-7 (9) cells, rendered oestrogen-unresponsive by transfection with a 
mixed cDNA library (Dr Bicknell, ICRF, Oxford), secreted three forms of 
IGF-II of 22, 15 and 7kDa, whilst oestrogen-responsive wild-type cells 
secreted no detectable IGF-II.
e) PE04 ER+ve ovarian cancer cells secreted 15 and 7kDa IGF-II, whilst PE014
ER-ve cells secreted higher levels of IGF-II consisting of 22, 15 and 7kDa. 
Total levels of IGF-II were dramatically higher when CM was prepared with 
5% DCFCS rather than SFM.
CHAPTER 7 - Tyrosine phosphorylation of the type 1 IGF receptor was analysed by
generation of a polyclonal antibody to PY.
a) An antibody was raised by injection of a rabbit with HC-PY. Affinity 
purification was performed over a column of PY-sepharose and antibodies 
eluted with phenylphosphate.
b) Immunoblotting of EGFR, in A431 and NR6+ cells indicated tyrosine 
phosphorylation after 2 minutes stimulation with EGF, that decreased after 5 
and 10 minutes stimulation. Immunoprécipitation was performed on activated 
receptor and could be specifically blocked with 5mM PY.
c) Competition ELISA indicated that 5mM PY blocked the antibody response 
(90%), whilst lOmM abolished the signal. There was cross-reactivity with PS 
(40%) and PT (10%).
d[) Type 1 IGF receptor phosphorylation was not detectable in breast cancer cells,
or the transfected MI7 cells by either immunoblotting, or immunoprécipitation 
of [32p]-orthophosphate labelled cell lysates.
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CHAPTER 9 GENERAL DISCUSSION
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The results summarised above have been discussed in detail at the end of each chapter. 
The aim of this discussion is to put the work in context with three general themes; 1) 
processing of IGF-II, 2) the role of IGF-II in oestrogen-mediated proliferation of breast 
cancer cells, and 3) progression to oestrogen-independence. Novel and important sets 
of data relevant to these topics have arisen from the development of a specific and 
sensitive method for analysing levels of IGF-II in CM. The first relies upon the fact 
that the method of immunoblotting allows visualisation of the size and nature of the 
peptide, which in the case of the MI7 cell line indicated secretion of three forms of 22, 
15 and 7kDa. The smallest form, comigrates with recombinantly produced mature 
IGF-n, whilst the other two are of a similar weight to precursor forms detected in the 
BRL-3A cell line (Yang et al., 1985a). This close similarity in molecular weight, and 
the separation of the 15kDa form by cation-exchange chromatography, as seen by 
Hudgins et al. (1992) with purification of 15kDa pro-IGF-II from human semm, leads 
us to believe that the forms secreted by MI7 cells represent pro-IGF-II. Furthermore, 
detection of a 24 and 22kDa form in the cytosol of the cells, may also indicate the 
presence of a signal peptide of 2kDa, which is consistent with sequencing of the 
peptide (Yang et al., 1985b). However, more data is needed to verify this, initially 
investigating whether our 15kDa precursor is glycosylated, and also the bioactivity of 
these large forms.
The reason for the secretion of these large forms may be that the processing machinery, 
normally involved in cleavage of prepro IGF-II to the mature form, is saturated, due to 
overexpression of IGF-II. This hypothesis is backed up by the appearance of the 
22kDa form in the MI5 cell line when secretion of IGF-II was induced by zinc, which 
was absent without zinc. Interestingly, the same pattern of secretion was seen in the 
ovarian cancer cell lines, with ER+ve PE04 cells only secreting the 15 and 7kDa 
forms, whilst ER-ve PEG 14 cell line secreted higher levels of IGF-II consisting of the 
22, 15 and 7kDa forms. This raises the possibility that the PEG 14 cells have 
progressed to oestrogen-independence by upregulation of IGF-II secretion, which can
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then act in an autocrine manner and stimulate proliferation, and so reduce the steroid 
sensitivity of the cells (as happens when MI7 cells are stimulated with zinc). If this has 
occurred, upregulation of IGF-II expression may have saturated the processing system 
(seen in MI5 cells when stimulated with zinc) and so resulted in secretion of higher 
levels of the large precursors. The data is all consistent with upregulation leading to the 
appearance of precursor forms.
The mechanism of processing is not clearly understood, with difficulties in the 
purification and sequencing of precursors, which are generally present at low 
concentrations. Also the number of processing sites present in prepro-IGF-H, means 
that proteolysis occurs rapidly, with freeze-thawing of CM from MI7 cells resulting in 
the appearance of several other forms, and the concentration method resulting in 
differential losses of the three forms. Compounding this problem is the fact that the 
precursors can be glycosylated. Tlie 15kDa pro-IGF-II purified from human serum 
Hudgins et al. (1992), actually consisted of lOkDa of peptide with 5kDa of 
glycosylation, that was on one amino acid, Thr^^, in the E domain of pro-IGF-II. The 
presence of glycosylation may account for the heterogeneous molecular weight of the 
IGF-n secreted by the MI5 and MI7 cells.
The second novel set of data arises from the regulation of IGF-II peptide levels by 
oestrogen. Several papers have described the induction of IGF-II mRNA in oestrogen- 
responsive breast cancer cell lines (Yee et al., 1988; Osborne et al., 1989), but none 
have analysed the effect on peptide levels, due to the technical difficulties in 
measurement (Section 1.3.2). The only data on hormonal regulation of IGF-II peptide 
expression is in xenograft studies in the nude mouse, where Brunner et al. (1993) 
showed at both the mRNA and peptide level that oestrogen decreased IGF-II 
expression in ER+ve T61 human breast cancer xenografts. However, this group also 
encountered problems with measurement of IGF-II peptide by RIA, with an initial loss 
of 50% of IGF-II when binding proteins were removed. Employing immunoblotting 
of CM from breast cancer cells, we were able to detect IGF-II in all of our non­
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transfected cell lines, and show oestrogen-induction of IGF-II secretion in hormone- 
sensitive cells, which agrees with published data on the regulation of IGF-II mRNA in 
these cell lines. Furthermore, the constitutive and higher expression in oestrogen- 
independent cell lines, also confirms the data of Brunner et al. (1992) concerning IGF- 
II mRNA expression in MDA-231 xenografts. The ability to detect IGF-II in all of our 
cell lines (MDA-231, HBL-100, MCF-7 McG and T47D responsive), however, 
contradicts much of the previous data in the literature, which suggests that IGF-II 
mRNA and peptide are present in only a limited number of cell lines (Yee et al., 1988; 
Osborne et al., 1989). Tliis difference probably arises from the use of techniques with 
different sensitivities, cell culture conditions and passages of cells (Section 6.7).
The fact that both IGF-I and II are potent mitogens at picomolar to nanomolar 
concentrations, can elicit a mitogenic response via a number of pathways, and their 
action is regulated by a complex number of factors, suggests that they are a candidate 
for having a role in breast cancer cell proliferation, and possibly oestrogen action. 
Research into the autocrine hypothesis has mainly searched for growth factors that are 
oestrogen-inducible in hormone-sensitive cells, and are expressed at higher constitutive 
levels in oestrogen-unresponsive cells, for example TGFa (Lippman et al., 1987). 
However, as discussed in Section 1.1.4, their are several mechanisms whereby breast 
cancer cells can progress to hormone-independence, and the two situations above 
(oestrogen mediated growth and oestrogen independence), can be viewed as 
autonomous events. These will be discussed separately.
The role of IGF-II in oestrogen-mediated proliferation of breast cancer cells is unclear. 
Several lines of evidence suggest that it may be involved. IGF-II is expressed by 
certain breast cancer cells, which also express the type 1 receptor. IGF-II peptide 
(Chapter 6) and mRNA (Yee et al., 1988) are inducible by oestradiol, and both IGF-II 
and oestradiol can synergise to give a greater mitogenic response via upregulation of the 
type 1 receptor (Stewart et al., 1990). However, the main argument against oestrogen- 
mediated proliferation via IGF-II is the fact that a-IR3, a monoclonal antibody to the
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type 1 receptor, does not block oestrogen-mediated proliferation. Two recent sets of 
data, however, may provide further evidence of a role for IGF or other growth factors 
in oestrogen-mediated proliferation. Firstly McGuire et al. (1992), have shown that 
IGFBP-1, which is not expressed by MCF-7 cells, if added exogenously, can inhibit 
oestrogen-mediated growth. Furthermore, Reddy et al. (1992) have used a tyrosine 
kinase inhibitor, apparently specific for EGFR phosphorylation, to inhibit oestrogen- 
mediated proliferation. However, considering the expanding role of tyrosine 
phosphorylation in signal transduction, and the fact that the inhibitor also inhibited In, 
IGF-I, IGF-II and TGFa mediated proliferation, this result remains controversial, 
probably simply strengthening the hypothesis for a role of growth factors in oestrogen 
action.
The role of IGF-II in progression of breast cancer cells to hormone-independence is 
similarly complicated. In vitro, transfection of oestrogen-responsive MCF-7 cells with 
v-H-ras renders them oestrogen unresponsive and able to form tumours in 
ovaiiectomised nude mice without oestrogen supplementation (Kasid et al, 1985). The 
cells secrete 5-fold higher levels of IGF immunoreactivity. Furthermore, transfection 
of oestrogen-responsive MCF-7 cells with IGF-II cDNA results in increased 
proliferation and oestrogen-independence (Daly et al., 1991; Cullen et al., 1992). In 
vivo, the most interesting results come from Arteaga et al. (1989), who showed that a- 
IR3 can block the growth of tumours from MDA-231 cells in the nude mouse, and 
Brunner et al. (1992), who indicated that oestrogen has no effect on IGF-II mRNA 
expression in MDA-231 xenografts, whereas expression is induced in MCF-7 
xenografts. Three sets of data in this thesis would support a role for IGF-II in 
progression and growth of oestrogen-independent breast cancer cells. Firstly, higher 
constitutive levels of IGF-II peptide were secreted by oestrogen-independent MDA-231 
and HBL-100 cells. Secondly, MCF-7 (9) cells rendered oestrogen-independent by 
transfection with a mixed cDNA library, secreted high levels of IGF-II, compared to 
control oestrogen-responsive cells, which contained no IGF-II. This may therefore be 
the mechanism whereby these cells have turned hormone-independent, presumably by
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transfection of the IGF-II gene in the mixed cDNA library, and so may simply 
represent a repeat of the work of Daly et û/. (1991). Thirdly, in two ovarian cancer cell 
lines, the ER-ve cell line (PE014), secreted higher levels of IGF-II than the ER+ve cell 
line (PE04), suggesting that these cells may have become oestrogen-independent by 
upregulation of IGF-II expression, which then results in saturation of processing and 
the appearance of large forms in the ER-ve cell line. Judgements made from two 
completely different cell lines must be viewed with caution, however, as in this case, 
the ER-ve cell line grows slower than the ER+ve line, which is the opposite to the 
situation with breast cancer cells.
Clearly, all the early data obtained pertaining to the biological activity of the IGFs, 
must be carefully considered with the new information on IGFBP action. The 
problem, however, is that the role of IGFBP's are as yet unclear. Also the role of the 
type 2 IGF receptor in signalling must be addressed. Finally, results indicating higher 
levels of IGF-II in cells when CM was prepared with serum versus serum-free media 
(Chapter 6), must be taken into account when consulting data in the literature regarding 
the proliferation of cells to oestrogen performed in stripped-serum.
The final goal of this research is to try and understand how breast cancer can escape 
hormonal control and grow more aggressively, and thereby produce better treatments. 
This provides the single largest clinical problem for breast cancer. The use of 
antibodies against the type 1 receptor, IGFBP-1 and tyrosine kinase inhibitors, all 
affecting the proliferation of breast cancer cells, suggest that it will not be long before 
this goal is reached.
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9.1 FURTHER WORK
1) Purification and sequencing of each of the large forms of IGF-II, using
techniques such as hollow-fibre biotechnology to produce large amounts of 
peptide, which will indicate at which amino acids these peptide have been 
cleaved, and so give some insight into processing of IGF-II.
2) Once purification is achieved, two important features of the precursors can be
analysed. The presence of any glycosylation, and the effect of this upon 
secretion and processing. Secondly, determination of the biological activity of 
the large forms.
3) Further investigation into the effect of oestradiol on IGF-II secretion by a
number of other breast cancer cell lines.
4) Measurement of IGF-II peptide levels in breast tumour specimens and serum, to 
determine either an autocrine, paracrine or endocrine role for IGF-II in breast 
cancer. IGF-II mRNA is easily detectable in tumour specimens, arising mainly 
from stromal elements, indicating the possible existence of large amounts of 
peptide, possibly existing in large precursor forms.
5) Further analysis of secretion of IGF-II by oestrogen-independent MCF-7 cells 
(Clone 9), and purification of the forms to confirm identity with those seen in 
the MI7 cell line. The effect of the secreted IGF-II on proliferation of these 
cells can be readily assessed, using a-IR3, and may indicate the mechanism 
whereby these cells have been rendered hormone-insensitive.
5) Characterisation of the three forms of IGF-II secreted by the ovarian cancer cell
lines, and investigation of levels in other ovarian cell lines. Determine why 
IGF-II levels are higher in CM prepared with 5% DCFCS rather than SFM, by 
examination of other secreted proteins, and the effect of binding proteins, to 
examine if serum is inducing IGF-II expression.
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